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Abstract 
Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-
ToF MS) is a technique by which protein profiles can be rapidly produced from 
biological samples. Proteomic profiling and biomarker identification using MALDI-ToF 
MS have been utilised widely in microbiology for bacteria identification and in clinical 
proteomics for disease-related biomarker discovery. To date, the benefits of MALDI-
ToF MS have not been realised in the area of mammalian cell culture during 
bioprocessing. 
 
This thesis explores the approach of ‘intact-cell’ MALDI-ToF MS (ICM-MS) combined 
with projection to latent structures – discriminant analysis (PLS-DA), to discriminate 
between mammalian cell lines during bioprocessing. Specifically, the industrial 
collaborator, Lonza Biologics is interested in adopting this approach to discriminate 
between IgG monoclonal antibody producing Chinese hamster ovaries (CHO) cell lines 
based on their productivities and identify protein biomarkers which are associated with 
the cell line productivities. After classifying cell lines into two categories (high/low 
producers; Hs/Ls), it is hypothesised that Hs and Ls CHO cells exhibit different 
metabolic profiles and hence differences in phenotypic expression patterns will be 
observed. The protein expression patterns correlate to the productivities of the cell lines, 
and introduce between-class variability. The chemometric method of PLS-DA can use 
this variability to classify the cell lines as Hs or Ls. 
 
A number of differentially expressed proteins were matched and identified as 
biomarkers after a SwissProt/TrEMBL protein database search. The identified proteins 
revealed that proteins involved in biological processes such as protein biosynthesis, 
protein folding, glycolysis and cytoskeleton architecture were upregulated in Hs. This 
study demonstrates that ICM-MS combined with PLS-DA and a protein database search 
can be a rapid and valuable tool for biomarker discovery in the bioprocessing industry. 
It may help in providing clues to potential cell genetic engineering targets as well as a 
tool in process development in the bioprocessing industry. With the completion of the 
sequencing of the CHO genome, this study provides a foundation for rapid biomarker 
profiling of CHO cell lines in culture during recombinant protein manufacturing. 
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1. Introduction of Thesis  
Mammalian cell lines have the potential to synthesize, perform complex folding and 
post-translational modifications (e.g. glycosylation) necessary for in vivo biological 
activity; and secrete complex proteins in large-scale suspension cell culture. These 
characteristics give them a significant advantage over their prokaryotic counterparts 
such as bacteria cells (Andersen and Krummen, 2002). The increasing demand for 
biotherapeutic products such as monoclonal antibodies necessitates improved large-
scale production of these complex heterologous proteins from mammalian cell lines. 
Consequently, the biopharmaceutical industry has endeavoured to enhance product titres 
and/or yield by investing in the engineering of cell culture processes resulting in high-
producing cell cultures. Examples of mammalian cell culture cell lines which have been 
extensively used in the biotechnology industry for the production of recombinant 
proteins for biotherapeutic applications include Chinese hamster ovary (CHO), baby 
hamster kidney (BHK), and mouse hybridoma (NS0). Biotherapeutic protein producing 
cell lines generated from the same parent cell line usually display a wide range of 
growth, productivity, and metabolic characteristics (Browne and Al-Rubeai, 2007). This 
behavior is advantageous with respect to mammalian cell engineering. Producing cell 
lines displaying favourable characteristics have resulted in the potential to identify gene 
targets for genetic engineering that will improve product yield (Pascoe et al., 2007).  
 
A number of genetic engineering approaches have been applied with the aim of 
improving product yield. Examples include delaying programmed cell death 
(apoptosis), enhancing cellular metabolism and protein processing, and manipulating 
the cell cycle (Dietmair et al., 2011). Engineering mammalian cells to reduce high 
concentrations of metabolic by-products such as lactate and NH4 is an example of 
changing a cell’s metabolic behaviour. Hybridoma cells transfected with glutamine 
synthetase (GS – enzyme that converts glutamate to glutamine) were able to grow in a 
medium void of glutamine (NH4 is the by-product of nutrient consumption – 
glutamine). This eliminated NH4 as a by-product, otherwise whose presence will inhibit 
cell growth and viability, reducing maximum product yield. However this product titre 
gain came at a price as the stability of the transformed cells were compromised (Paredes 
et al., 1999). Engineering approaches that target the cellular machinery responsible for 
protein processing can be directed towards improving protein folding. For example, 
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overexpression of an isoform of the foldase protein disulfide isomerase (PDI) (ERp57), 
and other proteins that aid protein folding (calnexin and calreticulin), increased the 
specific productivity (qP) of thrombopoietin -producing CHO cells by approximately 
two-fold (Hwang et al., 2003; Chung et al., 2004). In another study, overexpression of 
PDI did not change the productivity of the CHO cells (Mohan et al., 2007). These 
contrasting results indicate that the outcomes of these strategies may be cell line 
dependent (Dietmair et al., 2012). Consequently, steps towards enhancing cellular 
productivity can potentially be achieved through greater understanding of cellular 
protein biology and how this is affected by cellular engineering. 
 
With their track record in industry, high productivity and safety, CHO cells have 
gradually risen to prominence and become the most widely used platform for the 
production of biotherapeutics (Chu and Robinson, 2001). Despite their importance in 
biotechnology, limited information is available with respect to changes throughout the 
culture of CHO cells, due to insufficient genomic information. This is not the case with 
other organisms where genomic approaches (such as proteome and microarray analyses) 
have been applied. The sequencing of the E. coli (Blattner et al., 1997), mouse 
(Waterston et al., 2002), rat (Gibbs et al., 2004) and human (Lander et al., 2001; Venter 
et al., 2001) genomes has provided the potential for the application of genomic tools in 
the study of disease, metabolism, growth, apoptosis investigation in these organisms. 
The lack of genomic information has materialised into proteomic profiling of CHO cells 
to understand their biology. This has been carried out using two-dimensional 
Polyacrylamide Gel Electrophoresis (2D-PAGE) (López, 2007). Proteomic profiling 
studies using 2D-PAGE have previously been applied to mammalian cells under various 
conditions including CHO cell lines undergoing temperature shifts (Kaufmann et al., 
1999), modified cell lines (Krawitz et al., 2006), cells under hyperosmolality conditions 
(Lee et al., 2003), cells with butyrate, zinc, and tunicamycin addition during growth 
(Van Dyk et al., 2003), and NS0 cells displaying different productivity rates  (Smales et 
al., 2004). These studies have contributed to the understanding of the biology of 
mammalian cells under production, hence giving indications of potential genetic 
engineering targets that may be exploited to engineer improved cell lines. However, 
there are a number of drawbacks associated with 2D-PAGE. For example it is a lower 
throughput and time-consuming technique requiring about 3-4 days per run. The runs 
involve many steps and require a high level of laboratory skill to obtain good results. 
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Another drawback is the difficulties in separating high/low molecular weight proteins, 
low abundant proteins, hydrophobic proteins (e.g. membrane proteins). Membrane 
proteins are relatively insoluble in non-ionic detergents at low ionic strength and even 
when solubilised may precipitate at pH values close to their isoelectric points (Bunai 
and Yamane, 2005; Meleady, 2007). 
 
Recent initiatives to sequence the CHO cell genome (Hammond et al., 2011; Xu et al., 
2011), indicate that genomic approaches combined with bioinformatics could 
materialise in the proteomic profiling of CHO cells. The completion of the sequencing 
of the CHO genome has materialised into sequence-derived theoretical molecular 
weights (MWs) of CHO proteins to become increasingly available in compiled internet 
accessible protein databases (http://expasy.org/proteomics, 2012). This has provided the 
possibility of identifying potential protein biomarkers of CHO cells by matching the 
sequence-derived theoretical MWs of the database proteins with experimental MWs 
derived from high throughput proteomic technologies such as mass spectrometry. 
 
‘Intact-cell’ Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry 
(MALDI-ToF MS or MALDI) has been exploited extensively in the field of 
microbiology for the investigation of bacterial species (Demirev et al., 1999; Ryzhov 
and Fenselau, 2001; Warscheid et al., 2004; Parisi et al., 2008; Dieckmann et al., 2008; 
Ilina et al., 2009; Christner et al. 2010; Hotta et al., 2011; Wang et al., 2012). ‘Intact 
cell’ or ‘whole cell’ MALDI-TOF MS (ICM-MS or WCM-MS) was developed for the 
rapid identification of bacteria through protein profiling. The term (whole or intact cell) 
indicates that the cells to be analysed are not treated or processed to specifically remove 
or isolate any of the cellular components. In “intact cell” analysis, the cells are only 
manipulated to transfer them into the mass spectrometer for analysis and no additional 
steps are included in the procedure to deliberately disrupt cellular membranes or 
separate/recover analytes from the cellular material (Wilkins and Lay, 2006).  
 
Recently, the investigation of microorganisms by ICM-MS, primarily for bacterial 
identification, has been undertaken through two approaches. The first approach is by 
direct comparison of whole cell spectra, deemed to be a bacterial protein fingerprint, to 
reference spectra. This has been made possible by the creation of a bacterial fingerprint 
library of mass spectra from a range of known bacterial species (Mazzeo et al., 2006).   
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An alternative approach for the identification of bacteria which does not involve the use 
of a fingerprinting library has been developed. This is a bioinformatics approach and is 
based on matching a set of protein biomarker MWs in the spectrum against those of 
sequence-derived theoretical protein MWs. The latter approach has seen wide 
applications in the field of microbiology (Demirev et al., 1999; Ryzhov and Fenselau, 
2001). It has been made possible by the availability of protein biomarkers of bacteria in 
compiled internet-accessible protein databases of microorganisms with completely 
sequenced genomes. 
 
ICM-MS also raises many possibilities for the analysis of complex cellular systems 
such as mammalian cells. Biomarker profiles have been obtained from whole 
mammalian cells of neuronal origin (Li et al., 2000; van Veelen et al., 1993), 
additionally tissue sections have been profiled (Chaurand et al.,, 2006; Chaurand et al., 
2007; Crossman et al., 2006; Khatib-Shahidi et al., 2006; Reyzer et al., 2007). 
Differentiation between human (K562 and GM15226) and rodent (BHK21) mammalian 
cell types through their protein profile ‘fingerprints’ (Zhang et al., 2006), as well as 
between monocytes, T lymphocytes and polymorphonuclear leukocyte immune cells 
(Ouedraogo et al., 2010) has also been carried out using ICM-MS. These applications of 
ICM-MS in bacterial and mammalian cell protein profiling, demonstrate an outcome of 
the approach that could be useful for mammalian cell culture (MCC) in bioprocessing 
for protein profiling to study their biology.  
Despite the application of ICM-MS to bacteria and mammalian cells, there have been 
relatively few studies that have applied this approach to MCC in bioprocessing. ICM-
MS has been used in the profiling of insulin/glucagon-producing pancreatic islet α- and 
β-cells (Buchanan et al., 2007); detection of apoptosis in mammalian cells (Dong et al., 
2011); and characterisation of batches of IgG producing monoclonal antibody CHO cell 
lines (Feng et al., 2010; Feng et al., 2011). The application of MALDI analysis on MCC 
during biotherapeutic protein production leads to the issue of how to reveal the 
information in the mass spectra profiles relating to the state and behaviour of the cell 
lines in the culture. Thus the use of proper data analysis techniques for such spectra 
profiles is crucial in obtaining reliable information concerning potential biomarkers that 
may provide information on the state and behaviour of the cell lines. Multivariate data 
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analysis (chemometric) methods can be used to simplify complex proteomic data 
profiles, making visualisation and classification easier, and hence the possibility of 
detecting biomarker patterns. Methods such as principal component analysis (PCA) 
(Wise et al., 2005), and projection to latent structures – discriminant analysis (or partial 
least squares-discriminant analysis; PLS-DA) (Barker and Rayens, 2003) have 
previously been applied in proteomic profiling (Lee et al., 2003; Eriksson et al., 2004).  
 
PLS-DA (which is the focus of this thesis) is a variant of standard PLS regression. It has 
previously been used in biomarker profiling of MALDI generated data sets in terms of 
discriminating normal from diseased blood specimens, normal from diseased urine 
samples, and between microorganisms (Lee et al., 2003; Norden et al., 2005; Pierce et 
al., 2006). Having the dimensionality reduction advantage of PLS, PLS-DA is suited to 
extracting small, systematic variations from large, noisy data sets by identifying a lower 
dimensional latent variable space within which most of the information lies. It can 
potentially separate classes of samples with respect to the experimental hypothesis, 
forcing them to cluster together if they share a common characteristic. Separation is 
usually achieved on the basis of one or more peaks at certain mass-to-charge ratio (m/z) 
ratio values, offering the opportunity for the identification of specific m/z ratio areas in a 
mass spectra profile which represent potential protein biomarkers. 
 
1.1. Aim of the thesis 
The main aim of this research is to investigate the combined approach of ICM-MS and 
PLS-DA to discriminate between monoclonal antibody-producing mammalian cell lines 
based on their productivities and subsequently identify protein biomarkers (through 
protein database searches) that are differentially expressed in these cell lines.  
 
The rationale behind this approach is that by applying ICM-MS to the CHO cell lines 
would generate mass spectra data where most of the m/z ratio peaks represent molecular 
protein/peptide ions which are singly charged. Since MALDI works through a ‘soft 
ionisation’ principle (that is, little or no fragmentation) each protein/peptide fragment 
usually produces only a single ion (MH
+
) type as they are ionised by acquiring a single 
proton. Hence the mass of each protein/peptide fragment is equal to its m/z ratio value, 
meaning that the latter can be directly inferred as the MW of the protein/peptide 
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fragment.  Consequently, data analysis with PLS-DA would provide the possibility to 
rapidly identify the protein/peptide fragment ions by matching their experimental MWs 
(their m/z ratio values) to sequence-derived theoretical MWs of CHO cell proteins in 
internet accessible protein databases. These identified protein/peptide fragment ions can 
serve as potential productivity-associated protein biomarkers. 
 
The industrial collaborators, Lonza Biologics, are interested in utilising the ICM-MS 
and PLS-DA approach to separate IgG producing CHO cell lines during bioprocessing 
based on their productivities (antibody titre in mg mL
-1
) and identify potential protein 
biomarkers which are associated with the cell line productivities. Cell lines were 
classified into two categories (high/low producers; Hs/Ls), based on a threshold 
antibody titre of 1000 mg mL
-1
 above which cell lines were classed as Hs, otherwise Ls. 
It is hypothesised that Hs and Ls CHO cells exhibit different metabolic profiles and 
hence differences in protein expression patterns. These expression patterns correlate to 
the productivities (titre of IgG antibody produced) of the cell lines, and introduce a 
between-class variability. A multivariate data analysis method (PLS-DA) can be used to 
capture this variability and classify the cell lines based on these differences. This will be 
possible by training the PLS-DA model to capture the between class variability based 
on categories of cell lines, that is, Hs or Ls. Figure 1.1 shows an overview of the various 
steps involved in biomarker profiling using ICM-MS, PLS-DA and protein database 
search used in this thesis. It consists of the following;  
 Preparation of the biological samples and analysis by MALDI mass spectrometry. 
  Preprocessing (signal resampling, baseline correction, alignment, normalsation, 
smoothing and peak identification) of the spectra data generated to remove 
unwanted variation due to data acquisition issues whilst preserving biological 
information. 
 After sampling the preprocessed samples are separated into training and test sets, the 
training set is overviewed using PCA to study initial trends and later analysed using 
PLS-DA, whilst the test sets are retained for external validation of the PCA and 
PLS-DA models built. 
 PLS-DA scores and loadings plot are interpreted and information from the loadings 
plot is used for database search to identify protein biomarkers. This is followed by 
the biological interpretations of the results. 
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As mentioned above, it is hypothesised that identified protein expression patterns (or 
biomarkers) correlate to the productivities of the cell lines. Thus an important goal of 
this research would be the ability to infer the likelihood of a CHO cell line being a high 
or low producer based on these identified biomarkers. This could also provide insight 
into the biology of the mammalian cell lines during biopharmaceutical bioprocessing, 
and may give indications of potential genetic engineering targets that could be exploited 
to engineer enhanced cell lines. Predicting the likelihood of cell lines being Hs or Ls 
earlier in biotechnological process development may lead to early screening of Hs cell 
lines which will have the desired high productivity during manufacturing (bioreactor 
stage). The nature of other CHO cell lines can be inferred by subjecting their MALDI 
spectra data into the calibrated PLS-DA predictive models built with mass spectra data 
generated from known IgG monoclonal antibody-producing CHO cell lines. 
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Figure 1.1: An overview of the pipeline for biomarker discovery using ‘intact-cell’ 
MALDI-ToF MS, projection to latent structure - discriminant analysis and protein 
database search 
SAMPLE PREPARATION
Intact cell samples are prepared and subjected to 
MALDI-TOF MS analysis to obtain mass spectra data 
FIRST STEP:
SECOND STEP:
DATA PREPROCESSING
Signal resampling, Baseline correction, Alignment, 
Normalisation,  Smoothing, Peak identification  
THIRD STEP:
MULTIVARIATE DATA ANALYSIS
PCA overview, PLS-DA modeling, Cross validation, 
External validation, Model evaluation
FOURTH STEP:
DATABASE SEARCH
 UniProtKB/Swiss-Prot Protein Database searches 
are performed to identify protein biomarkers
Biological interpretation of the results
P
I
P
E
L
I
N
E
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1.2. Contributions of the Thesis 
The main contribution of this thesis is the application of ICM-MS, PLS-DA and protein 
database search approach to identify protein biomarkers from monoclonal antibody 
producing mammalian cell cultures during biopharmaceutical bioprocessing. More 
specifically, the key contributions of this thesis are as follows; 
 
1. Application of the ICM-MS, PLS-DA and protein database search approach to 
IgG monoclonal antibody-producing CHO cell lines during bioprocessing. 
While conceptually straightforward, to the knowledge of the author, no existing 
studies adopt this approach; consequently this is the first study where this 
methodology is used to identify potential mammalian cell biomarkers in the area 
of mammalian cell culture during bioprocessing (chapter 7).  
 
2. An Escherichia coli growth-phase-associated protein biomarker model, where 
ICM-MS, PLS-DA and a protein database search approach is applied to E. coli 
K-12 culture to identify potential protein biomarkers associated with the 
different growth phases of the culture. Mammalian cells are complex systems, 
hence this standard E. coli growth-phase-associated biomarker model is used as 
a proof-of-concept study for the study described above.  Samples were collected 
and analysed from the cultures at points in the three specific growth phases 
(exponential, stationary and decline phase). After establishing the growth curve 
of the bacterial cultures, the predictable timing of growth along the growth curve 
ensured that samples were collected at specific time points during the three 
growth phases. This increased the likelihood that differences between identified 
proteins will be related to the progression from one growth phase to another.  
 
Biologically, it is expected that E. coli cultures at the three different phases of 
growth exhibit different metabolic profiles and hence different protein 
expression patterns so that unique proteins can be induced and differentially 
expressed by these cultures. It is anticipated that the latter protein expression 
patterns correlate with the growth phase of the culture, and hence between-class 
(exponential, stationary and decline phase classes) variability will be evident. 
PLS-DA is used to capture these differences and hence classify the E. coli cells. 
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A database search by matching experimental MWs to sequence-derived 
theoretical MWs of E. coli cells using internet accessible protein databases was 
then carried out to identify potential growth-phase-associated protein 
biomarkers. 
 
3. One challenge involved in biomarker discovery using mass spectrometry is to 
provide an appropriate preprocessing method for the generated mass spectra 
data. Preprocessing is data dependent and one of the goals is to eliminate 
differences between spectra profiles as a consequence of experimental and 
instrumental procedures, while preserving the inherent biological information 
within the spectra profiles. A number of combinations of data preprocessing 
techniques/parameters were considered and empirically investigated to enable 
the most appropriate selection of the combination of methods/parameters. The 
parameters of the preprocessing methods were modified systematically and 
applied to the spectra data. The preprocessed data was used to calibrate PLS-DA 
models. The performances (predictive ability) of the constructed models using 
different preprocessing techniques/parameters were assessed. The combination 
of preprocessing techniques/parameters that gives an improved and optimum 
model performance was selected as the appropriate preprocessing method 
(section 3.6).  
 
It was reasoned that improved classification and predictive model performance 
indicates that predictive models capture as much information as possible relating 
to the experimental hypothesis. This will also imply that these models are valid, 
that is, providing accurate biological information pertaining from the data. Thus 
biomarkers derived from such models will have a high probability of being 
related to the experimental hypothesis as well as being valid. In addition to 
model performance, a result-driven approach further helped to validate the 
appropriate preprocessing methods/parameters. That is, a combination of 
preprocessing methods/parameters was considered as being valid if the 
preprocessed spectra data (after modeling the spectra data with PLS-DA), 
provided accurate information (from the PLS-DA loadings plot) important for 
the identification of protein biomarkers previously described in the literature. 
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1.3. Organisation of this thesis 
The following summarises the main components of the chapters of this thesis. 
 
Chapter 2 presents an introduction to biopharmaceutical therapeutics and gives an 
overview of different aspects pertaining to the production of biotherapeutic proteins in 
cultivated mammalian cells. It also describes expression systems, factors affecting 
intracellular expression and highlights methods involved in enhancing productivities of 
recombinant proteins in mammalian cell cultures. Additionally, the chapter explores the 
Chinese hamster ovary (CHO) cell line highlighting the advantages it has over other 
mammalian cell lines. The chapter concludes with a literature survey of the methods 
that are currently being used for improving large-scale protein production in 
mammalian cell lines. 
  
Mass spectrometry is introduced in chapter 3 with particular focus on Matrix Assisted 
Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-ToF MS). It 
describes how the MALDI-ToF MS instrument is used to collect data from E. coli 
cultures at different growth phases as well as IgG monoclonal antibody-producing CHO 
cell lines during culturing. Methods involved with the preprocessing of mass spectra 
data profiles are also reviewed. An empirical evaluation of preprocessing methods on 
the two sets of spectra data (E. coli growth profile model and IgG producing CHO cell 
lines) is presented.  
 
An introduction to proteomics and biomarker discovery relevant to this work is 
presented in chapter 4. It provides a summary of approaches used in biomarker 
discovery and highlights the top-down proteomics based approach of ‘intact-cell’ 
MALDI-ToF MS (ICM-MS), for the identification of microorganisms that may be 
relevant to biomarker discovery in the biopharmaceutical bioprocessing industry. The 
chapter also explores the potential advantage and usefulness of ICM-MS and internet-
accessible protein databases for rapid biomarker profiling in the area of mammalian cell 
culture in biopharmaceutical bioprocessing. It concludes with a literature review on the 
applications of ICM-MS on both bacterial and mammalian cells. 
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Chapter 5 provides an introduction to multivariate data analysis (chemometrics), and an 
overview of chemometric methodologies underpinning this research – principal 
component analysis (PCA) and projection to latent structures – discriminant analysis 
(PLS-DA). It explores the PLS-DA algorithm involved in modeling the two mass 
spectra data sets discussed in chapter 4. A review on the application of PLS-DA to 
proteomics mass spectra data is given. The chapter ends with a discussion of results of 
an example where PCA and PLS-DA were used to analyse MALDI-ToF mass spectra 
data generated from cell lysate samples of E. coli K-12 cells at different growth phases. 
  
A case study of an E. coli growth-phase-associated protein biomarker discovery model 
is presented in chapter 6, where ICM-MS, PLS-DA and the protein database search 
approach is applied to identify growth phase-associated protein biomarkers. The wet lab 
procedures for mass spectra data collection, PLS-DA modeling of the spectra data, and 
biomarker identification through database searches are presented. The detailed 
interpretations of the results as well as subsequent discussions are presented. 
  
Chapter 7 describes the second case study where WCM-MS, PLS-DA and protein 
database search approach are applied to IgG monoclonal antibody-producing CHO cell 
lines during bioprocessing, to identify productivity-associated protein biomarkers. 
Mammalian cells such as CHO are complex systems, hence the standard E. coli growth-
phase-associated biomarker model is used as a proof-of-concept or benchmark study for 
this case study.  The wet lab procedure for mass spectra data collection, PLS-DA 
modelling of the data, and biomarker identification through a database searches are 
presented. The detailed interpretation of the results as well as discussions is presented. 
 
A summary of the work, along with a discussion regarding the strengths and 
weaknesses of the proposed ICM-MS, PLS-DA and protein database search approach to 
biomarker discovery is presented in chapter 8. The chapter also highlights some areas of 
the research that could benefit from further investigation. 
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2. Biopharmaceutical Therapeutics 
2.1. Overview  
The main purpose of this chapter is to provide an introduction to biopharmaceutical 
therapeutic proteins as well as the science and technology of in vitro mammalian cell 
culture which is used in their production. The chapter also provides an appreciation of 
the impact that mammalian cell culture technology has had on the health and well-being 
of mankind. The chapter will begin by giving an overview of the various expression 
systems used for recombinant protein production as well as their advantages and 
disadvantages which influence their ability as potential hosts. It also explores the 
Chinese hamster ovary (CHO) cell line highlighting the advantages it has over other cell 
lines, which has made it the most widely utilised mammalian cell culture expression 
system. Additionally, the chapter will provide an outline of the general workflow of the 
steps involved in the production of a recombinant protein in stirred, serum-free cultures, 
when beginning from a recombinant vector and a mammalian host cell line. The chapter 
will end with a literature survey of the methods that are currently being used for 
improving large-scale production of heterologous proteins from mammalian cell lines. 
 
2.2. Introduction 
Biopharmaceutical proteins can be defined as pharmaceutical substances originating 
from biological sources and are the basis of approximately one-third of the drugs 
currently in development. Biopharmaceutical drugs or biotherapeutics are large, 
complex protein molecules derived from living cells, used clinically for therapeutic or 
in vivo diagnostic purposes (Sekhon, 2010). Biotherapeutics include monoclonal 
antibodies (MAbs), recombinant proteins and viral vaccines. 
 
Prior to the 1970’s only limited amounts of proteins for clinical use were available as 
they could only be sourced naturally from humans and animals. However, non-natural 
sources are now available with the advent of technologies such as recombinant DNA 
and hybridoma technology. Advances in these technologies have revolutionised the 
production of biotherapeutics. Recombinant DNA technology made possible the large 
scale production of biotherapeutics in the form of recombinant proteins. For its part 
hybridoma technology enabled the production of a new category of biotherapeutic 
proteins known as MAbs that have provided alternative treatment regimens for a 
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number of ailments including cancers infectious, and autoimmune diseases (Birch and 
Onakunle, 2005). 
 
A number of reasons resulted in the move to the production of recombinant proteins 
from recombinant DNA technology. Firstly recombinant proteins have been used 
mainly as a replacement for naturally sourced biotherapeutics such as human growth 
hormone (hGH) extracted from dried pituitary glands of dead humans (Birch and 
Onakunle, 2005). Human insulin became the first biotherapeutic to be manufactured and 
approved by the food and drug administration (FDA) via recombinant DNA technology 
in 1982. Other recombinant products including hGH, tissue plasminogen activator, 
erythropoietin, and blood-clotting Factor VIII have also been produced using 
recombinant DNA technology (Sekhon, 2010). Secondly, safety issues surrounding 
natural sources led to the switch to recombinant proteins. For example production of 
hGH was changed to Escherichia coli after it emerged that hGH from the pituitary 
glands of dead humans was a source of prion protein, the causative agent of 
Creutzfeldt–Jakob disease (Sekhon, 2010). Recombinant DNA technology also replaced 
blood serum from which the potentially dangerous hepatitis B vaccine was extracted; 
this viral vaccine is now produced in baker's yeast (Saccharomyces cerevisiae) (Birch 
and Onakunle, 2005). 
 
Substantial progress has been made with respect to new approaches to treat various 
diseases using MAbs and recombinant proteins. These biotherapeutics have been widely 
used for treatment mainly in the field of cancer and other important areas like infectious 
diseases, autoimmune and cardiovascular disorders (Birch and Onakunle, 2005). Recent 
therapeutic advances in 2011 include the first new treatments for the following diseases 
and disorders: Benlysta is the first drug to be produced in over 50 years, used for 
treating lupus; Adcetris is the first drug to treat Hodgkin's lymphoma since 1977; 
Anascorp is a new drug effective against scorpion stings; Corifact is used for treating 
Factor XIII deficiency; Nulojix is the first drug used against the rejection of organ 
transplants in more than 10 years; and Yervoy is a new drug for the treatment of 
advanced melanoma (Biopharma, 2012). Globally, more than 150 biopharmaceutical 
drugs are currently in the market and as more drugs are gaining approval, the challenge 
has been to provide and maintain suitable expression systems to meet the production of 
biotherapeutics. 
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2.3. Recombinant Protein Expression Systems 
The growing need for therapeutic, diagnostic and functional activity bioassay 
applications of recombinant proteins has enabled the advancement of bioprocessing 
technology for the production of recombinant proteins. However, the expression of a 
spectrum of these recombinant biotechnology products to meet market demands has 
been a major challenge (Andersen and Krummen, 2002). These demands can only be 
met by the heterologous synthesis of these recombinant proteins. Heterologous protein 
production involves the introduction of a foreign DNA into host cells for expression, a 
move which involves a number of considerations (Fig 2.1): isolation of the DNA to be 
introduced; construction of a recombinant vector (cDNA) having the DNA; and 
identification of a suitable expression system to accommodate the cDNA (Rai and Padh, 
2001).  
 
 
 
 
 
 
 
 
 
 
There are a wide range of expression systems available for large-scale recombinant 
protein production. The most commonly used systems include bacteria, insect cells, 
yeast, and mammalian based systems (section 2.3.4). Each has its own advantages in 
terms of cost, ease of use, and post-translational modifications (PTMs) of the protein 
products. Selection of the most appropriate expression system for recombinant protein 
Figure 2.1: Schematic diagram showing the steps involved in heterologous protein 
production 
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production must consider these elements. Most importantly, the choice of a suitable 
expression system is based on the system’s ability to produce the protein in a form 
identical to that found in the cell type from which the recombinant DNA was obtained. 
These expression systems are briefly reviewed in the subsequent sections. 
 
2.3.1.   Bacteria 
The bacteria expression system using Escherichia coli is perhaps the first choice for the 
heterologous production. This is primarily due to the organism being relatively easy to 
manipulate, the low cost of the culture media, the shorter time to obtain acceptable 
production yields, and the potential to use a great variety of strains and hence 
expression vectors. The limitations of this system are its lack of PTMs (for example 
glycosylation and disulfide bond formation), leading to incorrect modification of 
heterologously expressed eukaryotic or mammalian proteins. These proteins require 
proper PTM in order to function properly otherwise the mammalian immune system 
may recognise such proteins as foreign. Incorrect PTMs can also hamper secretion of 
large amounts of expressed eukaryotic proteins from the bacteria expression system. 
Another limitation of this system is the precipitation of large amounts of expressed 
proteins into inclusion bodies creating difficulties in terms of the purification of the 
final product (Hunt, 2005).  Although Escherichia coli remains the most widely used 
bacteria expression system, other bacteria which have been used include Streptococcus, 
Lactococcus, , Leuconostoc, Pediococcus and Lactobacillus species. 
 
2.3.2.   Yeast 
Yeasts are the favoured alternative expression systems for eukaryotic proteins. They 
have advantages in that they are relatively simple to manipulate and inexpensive to 
culture and also offer the possibility of PTM. Yeasts fall in the list of the second most 
commonly used expression systems and has been used as a replacement for bacteria. 
Expression in yeast can be both intracellular and extracellular through the application of 
short signaling sequences. The most common species of yeast used for intracellular 
heterologous protein expression is Saccharomyces cerevisiae since it can secrete the 
proteins it expresses. However S. cerevisiae has hyperglycosylation problems, where 
high mannose glycans are incorporated to the expressed proteins, a phenomenon which 
is not good for human therapeutics. Other yeast strains with better secretion properties 
are Pichia pastoris, Klyveromyces lactis, Schizosaccharomyces pompe, Yarrowia 
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lipolytica, and Hansenula polymorpha. Well developed yeast expression systems for 
large scale heterologous protein expression are based on P. pastoris. With the exception 
of S. cerevisiae, the other yeasts are capable of producing 10 - 100-fold more secreted 
proteins without hyperglycosylation. The main drawback in using a yeast expression 
system is that yeast cells have cell walls so recovering the protein from the interior of 
the cell after intracellular expression is a major challenge (Reyes-Ruiz and Barrera-
Saldana, 2006). 
 
2.3.3.   Insect Cells 
An expression system with insect cells is based on the Baculovirus Expression Vector 
System. It has emerged as a popular eukaryotic expression system for expression of 
recombinant proteins with the ability to produce proteins having the proper PTM: 
folding, O-linked and N-linked glycosylation, amidation, carboxymethylation, 
oligomerisation, phosphorylation, disulfide bond formation, proteolytic cleavage and 
acylation (Reyes-Ruiz and Barrera-Saldana, 2006). Baculoviruses are present in 
invertebrates, primarily insect species, and can be propagated to high titres for growth in 
suspension cultures, creating the potential to obtain large amounts of recombinant 
proteins in a relatively short time (Rai and Padh, 2001). Sf9 and Sf21 are the most 
commonly used insect cell lines for expression as they can be grown in suspension and 
can thus be used in a bioreactor. They are derived from the Spodoptera frugiperda 
larvae and are susceptible to baculovirus infections. Other commonly used insect cell 
lines include High Five cells (derived from Trichoplusia ni egg cell homogenates) and 
the Drosophilia system, which relies on stable cell lines (Reyes-Ruiz and Barrera-
Saldana, 2006). 
 
2.3.4.  Mammalian Culture Cells 
Mammalian cell lines are considered the ideal eukaryotic expression system for proteins 
intended for human therapeutics. Proteins requiring mammalian PTMs are typically 
expressed in this system. The drawbacks of using this expression system include high 
costs of maintenance when compared to bacteria or yeast cultures due to complexity of 
the facilities, long culture times and nutrient requirements. In addition, handling of such 
facilities requires qualified and trained personnel; safety risks are involved as the 
required growth factors are added by calf serum which can be contaminated with 
viruses or prions; and there is no guarantee of always obtaining high product yields. 
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Despite these limitations, mammalian cell lines offer the greatest degree of product 
fidelity having appropriate post-translational modifications. For example mammalian 
cell lines express proteins with glycosylation identical to native endogenous human 
proteins. They are also the expression system of choice especially if clinical efficacy of 
the biotherapeutics is determined by its authenticity. That is, proteins not properly 
glycosylated may be recognised as “foreign” by the immune system of higher 
mammals, resulting in an immediate response against such proteins preventing them 
from fulfilling their therapeutic purpose (Reyes-Ruiz and Barrera-Saldana, 2006). Some 
commonly used mammalian cell lines for the construction of mammalian expression 
systems for large-scale commercial recombinant protein production are Chinese hamster 
ovary (CHO), mouse myeloma (NS0), and baby hamster kidney (BHK-12). 
 
2.3.5.   Cell-free Systems 
Cell free systems are in vitro expression systems which contain cellular extracts 
obtained from either prokaryotic or eukaryotic cells, and provide the necessary 
molecular machinery and biochemical constituents required for transcription and 
translation. This system has the advantage of avoiding limitations associated with the in 
vivo systems of bacteria and eukaryotes, where over-expressed protein is toxic to the 
host cell, where the protein has insolubility problems or forms inclusion bodies, or 
where the protein is susceptible to rapid degradation by intracellular proteolytic 
enzymes. Common cell-free expression systems contain prokaryotic and eukaryotic 
cellular extracts (initiation, elongation and termination factors, 70S or 80S ribosomes, 
aminoacyltRNA synthetases, and tRNAs) from rabbit reticulocytes, wheat germ and E. 
coli (Reyes-Ruiz and Barrera-Saldana, 2006). 
 
2.3.6.   Plants 
Plants are an interesting alternative to the aforementioned expression systems and are 
capable of providing low cost in vitro expression systems. The advantage with plant 
expression systems is the absence of contamination from endotoxins and animal viruses 
which are associated with bacteria and eukaryotic expression systems. Plant expression 
systems have drawbacks mainly from an economic perspective making them 
unattractive as hosts for expression. It is time consuming to express recombinant 
proteins in plant expression systems typically taking about two years from the initial 
transformation event to small-scale evaluation and production. This is a consequence of 
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the relatively slow growth rate of terrestrial plants. Furthermore, with plant systems 
recombinant proteins are produced and deposited in specific organs such as leaves, 
fruits, and seeds rendering the protein purification complex and costly (Reyes-Ruiz and 
Barrera-Saldana, 2006). 
 
2.4. Monoclonal Antibodies  
2.4.1.   Overview of Monoclonal Antibodies 
Antibodies are protein molecules, known as immunoglobulins, synthesised by the 
immune cell of an animal in response to a foreign macromolecule known as an antigen 
(Farid, 2006). Monoclonal antibodies (MAbs) are pure populations of antibodies that 
recognise and attack the same molecular target. They are produced by a population of 
immune cells (B lymphocytes) derived from the same parent cell. MAbs began to be 
widely applied in research and development following the development of hybridoma 
technology in mice by Kohler and Milstein in 1975 for their large-scale production 
(Gombotz and Shire, 2010).  
Recently, MAbs have become one of the fastest growing classes of all 
biopharmaceuticals, with a total of 26 therapeutic MAbs approved in 2007 in the US by 
the Food and Drug Administration (FDA). These had a market value of more than 
$12,612 million (Gombotz and Shire provide a list of all the commercial MAb products 
approved in the U.S) (Gombotz and Shire 2010). The global market for therapeutic and 
diagnostic MAbs increased from $26 billion in 2006 to an estimated $31 billion in 2007. 
This upward trend continued in 2009 and 2010. For example Fig. 2.2 shows a pie chart 
of US sales of nine biotherapeutics drug categories, and table 2.1 shows data for the 
sales and the growth rates of the nine drug categories between 2009 and 2010 
(Aggarwal, 2011).  
 
Fig. 2.2 indicates that MAbs remained the best-selling class of biologics and in 2010, 
US sales of MAb products reached ~$18.5 billion, 9.7% higher than 2009 sales. The 
table indicates that MAbs and enzymes are the drug categories that showed the fastest 
growth rate during that period. The global market for MAbs is expected to top $56 
billion by the end of 2012 which represents a compound annual growth rate of 13% 
(Bccresearch, 2008). Projections for the next five years (2012 to 2017) suggest that 
MAbs are expected to be the biggest drivers in the global biopharmaceutical market. 
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This is mainly a consequence of the rich late stage pipeline and a strong uptake from 
both developed and emerging markets (Imarcgroup, 2012). MAbs play a major role in 
treating a wide variety of diseases including cancer, infectious disease, allergy, 
autoimmune disorders and inflammation. MAbs are produced in the following main 
forms: murine (100% mouse protein); chimeric (approximately 65% human and 35% 
mouse protein); humanised (95% human and 5% mouse protein); and fully human 
(100% human protein) (Gombotz and Shire, 2010). 
 
 
       Figure 2.2: A pie chart showing US sales of nine biotherapeutics drug categories 
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$10.20 
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$1.20 $0.80 
$1.20 $0.40 
MAbs
Hormones
Growth factors
Cytokines
Fusion proteins
Therapeutic enzymes
Recombinant vaccines
Blood factors
Anticoagulants
  2009 
sales ($) 
2010 
sales ($) 
2009 growth 
rate (%) 
2010 growth 
rate (%) 
MAbs 16.9 18.5 8.3 9.7 
Hormones 9.8 11.0 14.7 12.3 
Growth factors 10.4 10.2 -9.1 -2.0 
Cytokines 3.9 4.1 6.8 4.6 
Fusion proteins 3.9 4.0 1.1 4.5 
Therapeutic enzymes 1.1 1.2 -4.2 4.9 
Recombinant vaccines 0.7 0.8 -37.0 13.0 
Blood factors 1.3 1.2 5.0 -2.6 
Anticoagulants 0.3 0.4 -1.2 7.9 
 
 
 
Table 2.1: The table shows the growth rates of the categories between 2009 and 
2010 (data obtained from Aggarwal, 2011) 
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2.4.2.  Challenges with Monoclonal Antibody Development 
The first therapeutic MAbs to be produced, Orthoclone (an immunosuppressant drug 
against kidney transplant rejection) had little success as far as commercialisation was 
concerned. Clinical trials failed as patients who received infusions of the early 
therapeutic MAbs developed immune responses against the administered product. Such 
products were also rapidly destroyed by the liver even before they could reach their 
therapeutic target (Ezzell et al., 2001). This behaviour could be attributed to the fact that 
MAbs were made with hybridoma technology and were of mouse origin. The human 
immune system recognises these as being foreign and generates human anti-mouse 
antibodies (HAMA response) against the administered products. 
 
The therapeutic properties of MAbs strongly depend on their glycosylation pattern. 
Most of the currently approved MAbs are produced in mammalian cell lines, as they 
have the propensity to express proteins with almost human-like glycosylation. 
Moreover, the advancement of humanisation technology has facilitated the 
incorporation of murine (mouse) residues complimentarity determining regions 
(responsible for antigen binding) into a human antibody framework giving rise to 
antibody sequences with up to 90–95% human content (Gombotz and Shire, 2010). For 
example, a humanised MAb drug, mogamulizumab (Poteligeo®), with engineered 
glycosylation to enhance the pharmacological properties - designed to treat cancer - has 
recently been approved globally. This is the first glyco-engineered antibody to reach the 
market in the field of therapeutic antibodies (Subramaniam et al., 2012). 
 
2.5.    Mammalian Cell Cultures for production of MAbs  
2.5.1.  Introduction 
The cultivation of mammalian cells in vitro (for example as suspension culture in 
bioreactors) is known as mammalian cell culture. It has evolved from an experimental 
science in the 20
th
 century to a modern quantitative science in recent times. It has seen 
wide application in terms of research and development in the industrial, academic and 
medical fields (Kretzmer, 2002). Mammalian cell culture has been applied in the areas 
of cell and molecular biology, providing reproducible model systems in which the 
physiology and biochemistry of the cell can be studied; the area of medical sciences for 
efficacy and toxicological assessment of potential new drugs; and for the large scale 
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production of biotherapeutics including vaccines, recombinant proteins and monoclonal 
antibodies. 
 
2.5.2.   Chinese Hamster (CHO) Ovary Cell 
There are some key issues that affect the choice of a mammalian cell line for use in a 
large scale manufacturing process during therapeutic MAb production. These include 
the capability of attaining high product yield; the ability to produce post-translationally 
modified products which impact on the pharmacokinetic and pharmacodynamic 
properties of the product (solubility, stability and therapeutic efficiency, time taken to 
be cleared from the body); the ability to be amenable to genetic manipulation to easily 
accommodate a foreign DNA; the ability to rapidly and consistently produce safe 
products; and the ability for the cells to adapt and grow in suspension cultures is an 
important characteristic which enables volumetric scalability and use of large stirred-
tank bioreactors (Jayapal et al., 2007).  
 
CHO cell lines meet these criteria and have become the most widely applied 
mammalian cell line industrially, for the large-scale production of therapeutic MAbs, 
from a range of alternative cell lines including NS0, BHK-12, mouse myoloma cell line 
(SP2/0), human embryonic kidney (HEK-293) and human-retina-derived cell line (PER-
C6). Fig. 2.3 shows that the majority of therapeutic Mabs approved globally in 2012 
were produced in CHO cell lines. Of the 30 MAbs that were approved and licenced 
globally as of March 2012, 12 (40%) were produced in CHO cells, whilst 7 (23%) were 
produced in SP2/0 cells, 5 (17%) were produced in NS0 cells, 2 (7%) were produced 
using hybridoma technology and 2 (7%) in E. coli (Reichert, 2012). Moreover, there are 
derivatives of CHO cell lines, (for example dhfr
-
 CHO) deficient in their ability to 
produce the dihydrofolate reductase enzyme (DHFR), an essential enzyme which 
catalyses the conversion of folate to dihyfrofolate (Simonsen and McGrogan, 1994). 
Hence a well-established expression vector (the dihydrofolate reductase (DHFR) 
expression vector system) can be used as a basis to develop platform technologies 
which allows for the transfection, amplification, selection and expansion of high 
producing and stable CHO cell clones based on this property (DHFR deficiency).   
 
Another vector system based on an amplifiable gene, glutamine synthetase (GS) is an 
alternative to DHFR system that provides a well characterised platform technology 
     Biopharmaceutical Therapeutics 
 
24 
 
usable in CHO cell lines, providing them with an added advantage over other cell lines. 
GS is a dominant selectable marker that can be used with GS-negative and positive NS0 
cells and provide a possibility of gene amplification (Birch and Onakunle, 2005). The 
next section provides a brief description of the production of therapeutic MAbs in a 
typical CHO cell suspension culture system. 
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2.6. Production of Recombinant Therapeutic Monoclonal Antibodies 
by Mammalian Cells in Suspension Culture  
2.6.1. Cell Line Development 
There is a general format that is typically used in producing a recombinant protein in a 
stirred, serum-free culture beginning from a recombinant vector (plasmid) and a 
mammalian host cell line. This format was used at Lonza Biologics in producing the 
MAb, Immunoglobulin G (IgG), using a CHO cell line generated in-house (Lonza 
Biologics, Slough, UK). The development of a manufacturing process for a recombinant 
therapeutic MAb follows a well-established procedure. In this project, the 
manufacturing process was carried out in accordance with established procedures 
explained in detail in Chu et al. (2005), in Smales and James, (2005). Details of the 
materials, reagents and protocols involved are provided in Chu et al., (2005). Cell line 
development was carried out in this project and samples were collected for MALDI 
analysis as described in section 3.3.6.2.  
 
2.7.    Enhancing Productivities of Recombinant proteins in 
Mammalian Cell Cultures 
2.7.1. Introduction 
As previously mentioned mammalian cells are the host of choice for production of 
biotherapeutics with human-like post-translational modification. However, they are 
slow, expensive and productivities are low when compared to bacteria and yeast 
expression systems. The well-established scheme for cell line development during the 
manufacturing process used at Lonza Biologics in producing the MAb, IgG has 
described in section 2.6. Although this has provided the opportunity for optimisation of 
medium composition and high-producing cell line screening which has delivered 
significant increase in volumetric product titres over the past decades, there has been 
little increase in spectfic productivity (qP) since 1990 (Dietmair et al., 2012). 
  
Mammalian cell line engineering with superior growth characteristics, and optimised for 
the production of high concentrations of proteins, has been noted to significantly reduce 
the development time for a high productivity cell line. Consequently, significant effort 
has been invested in using various genetic engineering strategies to improve those 
aspects of the cell line related to product titres. For example aspects of the cell line such 
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as delaying apoptosis, enhancing the cell’s processing capacity, increasing the rate of 
cell proliferation, and increasing the cell’s metabolic efficiency have been carried out 
(Mohan et al., 2008; Schroeder, 2008; Lim et al., 2010).  
 
In this respect, an approach to identifying protein biomarkers whose genes may act as 
potential genetic engineering targets as well as serving as a basis to identifying high 
producing cell lines earlier in process development is presented in this thesis (chapter 
7). Genetic engineering and the selection of high producing cell lines would enable the 
optimisation of protein production at high concentrations. New cell lines with optimised 
growth and productivity properties (potentially capable of producing high yields of 
MAb products) can be created by manipulating the genes in the cells that are 
responsible for controlling growth and productivity. Selecting only high producing cell 
lines will also have the benefits of potentially providing high yields of MAb products. 
Before this approach is presented, it is important to review some of the strategies for 
improving mammalian cell line productivities that have already been proposed in the 
literature. 
 
2.7.2. Review on Enhancing Productivities of Recombinant proteins in 
Mammalian Cell Cultures 
Methods currently applied for improving the large-scale production of heterologous 
proteins from mammalian cell lines include optimisation of the cell culture 
environment, bioprocess design and improving expression vectors through genetic 
engineering (Bebbington et al., 1992; Zhou et al., 1997; Fussenegger et al., 1998; Ibarra 
et al., 2003). Bebbington et al., (1992) reported a method in which transfectants were 
selected in terms of growth in a glutamine-free medium using the glutamine synthetase 
(GS) selectable marker. cDNA amplification as well as selection for transfectants was 
subsequently carried out using the specific inhibitor of GS, methionine sulfoximine. 
DNA sequences encoding a chimeric IgG4 antibody were expressed in NS0 cell line 
transfected with cDNA vectors controlled by human cytomegalovirus major immediate 
early (hCMV-MIE) promoters. High levels of productivities of up to 560 mg/L antibody 
were observed.  
 
In another study Fussenegger et al., (1998) saw an increase in qP by decreasing the cell 
specific growth. In this study they reprogrammed the regulatory complex involved in 
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the CHO cell cycle by blocking proliferation at high cell densities leading to an 
extended period of high production. This led to a 10–15 times increase in the production 
of the heterologous protein, secreted alkaline phosphatase. Alternatively, rather than 
causing the cessation of cell proliferation, Ibarra et al., (2003) instead increased 
productivity by inducing the overexpression of anti-apoptotic genes, which 
overexpresses proteins against apoptosis (programmed cell death). An NS0 cell line, 
which expressed a chimeric IgG4 antibody, was further engineered to constitutively 
overexpress the anti-apoptotic proteins (Bcl-2 and p21CIP1). Effects of overexpression 
of these anti-apoptotic proteins on cell proliferation, cell viability, and antibody 
production were investigated in batch and continuous perfusion cultures, and mixed 
results were obtained. Mutant Bcl-2 expression did not show any significant 
improvement in cell viability of arrested cells. In contrast, p21CIP1 protein arrested cell 
proliferation, and gave a 4-fold increase in antibody production, the mutant Bcl-2 had 
observed change in cell viability. 
 
2.8. Summary 
As the demand for biotherapeutics continues to increase, there is the need for this to be 
matched by increased global large-scale recombinant protein production. There are a 
wide range of expression systems available for large-scale recombinant protein 
production, with the most commonly used ones being bacteria, insect cells, yeast, and 
mammalian cell based systems including  CHO, NS0, BHK-12. The choice of 
expression system for the production of a recombinant protein is influenced by a 
number of factors. All the expression systems have some advantages as well as 
limitations which must be considered before selecting the most appropriate one. The 
factors include cost, yield, propensity for post-translational modification and the 
economics of scale-up. Mammalian cell lines are considered to be the ideal eukaryotic 
expression system for the production of biotherapeutics as they are capable of producing 
proteins with posttranslational modification patterns closest to those in humans. Proteins 
with glycosylation patterns not resembling those found in higher mammals will not 
work in humans therapeutically, hence failing to fulfil the very purpose for which they 
were manufactured.  
Therapeutic MAbs have become one of the fastest growing classes of all 
biotherapeutics, expecting to top $56 billion by the end of 2012 representing a 
compound annual growth rate of 13% (Bccresearch, 2008). Advances in technology as 
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well as the increased global capacity of mammalian cell culture have made the latter the 
most utilised system for large-scale commercial manufacture of therapeutic MAbs. 
Although there are numerous mammalian cell lines that can serve as suspension cultures 
in bioreactors (for example NS0, BHK, SP2/0, CHO, and PER-C6) CHO cell lines have 
emerged as the cell line of choice industrially, for the large-scale production of 
therapeutic MAbs. Compared to others, CHO cell lines have the advantage of well-
established expression vector systems (the DHFR and GS systems) with platform 
technologies that allow for the transfection, amplification, selection and expansion of 
high producing and stable CHO cell clones.  
During the production of a recombinant protein in a stirred and serum-free culture, cell 
line development (involving transfection, amplification, selection and expansion of cell 
lines) is very important for generating high producing cell lines with the potential to 
increase productivity. However, cell line development times are usually long (about 14 
weeks) and there has not always been an increase in qP after successful screening and 
selection of high producing cell lines.  
 
Methods such as optimisation of the cell culture environment, bioprocess design and 
expression vector genetic engineering are currently being applied to improve the large-
scale production of recombinant proteins therapeutics from mammalian cell cultures. 
Specifically, emphasis has been placed on using various genetic engineering strategies 
to improve cell line product titres. Cellular aspects including delaying apoptosis, 
increasing the rate of cell proliferation, and increasing the cell’s metabolic efficiency 
have been assessed and manipulated to engineer useful variants of cell lines. However 
these have had mixed results where an increase in productivity is not guaranteed for all 
the cell lines. This suggests that the understanding of molecular details of mammalian 
cells is limited, and the ability to isolate cell lines and eventually identify potential 
genetic engineering targets will come from a better understanding of the cell’s 
phenotypic biology. 
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3. Mass Spectrometry  
3.1. Overview 
In chapter 2, the production of therapeutic proteins in mammalian cell cultures was 
discussed along with a literature review of some of the genetic engineering strategies 
that have been used to modify cell lines with the aim of enhancing cellular productivity. 
Mixed results were obtained with only a few studies reporting significant improvements 
of productivity. This suggests that more genes that can be manipulated by genetic 
engineering may be required. Furthermore, the ability to isolate cell lines and eventually 
identify potential genetic engineering targets will require a better understanding of the 
cell’s phenotypic biology. The area of highthroughput data-rich biology is termed “-
omics” and include proteomics, transcriptomics, genomics and metabolomics. These 
approaches can be used to study the overall biology of a cell and they have played a 
major role in providing knowledge in the biological sciences. Examples of such 
techniques include two-dimensional gel electrophoresis (2-D-PAGE) and mass 
spectrometry used for proteomic profiling. 
 
In this chapter, the mass spectrometry technique of matrix assisted laser 
desorption/ionisation time-of-flight mass spectrometry (MALDI-ToF MS) is 
introduced. The chapter begins with an overview of mass spectrometry with specific 
emphasis on describing the MALDI-ToF mass spectrometer. A description of how the 
MALDI-ToF MS instrument was used to collect data from E. coli cultures at different 
growth phases as well as from the IgG monoclonal antibody- producing CHO cell lines 
during culturing. Aspects relating to mass spectrometry data preprocessing are also 
discussed and preprocessing results from the aforementioned spectral data sets are 
reported. Finally, the chapter concludes with a review of applications of mass spectra 
data preprocessing. 
     MALDI-ToF Mass Spectrometry  
 
31 
 
3.2. Introduction 
Over the years, advancements in the field of proteomics have led to the development of 
a number of analytical techniques based primarily on chromatography and 
electrophoresis, including 2-D PAGE, two-hybrid analysis, high performance liquid 
chromatography (HPLC), and protein microarrays. This toolkit of techniques, have been 
developed to a high technical standard, but are inappropriate with respect to selectivity, 
sensitivity, cost-efficiency ratio, accuracy and speed (McGuire et al., 2008). The ability 
of mass spectrometry (MS) to meet these demands and handle the complexities 
associated with the proteome has led to its increased popularity (Han et al., 2008).  
 
MS is a microanalytical technique used for the identification of unknown compounds, 
quantification of known compounds, and for helping understand the structure and 
chemical properties of a given analyte. The basic principle of MS is the experimental 
measurement of the mass (in terms of mass-to-charge (m/z) ratio) of gas-phase 
molecular ions produced from the molecules of a sample. Unique features of MS 
include its ability to directly determine the nominal mass of a sample, and to produce 
and detect fragments of the molecule that correspond to discrete groups of atoms of 
different elements that reveal structural features (Watson and Sparksman, 2007).  
 
The fundamental basis of MS is a mass spectrometer with the data generated termed 
mass spectrum. The components of a mass spectrometer are: (i) a sample inlet (ii) an ion 
source, (iii) a mass analyser, (iv) a detector and (v) a software system to store and 
analyse data (Fig. 3.1). From Fig. 3.1, the full meanings of the abbreviations are APCI 
(atmospheric pressure chemical ionisation), AP-MALDI (atmospheric pressure 
MALDI), CI (chemical ionisation), ESI (electrospray ionisation), FI (field ionisation), 
and LSIMS (liquid secondary ion mass spectrometry). 
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The sample to be analysed is introduced into the ionisation source of the instrument. 
Sample molecules are then ionised into gaseous ions through the application of electric 
and magnetic fields. These ions are accelerated and transferred into the analyser region 
of the mass spectrometer where they are separated according to their individual m/z 
ratios. The separated ions are detected and this signal is sent to the data system where 
the m/z ratios of the ions are stored together with their relative abundance (Bergquist et 
al., 2007). The vacuum system removes molecules thereby providing a collision-free 
path for the ions from the ion source to the detector. The software system coordinates 
the functions of the individual components and records and stores the data in the format 
of a mass spectrum (Watson and Sparksman, 2007). A mass spectrum is a pattern 
representing the distribution of molecular ions by m/z ratio in a sample, with the length 
of each m/z ratio peak representing the relative abundance (intensity) of the molecular 
ion. Fig. 3.2 is an example of a MALDI-ToF mass spectrum from a CHO cell line (a) 
and an E. coli cell sample (b). 
Figure 3.1: A conceptual illustration of the mass spectrometer showing the various 
components 
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3.3. Matrix-assisted Laser Desorption/Ionisation Time-of-Flight 
(MALDI-ToF) Mass Spectrometry  
3.3.1. Introduction to MALDI 
When first introduced to mass spectrometry, lasers were directly applied to the analyte 
without the use of a matrix, an organic compound within which the analyte is embedded 
prior to analysis. In the 1960s, a technique called laser desorption (LD) used ultra violet 
(UV) lasers to transfer energy and ionise the analyte through electron excitation (or 
vibrational excitation when infrared (IR) lasers were used) (Watson and Sparksman, 
2007). The limitation of this was that as the lasers were applied with intense pulses for 
short durations, compounds with large molecular weights and those that were thermally 
labile could not be analysed. Applying the lasers directly led to destruction of the 
analyte. Previous experiments in resonant and non-resonant laser desorption had 
demonstrated that large molecules may be thermally dissociated upon energy transfer 
(Gantt et al., 1999). Furthermore, ions produced from molecules with masses greater 
than 500 Daltons (Da) were likely to undergo fragmentation. These limitations were 
overcome through the development of MALDI in the late 1980s (De Hoffmann and 
Stroobant, 2008). 
  
The MALDI technique was introduced principally by Karas and Tanaka in 1987, for 
which they were awarded part of the 2002 Nobel Prize in Chemistry (Watson and 
Sparksman, 2007). MALDI has since become a widespread and powerful source for the 
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Figure 3.2: Matrix-assisted laser desorption/ionisation time-of-flight (MALDI-ToF) mass spectra: 
(a) CHO cell line and (b) E. coli cell 
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production of intact gas-phase ions from a wide variety of large thermally labile 
compounds including proteins, oligonucleotides, synthetic polymers and large inorganic 
compounds. The routine technique for MALDI where the analyte is embedded in an 
organic matrix, as used today was developed by Karas and Tanaka as described in the 
following sections. 
 
3.3.2. Principles of MALDI 
The MALDI technique is a two-step process. In the first step, the sample is pre-mixed 
with a UV-light absorbing matrix solution, usually weak organic acids. The matrix-
analyte solution mixture is then dried to remove any liquid solvent. The result is a co-
crystal of matrix-analyte where the analyte molecules become incorporated into the 
matrix crystals so that they are completely isolated from one another. The second step, 
which occurs under vacuum conditions inside the ion source, involves irradiation of the 
matrix-analyte mixture with intense UV laser (337 nm) pulses. Fig. 3.3 is an illustration 
of the MALDI desorption ionisation process. The exact mechanism of the process is 
still not fully understood.  However, as shown in Fig. 3.3, one thought is that irradiation 
by the laser induces rapid heating of the co-crystals through the accumulation of a large 
amount of energy resulting in the vaporisation of the matrix. The analyte molecules 
within the co-crystal vaporise as well but without having to directly absorb energy (De 
Hoffmann and Stroobant, 2008). 
 
A number of chemical and physical processes for the formation of ions have been 
proposed including gas-phase photoionisation, excited state proton transfer, ion–
molecule reactions, and desorption of preformed ions. The most widely accepted ion 
formation mechanism involves proton transfer to the analyte molecules in the solid 
phase before desorption. Alternatively, it can be a gas-phase proton transfer to analyte 
molecules in the vaporised co-crystal complex from photoionised matrix molecules. 
Protein molecules are usually ionised by adding a proton (H
+
) to the molecule  (M) to 
create a singly charged protein molecular ion [M+H]
+
, but there may also be some 
doubly charged proteins [M+2H]
+
 (Fig. 3.3) (Watson and Sparkman, 2007). The ions in 
the gas phase are then accelerated by an electrostatic field towards the analyser. 
 
 
     MALDI-ToF Mass Spectrometry  
 
35 
 
 
 
 
 
 
 
 
3.3.3. Matrix 
The matrix which consists of an organic solid or liquid species, performs two important 
functions: (1) it absorbs photon energy from the laser beam and transfers it into 
excitation energy, and (2) it serves as a solvent for the analyte, so that the 
intermolecular forces are reduced and aggregation of the analyte molecules is kept to a 
minimum. Desirable attributes of a typical MALDI matrix are: 
 Strong light absorption at the wavelength of the laser flux. 
 The ability to form micro-crystals with the analyte. 
 A low sublimation temperature, which facilitates the formation of an instantaneous 
high-pressure plume of matrix-analyte material during the laser pulse duration. 
 The participation in a photochemical reaction so that the analysed molecules can be 
ionised to produce large amounts of ions. 
 
The matrix is usually a solution of organic molecules. However, when the matrix is in a 
solid form, the analyte and the matrix are mixed together in a mutually soluble organic 
solvent, and allowed to co-crystallise. The co-crystallisation of the analyte and the 
matrix is critical to the success of the MALDI experiment. Studies of protein ground up 
in a dry crystalline matrix failed to produce any spectra (Horneffer et al., 2006). The 
ratio of matrix molecule to analyte molecules are typically between 500:1 and 5000:1. 
This ratio ensures that the analyte molecules are diluted in the matrix hence separating 
the analyte molecules to prevent analyte-analyte molecular interaction during the 
ionisation process. Typically examples of MALDI matrices are α-cyno-4-
Figure 3.3: Diagram illustrating the ionisation principle of MALDI 
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hydroxycinnamic acid (CHCA), 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic 
acid), 3-amino-4 hydroxybenzoic acid and 2,5-dihydroxy-benzoic acid (DHB). 
 
3.3.4. The MALDI -Time-of-Flight (ToF) Mass Spectrometer 
The linear time-of-flight (ToF) analyser is the simplest analyser compared to others 
such as the reflectron and orthogonal acceleration analysers. It is widely used alongside 
the MALDI (the MALDI–ToF mass spectrometry platform). It has recently seen wide 
applications to electrospray as well as gas chromatography electron ionisation mass 
spectrometry (GC/MS). A MALDI instrument can be used in either linear or reflectron 
mode (Fig. 3.4). In linear mode (which is the focus of this thesis) the ions travel down a 
linear flight path and their m/z ratios are determined based on the time taken for the ion 
to reach the linear detector. A reflectron MALDI has an ion mirror at its end which 
reflects the ions back (at a slight angle) to the detector, into a different flight path. These 
deflected ions are detected at the level of the microchannel detector. Hence, this 
instrument is called a time-of-flight (ToF) instrument.  
 
The relationship that allows the m/z ratio to be determined is:  
 
                        
                                                             
 
 
(
 
 
)                                                       (3.1)   
Figure 3.4: Schematic representation of a linear or reflectron mode MALDI-ToF 
Mass Spectrometer 
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where E is the energy imparted to the charged ions as a result of the voltage that is 
applied by the instrument and, v, is the velocity of the ions along the flight path. Since 
all the ions are exposed to the same electric field, all similarly charged ions will have 
similar energies. Therefore, based on equation 3.1, heavier ions will have lower 
velocities and hence ions take longer to reach the detector because of their lower 
velocity, whilst the lighter ions will reach the detector first because of their greater 
velocity (Watson and Sparkman, 2007).    
 
The time for an ion to reach a detector from the source is given by equation 3.2, in 
which (t - to) is the time-of-flight for an ion from the source to the detector, m is the 
mass of the ion, z is the charge of the ion, d is the length of accelerating region in the 
electric field, L is the length of non-accelerating region without the electric field, and Vo 
is the potential of the electric field. 
 
       [
   
  
]
 
 
   [
 
    
]
 
 
                                               (3.2) 
  
After rearranging equation 3.2 for m/z ratio, the quadratic relationship between m/z ratio 
and ToF is apparent in equation 3.3. The constants a and b depends on the instrument, 
potential applied at the source, electric field, and length of the flight tube: 
                                     
                                                 
 
 
         
                                                      (3.3)                    
                                                                                              
The quadratic relationship between m/z ratio and ToF (equation 3.3) means that ions 
having the same m/z ratio will also have the same ToF and thus impact the detector at 
the same time. A cascade of secondary electrons is released when the ions strike the 
detector. This electron current is captured by an anode and converted to a voltage using 
a preamplifier. The resulting voltage is recorded by a digital storage oscilloscope or by a 
digitizer card in a computer, and the amplitude of the signal corresponds to the number 
of ions that struck the detector in each bin of ion flight time. Other sources of noise 
from physical and electrical components of the mass spectrometer are also recorded (for 
instance, high frequency noise) (Shin and Markey, 2006). After the instrument is 
calibrated with compounds of known mass, the constants in the quadratic equation 3.2 
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relating time to m/z ratio are determined, and the m/z ratio of the detected ions are 
calculated (section 3.3.6.1) (Watson and Sparkman, 2007). 
  
3.3.5. Advantages of MALDI-ToF MS 
MALDI-ToF was used in this thesis for biomarker studies because of its various 
advantages. Firstly, it is more sensitive than other laser ionisation techniques and the 
matrix separates single analyte molecules from each other and minimises the 
aggregation due to a large excess of matrix molecules. Furthermore, energy is 
transferred from the matrix molecules to the analyte molecules to help them to ionise. In 
this way, the energy imparted by the laser is absorbed and retained by the matrix 
molecules. This prevents the analytes from dissociation and increases the efficiency of 
energy transfer from the laser to the analyte leading to an increase in sensitivity 
(Harrington et al., 2006).  
 
Generally, MALDI-ToF is considered a soft ionisation technique, that is, there is little 
or no fragmentation of the protonated ions formed during the MALDI process. This 
absence of fragmentation is a key advantage of MALDI-ToF MS compared to other 
classical mass spectrometry proteomic approaches such as electrospray ionisation (ESI) 
MS (Bergquist et al., 2007). Since MALDI has the inherent advantage that most ions 
are singly charged, the mass of the molecular ion usually is equal to the m/z ratio and 
each analyte typically only produces a single ion type. By recording the ToF, the mass 
of the molecular ion (MH
+
) and hence peptide/protein can be directly determined. This 
makes it particularly appealing for protein biomarker discovery and identification. The 
experimental molecular weights (MWs) of MALDI protein molecular ions can be 
matched against sequence MWs of organisms with sequenced genomes, directly 
identifying the protein (chapters 6 and 7). 
  
MALDI is also more widely applicable than the other laser ionisation techniques. 
Adjusting the wavelength to match the absorption frequency of each analyte is not 
required since it is the matrix that absorbs the laser pulse. Furthermore, because the 
process is independent of the absorption properties and size of the compound to be 
analysed, MALDI allows the desorption and ionisation of analytes with very high 
molecular mass including those in excess of 100 000 Da. For example, MALDI allows 
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the detection of femtomoles of proteins with MWs of up to 300 000 Da (De Hoffmann 
and Stroobant, 2008). 
 
3.3.6. MALDI-ToF Data Analysis 
In this thesis two case studies were carried out involving the use of MALDI-ToF mass 
spectrometry. In the first case study Escherichia coli (E. coli) K-12 cells were grown in 
culture and samples were collected when the cultures reached exponential, stationary 
and decline phases. Cell pellets prepared from the samples collected were subjected to 
MALDI-ToF mass spectrometry analysis. In the second case study, IgG monoclonal 
antibody Chinese hamster ovaries (CHO) cell lines (Lonza Biologics, Slough, UK) were 
harvested during cell line development. Samples were then prepared for MALDI-ToF 
analysis. The sample preparation procedures as well as the MALDI-ToF analysis are 
described in the following sections. 
 
3.3.6.1. MALDI-ToF Analysis E. coli K-12 cells in different growth phases 
Intact Cell Pellet Sample Preparation: Cell pellets to be analysed that had been stored 
under -70
o
C were re-suspended in 300µl distilled water, followed by the addition of 
900µL of pure ethanol to give a final ethanol concentration of 75%. The suspension was 
mixed thoroughly by vortexing. A two-layer method was used for matrix/analyte 
sample preparation. In this two-layer method, 1µL of suspension from the previous step 
was deposited onto a sample spot of a MALDI target plate (MSP 96 target, ground 
steel; Bruker Daltonics, Germany) and was allowed to air-dry at room temperature. 
Finally, 1μL of the saturated sinapinic acid (SA) matrix solution was deposited onto the 
dried sample and allowed to dry at room temperature for co-crystallisation to take place. 
At this stage, the plate was ready for MALDI analysis. For the matrix preparation, SA 
(20 mg/mL), was prepared fresh by weighing 10mg of the SA powder and dissolving in 
500µL of 40:60 ACN/TFA (0.1%, v/v). This was mixed thoroughly and sonicated for 
15 minutes, then vortexed to mix and completely dissolve all traces of powder. The 
saturated solution was then ready for use.  
 
Cell Lysate Sample Preparation: The ethanol suspension was made, as described for 
the intact cell pellet sample preparation procedure. Fifty microlitres of 70% formic acid 
was added to the pellets and mixed well.  This was followed by the addition of 50µL 
pure acetonitrile and centrifuged at 17949 × g for 2 minutes.  One-microlitre of the 
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bacterial lysate was spotted onto a sample spot of a MALDI target plate and overlaid 
with 1μL of the saturated SA matrix solution. This was allowed to dry at room 
temperature and was then ready for MALDI-ToF analysis. All the bacterial suspensions 
were prepared on the same day. 
 
Instrumentation and Data Analysis 
The mass spectra were acquired with an Ultra Flex MALDI-ToF mass spectrometer 
(Bruker Daltonics, GmbH, Germany) (Fig. 3.5), based in the School of Biosciences, 
University of Kent, Canterbury, Kent, UK. Before the samples could be analysed, a 
series of cell pellet samples were first spotted onto the MALDI plate and used as test 
samples for instrument optimisation studies. During optimisation, the parameter settings 
of the instrument were modified to identify the combination of parameters that would 
give visible and intense spectra signals with less noise. Factorial design was used with 
different MALDI-ToF parameters as design variables. Table A.1 of Appendix A shows 
the optimisation results. Based on the results of instrument optimisation, the following 
parameters were set in the mass spectrometer for MALDI spectra acquisition: 
accelerating voltage 24.24 kV, a pulse ion voltage 88% (21.23 kV) of the total 
accelerating voltage, a laser firing rate of 20 Hz, a delayed extraction time of 300 ns, a 
lens voltage of 5.5kV, matrix suppression 2 kDa, and a linear detector voltage of 1.681 
kV. The instrument was controlled by FlexControl v2.4 (Bruker Daltonics), operated in 
positive polarity and linear mode targeting a mass range of 2,000 – 30,000 m/z ratio. 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.5: Schematic diagram to illustrate the MALDI spectra data collection 
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MALDI data acquisition was performed manually. Five single composite spectral scans 
were acquired from each sample spot, which were summed to give a 6
th
 spectrum. Each 
composite spectra scan was the average of 20 single laser shots fired from the same 
location. Once the signal was depleted (that is, areas in sample consumed due to the 
laser irradiation), a new scan position was selected manually. As shown in Fig. 3.6, each 
of the 6 groups of sample was spotted 20 times to obtain sufficient spectra for data 
modelling. The samples were named as di (intact cell pellets for cultures at decline 
phase), mi (intact cell pellets for cultures at mid-log or exponential phase), si (intact cell 
pellets for cultures at stationary phase), dl (cell lysate for cultures at decline phase), ml 
(cell lysate for cultures at exponential phase), and sl (cell lysate for cultures at stationary 
phase).  So for each of the 20 spots per sample, 6 spectra per MALDI spot (5 single and 
1 sum), 120 spectra were obtained to give a total of 720 spectra for the six samples. 
After data acquisition, the raw mass spectra data were saved and exported as text files. 
 
Instrument Calibration 
Before MALDI analysis, external mass calibration was used to calibrate the instrument. 
The calibrant used as a standard was a protein mixture containing insulin (MW 5,735), 
ubiquitin (MW 8,566), cytochrome C (MW 12,361), myoglobin (MW 16,952) and 
myoglobin (MW 8,477) (Bruker Daltoniks, Germany), all covering the mass range 
4,000 - 20,000Da. About 50µL of SA was pre-mixed with calibrant by pipetting up and 
down until the solution became cloudy. The solution was kept ready for use. About 1µl 
of calibrant was spotted onto of the MALDI target plate onto six specific sample spots 
surrounded by 20 spots containing samples to be analysed (Table A.2, Appendix A). 
The instrument used the conventional three-term calibration equation as follows:  
 
                                 2/32
2/1
1 )/()/( zmCzmCCToF o                                     (3.4) 
where, Co represents any internal delay in the acquisition system, C1(m/z)
1/2
 is the time-
of-flight (ToF) of an ion with zero initial velocity from the target surface to the detector, 
and  C2(m/z)
3/2
 is a small flight time correction for the ion velocities at the onset of the 
extraction pulse (Moskovets & Karger, 2003). As can be seen from Tables 3.1 and 3.2 
the ToF of the molecular ions (with their accurately known reference masses) recorded 
by the instrument were used to calculate the constants C0, C1 and C2 from equation 3.4. 
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Fit result 
Equation terms Values 
C0 425.47 
C1 1256359.66 
C2 0.00 
Initial ppm 1500.00 
Result ppm 266.81 
Calibration result 
Ions Reference 
mass 
Current 
mass 
Error (100 
ppm) 
Insulin [M+H]
+ 
avg 5734.52 5736.51 347.28 
Ubiquitin [M+H]
+ 
avg 8565.83 / / 
Cytochrome C [M+H]
+ 
avg 12360.97 12357.95 -244.03 
Myoglobin [M+H]
+ 
avg 16952.31 16955.55 191.00 
Cytochrome C [M+2H]
2+ 
avg 6181.05 / / 
Myoglobin [M+2H]
2+ 
avg 8476.66 8474.45 -261.00 
Table 3.1: Linear calibration information for E. coli cell lysate samples 
Fit result 
Equation terms Values 
C0 427.10 
C1 1259863.64 
C2 0.00 
Initial ppm 1500.00 
Result ppm 250.20 
Calibration result 
Ions Reference 
mass 
Current 
mass 
Error (100 
ppm) 
Insulin [M+H]
+ 
average (avg) 5734.52 5735.97 252.43 
Ubiquitin [M+H]
+ 
avg 8565.83 / / 
Cytochrome C [M+H]
+ 
avg 12360.97 12356.47 -364.45 
Myoglobin [M+H]
+ 
avg 16952.31 16956.02 218.91 
Cytochrome C [M+2H]
2+ 
avg 6181.05 / / 
Myoglobin [M+2H]
2+ 
avg 8476.66 8476.01 -77.03 
Table 3.2: Linear calibration information for intact E. coli cell samples 
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The calibration molecular ions were a singly charged protonated molecules of insulin, 
ubiquitin, cytochrome C and myoglobin, and doubly charged protonated molecules 
cytochrome C and myoglobin. The constants were then used to calculate the current 
masses of the molecular ion to generate a calibration. The ToF of molecular ions from 
samples analysed by the instrument are subsequently converted to m/z ratio via the 
calibration (equation 3.3). The error given in parts per million (ppm) is the difference 
between the reference and current masses of the calibration molecular ions. The mass 
accuracy in the instrument was 100 ppm, i.e., for the proteins, experimental MW masses 
should be within 0.01% of their theoretical MWs (+/- 1 mass unit for 10,000 MW 
protein. After performing the calibration, the spectra were preprocessed in order to 
remove systemic errors. 
 
3.3.6.2. MALDI-ToF Analysis of IgG Monoclonal Antibody Producing CHO Cell 
Lines 
Sample Preparation for MALDI-ToF Analysis  
Samples were prepared in accordance with protocols determined by collaborators of this 
project at the School of Biosciences, University of Kent, UK. Aliquots of required 
volumes of intact cells (0.5×10
6
 cells) from exponential cultures in 96 deep well plate 
(DWP) were pelleted in microfuge tubes using a centrifuge at 956 × g for 5 minutes. 
The supernatant was removed and 1mL of ice-cold PBS buffer was added to the cell 
pellet, with gentle pipetting up and down to resuspend cells. Cells were centrifuged at 
3000 rpm for 5 minutes again and the PBS buffer was removed. Cell pellets were then 
resuspended in 0.35M of sucrose (previously prepared and stored at -20
o
C) with gentle 
pipetting up and down. The cell samples were kept in an ice bath in-between the 
washing steps and centrifugation. Finally, after another round of centrifugation, at956 × 
g for 5 minutes, the cell pellets were transferred to -70
o
C.  
 
Sinapinic acid (SA, Sigma; 20 mg/mL), was prepared fresh for 20 samples, by 
dissolving in 1.2mL of buffer and made up with buffer. This was mixed thoroughly and 
sonicated for 15 minutes in a water bath. The matrix solution was spun at 956 × g for 5 
minutes after which 50µL of the solution was added to each cell pellet sample which 
had been removed from -70
o
C, and allowed to reach room temperature. Cells were then 
re-suspended in the sinapinic acid solution by pipetting up and down in order to 
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dislodge clumps of cells. All samples were then transferred to 4
o
C and left for 3hours 
prior to spotting (1µL of sample each) on the MALDI plate.  
 
A two-layer method was used for matrix/analyte sample preparation to spot the sample 
for MALDI analysis. In this two-layer method, 1µL of sample suspension was deposited 
onto a sample spot of a MALDI target plate (MSP 96 target, ground steel; Bruker 
Daltonics, Germany) and was allowed to air-dry at room temperature. Finally, 1μl of the 
saturated SA matrix solution was deposited onto the dried sample and allowed to dry at 
room temperature for co-crystallisation to take place. The plate was ready for MALDI 
analysis. MALDI data analysis was carried out as explained in section 3.3.6.1. 
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3.4. Mass Spectra Data Preprocessing 
3.4.1. Introduction 
A MALDI-ToF mass spectrometry (MS) instrument generates a mass spectrum with 
each being the result of two measurements, m/z ratio and intensity, that is corrupted by 
noise due to data acquisition issues. The first step in the analysis is to preprocess the 
spectra to remove systematic noise and bias while preserving the information content 
inherent within the profiles. The goal of preprocessing is to take the MS proteomic data 
set, and generate a data set whereby statistical techniques can be applied. 
Issues with the data acquisition can be divided into two areas: 
 Flawed experimental technique. This includes samples prepared utilising 
different procedures, spectra data sets not acquired randomly to minimise 
systematic errors; and comparing spectra acquired with different MALDI 
instruments. In this situation the experimental processes need to be addressed 
(Baggerly et al., 2004). 
 Instrument miscalibration, noise, and variation in sensitivity. Problems 
associated with these issues can be minimised by applying preprocessing 
methods described in this section (Monchamp et al., 2007).  
Preprocessing aims to consider the issues of (i) reducing noise (ii) reducing the amount 
of data, and (iii) ensuring the spectra are comparable. 
  
Preprocessing of mass spectra includes a number of techniques including signal 
resampling, baseline correction, m/z ratio alignment, intensity normalisation 
smoothing/filtering, and peak identification (Hilario and Kalousis, 2008; Monchamp et 
al., 2007). However, these tasks are inter-related and different combinations may have 
to be tested to identify an acceptable procedure. A good preprocessing method should 
be able to eliminate differences between spectra profiles as a consequence of 
experimental and instrumental procedures, while preserving the inherent biological 
information within the spectra profiles (section 3.6). A number of techniques for 
MALDI-ToF MS data preprocessing have been described in the literature and the 
sequence has been proposed by Monchamp et al., (2007) (Fig. 3.6). In this thesis, the 
proprocessing techniques are applied using functions from the Bioinformatics Toolbox 
of MathWorks.  
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3.4.2. Signal Resampling 
As proposed by (Monchamp et al., 2007), resampling is the first preprocessing 
technique to be performed. Resampling is the process of calculating a new signal with 
intensity values at selected m/z ratio points. By selecting m/z ratio points, the signal can 
be down-sampled (fewer points than the original signal), up-sampled (more points) or 
synchronised (approximately the same amount of points).  
 
Resampling can be used to create a constant scale for the m/z ratio values, allowing for 
the comparison of different spectra utilising the same reference m/z ratio vector and the 
same resolution. Unequal spacing of the m/z ratio values can occur (due to random and 
systematic errors) with the same instrument or when different instruments are used to 
generate the spectra. Resampling has several advantages: 
 
Signal resampling
Baseline correction
Spectral alignment
Normalisation
Smoothing
Peak identification
Figure 3.6: Typical preprocessing task workflow for mass 
spectra data (Monchamp et al., (2007)) 
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 During down-sampling, the m/z ratio vector can be converted into a vector with 
fewer data points, whilst preserving the information content of the spectra. This 
is important when working high-resolution data sets, as the quantity of data can 
be impractical to work with using computationally intensive algorithms. If the 
sampling rate is higher than the resolution of the instrument redundant values 
may become immersed in noise. These values may be removed by down-
sampling (Monchamp et al., 2007).  
 Resampling can be used to fill “missing” values. Abundances may be “missing” 
for certain m/z ratio values so resampling can provide a value. A mass 
spectrometer may have trouble detecting the weak signals of low-abundance 
peptides during MS experiments. Even when the signal is detected by the 
instrument, the peak intensities may be too low to be distinguished from 
background noise during data processing. Therefore, the lower the ion 
abundance, the more likely the peptide will be “missing” in the mass spectra 
data. Bias maybe introduced during subsequent analyses if these “missing” 
values are ignored. Filling the “missing” values helps when data needs to be 
visualised (Wang et al., 2006). 
 
Care must be taken when resampling the mass spectra profiles not to set the number of 
resampling units too low since information may be masked or removed due to the 
signals losing resolution. The ‘msresample’ function from the bioinformatics toolbox of 
MathWorks is used for resampling 
(http://www.mathworks.com/products/bioinfo/demos.html). With this function, the 
selection of the m/z ratio vector is carried out by down-sampling a raw mass spectrum to 
give an output spectrum with the spacing between the points increasing linearly within 
the specified range.  
 
Prior to down-sampling, the function prefilters the spectrum to prevent aliasing by using 
an antialias filter, a linear-phase finite impulse response (FIR) filter with least-squares 
error minimisation. Aliasing is a phenomenon whereby it is difficult to distinguish 
between high frequency and low frequency signals with the latter being mistaken for the 
former in the down-sampled spectra. The high frequency signals in MS data are mostly 
noise. The ‘msresample’ function automatically sets the cut-off frequency to a value 
equal to the minimum distance between two contiguous data points within the m/z ratio 
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vector range (MATLAB, 2008). This filter allows those frequencies below the cut-off 
frequency to remain unchanged while it suppresses those above the cut-off frequency.   
 
As an example, the effects of resampling on raw spectra data are shown in Fig. 3.7. Fig. 
3.7(a) and (b) shows a CHO cell line spectrum before and after down-sampling from 
24000 to 10000 bins. Note the change in the thickness of the plots as a result of a 
reduction in the number of m/z ratio data points by eliminating redundant ones, but the 
relative intensity pattern of the down-sampled spectrum (Fig. 3.7(b)) looks very much 
like the raw spectrum.  
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Figure 3.7: Mass spectra of CHO cell line samples illustrating the 
effects of resampling 
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Fig. 3.8(a) shows the process by which the ‘msresample’ function reduces original m/z 
ratio data points in a raw spectrum of an E. coli cell sample to a subset which is much 
easier to handle. The red spots and line in the graph represent the newly calculated m/z 
ratio data points that would best fit the original raw spectra data. The blue spots 
represent the original m/z points. Fig. 3.8(b) indicates the E. coli cell sample spectrum 
with the resampled m/z ratio data points. Note how the resampled spectra (Fig. 3.8(b) 
and Fig. 3.8(b)) still show variation in baseline after the number of data points has been 
reduced suggesting that baseline correction is required. 
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Figure 3.8: Mass spectra of E. coli cell samples illustrating the effects 
of resampling 
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3.4.3. Baseline Correction 
After signal resampling, baseline correction is applied on the data. Varying baseline is 
caused by chemical noise from sources such as the sample ion dispensing, matrix 
chemical contamination, and data collection. Baseline correction is applied after 
resampling as it uses spectra with aligned m/z ratio vectors.  
 
Observed mass spectra can theoretically be decomposed into three components 
(Guangtao and Wong, 2008); 
  
                                
                                                                                                                   (3.4) 
 
 
where f(i, j) is the observed value, b(i, j) is the baseline value, s(i, j) is the true signal 
and ε(i, j) is the noise for ith sample at jth m/z ratio. The baseline is considered to be the 
low frequency component of the observed signal. Baseline variation is especially 
significant at low peak intensities because the signal to noise ratio is larger. The 
consistent decrease in baseline exhibited by MS data may be caused by the interaction 
of the matrix material with itself as well as with the sample proteins, during the MALDI 
analysis. More specifically, the baseline originates from small clusters of the matrix 
material and since the likelihood of cluster formation decreases with cluster size, the 
baseline diminishes consistently with an increase in m/z ratio (Shin and Markey, 2006).  
 
Baseline correction estimates a low-frequency baseline, which is latent within the high-
frequency noise and signal peaks and then subtracts this baseline to give a baseline 
corrected spectrum. This is done in three steps: (1) the baseline in a small window of 
width 200 m/z ratio is first estimated; (2) spline interpolation is then performed to 
regress the varying baseline to the estimated window baseline; and (3) the estimated and 
regressed baseline is subtracted from the spectrum (MATLAB, 2008). The 
bioinformatics toolbox of MathWorks uses the ‘msbackadj’ function to perform 
baseline correction (http://www.mathworks.com).  
 
In baseline correction, an iterative algorithm uses quantile value (i.e. equal proportions 
of spectral points are taken at regular intervals), for the observed value within a window 
to remove the varying baseline from a spectrum by iteratively calculating the best fit 
straight line through a set of estimated baseline points (Fig. 3.9). As demonstrated in 
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Fig. 3.9, the number of points above and below the best fit straight line (line in red) is 
then counted. If there are fewer points above the line than below, they are considered 
peaks and discarded. A new line is then fitted through the remaining data points. After 
repeating the process until the number of points above the line is greater than or equal to 
those below the line, this final line is subtracted from the spectrum to get the baseline 
corrected spectrum (Veltri et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.10 shows examples of raw mass spectrum of a CHO cell line (a), and the baseline 
corrected spectrum (b). Fig 3.11(a) shows how the ‘msbackadj’ function calculates the 
new baseline of the resampled spectrum of E. coli cell samples. Note the red line 
indicates the newly estimated baseline. Fig. 3.11(b) is the baseline corrected spectrum 
of the E. coli cell clearly showing a uniform baseline. 
 
 
 
 
 
 
 
 
 
Figure 3.9: An example baseline correction within a window 
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Figure 3.10: Mass spectra of CHO cell line samples demonstrating the 
effects of baseline correction 
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Figure 3.11: Mass spectra of E. coli cell samples demonstrating the 
effects of baseline correction 
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3.4.4. Spectra Alignment 
Instrument measurement error (0.03% - 0.06%) can cause miscalibration leading to 
variations in the relationship between the observed m/z ratio vector and the true ToF of 
the ions. Therefore, systematic shifts can appear in repeated experiments and the spectra 
for two identical proteins acquired can have different m/z ratio values. Alignment 
consists of aligning corresponding peaks across samples to address this problem (Veltri, 
2008). 
Alignment is usually applied when: 
 Known profiles of peaks are expected in the spectrogram of a biological sample 
which can be used to standardise the m/z ratio values. This can allow an easy 
and effective comparison of different spectra;  
 Internal and external calibration standards of known spectral profiles to aid 
calibration show variation in m/z ratio peak positions. Calibration standards are 
usually a set of known proteins which are expected to appear with reference 
peaks at specific m/z ratio points. However, there may be a slight shift across 
spectra with respect to the m/z ratio points of the reference peaks. So alignment 
needs to be performed to adjust the known peaks from the celebrants to their 
correct location. 
 
During alignment, a smooth function (which can be any higher-order polynomial) twists 
the spectral signals by resampling them. It builds a new signal with two or more peaks 
represented by a normal distribution. The m/z ratios of the new signal are shifted and 
adjusted until a cross-correlation between the mass spectrum and the new signal reaches 
a maximum value closest to the true peak location. After determination of a new m/z 
ratio vector, a new spectrum is calculated by piecewise cubic interpolation and shifted 
from the original m/z ratio vector (Monchamp et al., 2007).  
  
Alignment can be carried out by the ‘msalign’ function from the bioinformatics toolbox 
of MathWorks (http://www.mathworks.com). Fig. 3.12 and Fig. 3.13 shows an overall 
spectra heat map (Fig. 3.12(a) and (b)) and two overlaid spectra (Fig. 3.13(a) and (b)) of 
an E. coli cell sample demonstrating the alignment of peaks in the original spectra.  
Baseline-corrected spectra were aligned to the reference peaks of 6411, 6855, 7273, 
7333, 7869, 9061, 9218, 9532, and 9736. A close look at the heat maps show the spectra 
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peaks are more aligned along the m/z ratio reference peaks after alignment (Fig. 3.12(b)) 
than before alignment (Fig. 3.12(a)). After alignment, Figs. 3.13(a) and (b) show 
observed improvements in peak alignment between spectra based on peak height. 
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Figure 3.12: Heat maps of mass spectra of E. coli cell samples illustrating the effects 
of alignment 
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Figure 3.13: Mass spectra of E. coli cell samples illustrating the effects of 
alignment 
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3.4.5. Normalising the Relative Intensity 
In repeated experiments, it is also common to find systematic differences in the total 
amount of desorbed and ionised proteins. Sample size may differ, sample preparation 
may not be consistent between different technicians, there may be ion saturation or 
changes in the sensitivity of the instrument. This may result in variations in the 
amplitude of the ion intensities. Normalisation is a row-oriented transformation used to 
force the intensities of the data to the same scale thereby enabling the comparison of 
different samples (Veltri, 2008).  
 
There are a number of normalisation methods (Fung and Enderwick, 2002; Wang et al., 
2003). In the bioinformatics toolbox of MathWorks, the normalisation function, 
‘msnorm’, provide a number of options (http://www.mathworks.com): 
  
Area normalisation: To compensate for systemic differences, the relative intensities of 
the spectra are normalised to the average area under the spectra curves or the height of a 
selected peak. The area under the spectra curve (AUC) can be defined as,  
                                                                 ∑   
 
                                                (3.5) 
 
where Xi is the signal at ith m/z ratio, and n is number of m/z ratio values.  
Normalisation can be carried out by dividing the spectra signals by a constant, 
                                                           
                                                       
            
      
  
                                              (3.6)                                                       
where Xi is the signal at ith m/z ratio, n is number of m/z ratio values, and Ai is a 
constant.  
Area or height of an internal standard: A second normalisation method uses the area 
or height of an internal standard. The internal standard can be a compound with a 
known mass and the same amount of the substance is added to each analyte. Differences 
in the area of the internal standard should be proportional to the differences in the area 
for proteins in the analyte. For example, the maximum intensity of every signal can be 
rescaled to a specific value, for instance 100, with respect to the highest peak in the 
signal. It is also possible to ignore problematic regions; for example, the low-mass 
region (m/z ratio < 4000 Da) which may be due to matrix molecules may be ignored. 
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This is done by choosing a threshold value that eliminates the large amount of noise at 
the lower m/z ratio values but does not remove any important proteins (MATLAB, 
2008). The example shown in Fig. 3.14 and Fig. 3.15 shows the effects of normalisation 
on spectra. It is a mass spectrum before and after normalisation of a CHO cell line 
sample (Fig. 3.14(a) and (b)) and an E. coli cell sample (Fig. 3.15(a) and (b)). Notice the 
change in scale of the relative intensity axis of the spectra before and after normalisation 
because the base peak (largest peak in the spectrum) was rescaled to 100%. All other 
peaks were then normalised based on the respective base peaks. 
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Figure 3.14: Mass spectra of a CHO cell lines sample illustrating the 
effects of normalisation 
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Figure 3.15: Mass spectra of E. coli cell samples illustrating the effects of 
normalisation 
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3.4.6. Smoothing (Noise Filtering)  
Standardised spectra usually contain a mixture of noise and signal. Noise can be defined 
as unwanted signal interfering with the clarity of desired signals. Some applications 
require the denoising of the spectrograms to improve the validity and precision of the 
observed m/z ratio values of the peaks in the spectra. Additionally, denoising facilitates 
the application of peak detection algorithms to select significant features as noise which 
may be confused for peaks are removed. Filtering usually involves removing high 
frequency noise (Monchamp et al., 2007). Filtering is usually carried out after 
resampling, baseline correction, alignment and normalisation. There are two main 
smoothing techniques reported in the literature; 
 
Lowess filter smoothing: Lowess filters smoothes a mass spectrum by using a locally 
weighted linear regression method. In summary, Lowess smoothing finds a data value 
by averaging the values within a span of data points. Smoothing is directly proportional 
to the span size (i.e. the segment size containing a specific number of m/z ratio data 
points), so care must be taken when choosing the span size as a large span size may lead 
to information loss. For example a span size of 10 means performing a locally weighted 
regression smoothing algorithm by applying a full least-square fit to the 10 m/z ratio 
data points within the span. The step is repeated for every point in the signal 
(Monchamp et al., 2007). 
 
Savitzky-Golay filters: This technique (Savitzky-Golay, 1964), smooths mass spectra 
using a least-squares digital polynomial filter. Digital polynomials have points with 
coordinates often referred to as pixels.  This method of smoothing is basically a 
generalisation of the Lowess method. The filter coefficients can be derived by 
performing a linear least squares fit using a polynomial of a given degree. As a result, 
the algorithm preserves signal features such as the resolution between ion peaks and the 
height of the peaks. A higher degree of polynomial will fit the data better. Smoothing is 
controlled by the span size and the polynomial order. The data at both ends are 
truncated and the larger the segment size, the more the smoothing.  For instance for 
low-resolution mass spectra data, the span sizes commonly used are 15 - 20 (Monchamp 
et al., 2007).  
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The ‘mssgolay’ function of the bioinformatics toolbox of MathWorks uses the Savitzky-
Golay filter to carry out smoothing (http://www.mathworks.com).  Fig. 3.16 shows an 
example of mass spectra before and after smoothing.  Fig. 3.16(a) and (b) shows the 
spectrum of a CHO cell line sample before and after smoothing respectively. A portion 
of the spectrum has been enlarged so that the high frequency noise is apparent. As 
expected the scale of the noise within the raw spectrum is decreased after filtering. Fig. 
3.17(a) demonstrates how the ‘mssgolay’ function filters a resampled, baseline corrected 
and normalised spectra of an E. coli cell sample. In the figure, a raw spectrum (blue) 
can be seen with overlays of Savitzky-Golay smooths (green). Fig. 3.17(b) shows the 
completely smoothed spectrum. 
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Figure 3.16: Mass spectra of CHO cell line samples illustrating the effects of noise 
filtering 
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3.4.7. Peak Identification 
After baseline adjustment, alignment, normalisation of the intensities and smoothing of 
spectra, peak identification can be considered.  One approach of doing this is by looking 
at the first derivative of the smoothed spectra. Alternative peak detection methods uses 
descrete wavelet transforms (DWTs). The ‘mspeaks’ function of the bioinformatics 
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Figure 3.17: Mass spectra of E. coli cell samples illustrating the effects of 
noise filtering 
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toolbox of MathWorks uses this approach to perform peak identification 
(http://www.mathworks.com). 
   
As previously mentioned, a mass spectrum can contain tens of thousands (10,000 up to 
1,000,000) of m/z ratios, each with a corresponding signal intensities. However, mass 
spectra can contain regions that do not contain useful information. Extracting the 
relevant signals from a mass spectrum is therefore a means to reduce its dimensionality. 
Fig. 3.18 shows two mass spectra of E. coli cell samples demonstrating peak 
identification. A relative intensity of 10 was specified for peak identification in the 
algorithm, that is, only peaks with a relative intensity of 10 and above were identified.        
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Figure 3.18: Two mass spectra of E. coli cell samples demonstrating peak identification 
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3.5. Review of the Applications of Mass Spectra Data Preprocessing 
Several studies have been carried out to demonstrate the importance of preprocessing 
techniques on mass spectra data. A number of baseline correction methods have been 
reported in previous mass spectra proteomic studies. Tibshirani et al. (2004) used a 
logarithmic transformation on MALDI-ToF data, to reduce the dependence of signal 
width on mass values. By log-transforming the data, the peak widths were 
approximately constant across the m/z ratio range, correcting the baseline and 
facilitating peak detection, and multivariate data analysis. Filters with fast Fourier 
transform technique have also been used on MALDI-ToF mass spectra data to estimate 
the baseline. In this approach, the filters first to estimate the baseline level of the spectra 
and remove unwanted maxima and minima (Breen et al. 2000). Using a two-step 
algorithm, Coombes et al. (2003) combined baseline correction and peak detection. The 
algorithm first detected peaks as well as the base of the peaks. It then interpolated across 
the bases linearly after removing the peaks. The baseline was computed subsequently as 
the local minimum in a window of specified width. Finally a revised spectrum is 
constructed by subtracting the baseline from the original spectrum to give a final 
baseline-corrected spectrum. 
  
Other approaches to alignment such as cubic splines have been proposed for mass 
spectra data sets (Jeffries, 2005).  Du et al. (2006) provided a different approach where 
a continuous wavelet transform (CWT)-based peak detection algorithm was applied to 
identify peaks with different scales and amplitudes. By transforming the spectrum into 
wavelet space, the pattern-matching problem was simplified and in addition provided a 
powerful technique for identifying and separating the signal from the spike noise and 
coloured noise. The algorithm evaluated with surface-enhanced laser 
desorption/ionisation time-of-flight (SELDI-ToF) spectra data showed that no baseline 
removal or peak smoothing preprocessing steps were required before peak detection; 
and it improved the peak detection across different scales of the CWT algorithm and on 
spectra showing varying peak intensities. 
 
Some studies have been undertaken where various normalisation techniques were used 
(Satten et al., 2004; Wagner et al., 2003). In one such study, Satten et al. (2004) 
proposed a standardisation procedure where the spectra is centred using a local estimate 
of the median spectral intensity, and divided by a local estimate of the interquartile 
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range. The interquartile range is chosen over the standard deviation as a measure of 
scale because it is less likely to be sensitive to peak intensity values. Wagner et al. 
(2003) choose to normalise with respect to the sum of the intensities. Each peak 
intensity was divided by the sum of all peak intensities and multiplied by 1000, so that 
the processed intensities could be interpreted over a uniform range across fractions and 
samples. 
 
Other smoothing techniques have been proposed in various studies.  Barak (1995) 
suggested an extension to the Savitzky-Golay algorithm, in which the window width 
and the degree of the polynomial can be defined for adaptively every m/z ratio data 
point window size. The digital filter used varies the degree of the fitting polynomial as 
it slides down the m/z ratio data point window, leading to an improvement in noise 
reduction compared to Savitzky-Golay filters with optimally-chosen polynomial 
degrees.  
 
3.6. Preprocessing Studies for MALDI-ToF data generated from E. 
coli K-12 cells in different growth phases 
As previously explained preprocessing is important especially if biomarker 
identification is the final goal of mass spectra data modeling. Incorrect or inadequate 
preprocessing may lead to the incorrect identification of biomarkers and make it 
difficult to reach meaningful biological conclusions, which could have serious 
implications if such biomarkers are clinically relevant.  In this thesis, before the mass 
spectra generated were subjected to multivariate data analysis for biomarker 
identification, preprocessing was carried out.  
 
Preprocessing was carefully considered and empirically investigated to select an 
appropriate combination of preprocessing techniques and associated parameters. The 
parameters of the preprocessing methods were modified systematically and applied to 
the spectra data. The preprocessed spectra data was used to calibrate PLS-DA models 
(chapter 5). The qualities and performances of the constructed models using different 
preprocessing techniques/parameters were assessed. Factorial designs (and random 
designs) was used with different parameters of the preprocessing techniques defining 
the design variables and the PLS-DA root mean square error of prediction (RMSEP) 
(model performance), RMSE cross validation (RMSECV) (model quality), and R
2 
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calibration and prediction (model quality and performance respectively) as the response 
variables to determine the optimal combination. In random design, the parameters were 
modified systematically (but not through factorial designs) and tested in order to 
increase the range of the factorial design and test parameter combinations that were not 
covered in the factorial design. 
 
The preprocessing was carried out using MATLAB
®
 v.7.6.0.324 (R2008a the 
MathWorks, Inc.) and functions from the Bioinformatics toolbox of MathWorks (v 3.1, 
R2008a, Eigenvector Research, Inc.). Sixty E. coli cell sample mass spectra data sets 
were preprocessed using the sequence in accordance with the recommendation by 
Monchamp et al., (2007) (Fig. 3.7). The data sets were first cropped and down sampled 
from 12722 to 8423 data points prior to the analyses. Cropping involved removing 
extremes of the intensity vector where missing m/z ratio values were found. For 
example the m/z ratio region from 0-4000 is usually considered as noise since signals in 
this area are from matrix ion molecules. This region was removed during cropping. 
 
3.6.1. Selecting the Appropriate Combination of Spectral Preprocessing 
Technique 
3.6.1.1. Cropping and Signal Resampling 
Initially, cropping and signal resampling were investigated the model quality 
(RMSECV and R
2
) of the constructed models using different cropping and signal 
resampling parameters were used as output to verify the suitability of the two 
preprocessing methods on these mass spectra data sets. Table 3.3 and 3.4 show the 
percentage R
2
 and RMSECV values across a number of latent variables (2 to 11) 
demonstrating the effect of cropping and signal resampling on the quality of PLS-DA 
models. As see from the tables, the percentage RMSECV of the three growth phases 
representing three classes were recorded as RMSECV1 (decline phase), RMSECV2 
(exponential phase) and RMSECV3 (stationary phase) respectively. The average value 
of the three latter values was calculated and recorded. This procedure was repeated for 
the R
2
 values.  
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Resampling was carried out after cropping the data.  The data sets were resampled by 
down sampling to 7000 bins within the range 2350 to 20400 m/z ratio values. Initially, 
attempts to resample to other data points such as 8000, 9000, 10000 or 11000 m/z ratio 
values were unsuccessful, rejected by the software suggesting that discriminatory 
information may be lost from data. The RMSECV and R
2
 values were plotted against 
the latent variables (Table A.3 in Appendix A and Fig. 3.19). As seen in Fig. 3.19, 
results suggest that LV2 had the worst model qualities with low average R
2 
(32.5%) 
with a correspondingly high RMSECV (39.3%), which increases until LV4 is reached, 
from where the graphs start levelling out. This suggests that to obtain models with good 
qualities, LV4 to LV11 should be considered for the models. Furthermore, there was no 
change on R
2
 or RMSECV to raw spectra, and spectra that was cropped and/or 
resampled. This suggest that cropping and resampling may not be necessary or suitable 
for this data set, at least on their own, as far as the qualities of predictive models are 
concerned. Probably they may be more effective if applied alongside the other 
preprocessing techniques of baseline correction, normalisation, alignment and 
smoothing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19: Graphs showing the effect of cropping and resampling on quality of PLS-
DA models across latent variables 2 to 11 
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3.6.1.2. Baseline Correction 
Table 3.5 and 3.6 show the recorded values of RMSECV and R
2
 for the three classes 
and their averages respectively for different latent variables and parameter settings after 
baseline correction. Since the raw data had a vertical shift of in the mass spectra profile 
at the lower m/z ratio region, baseline correction on these mass spectra data set was a 
necessity. As summarised in Table 3.5, the window size was fixed at 200 and the 
quantile value at 0.2; LV4 gave the optimal model with the highest R
2
 value (62.5%) 
and the lowest RMSECV (3.01%) This is demonstrated in Fig. 3.20. As seen in Fig. 
3.20, R
2 
increased sharply until LV4 is reached while RMSECV fell sharply to the same 
LV; from where they level out up to LV11. Thus the optimal parameter settings 
(window size and quantile vale) for baseline correction were tested on LV4 (Table 3.6). 
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Figure 3.20: Graph showing the influence of latent variable on the quality of PLS-DA 
models 
 
As shown in Table 3.6, a 2
2
 full factorial design matrix (with 2 center points) was set up 
with two variables, window size and quantile value set at 100-500 and 0.1-1 as lower 
and higher levels. A combination of window size, 500 and quantile value 0.1 gave the 
optimal model with average R
2
 of 72.4% and RMSECV of 23.6%. Thus two different 
random designs were set up to investigate the window of 500 and 0.1 quantile value 
more closely.  
 
In the first random design (random design 1) the quantile value was fixed at 0.1 whilst 
the window size was increased progressively from 100 to 1000 at intervals of 100.  The 
optimal model (R
2
 of 72.3% and RMSECV of 24%) was found when window size was 
400 and quantile value 0.1. In the second random design (random design 2) the quantile 
value was increased progressively from 0.1 to 1 at intervals of 0.1 whilst the window 
size was fixed at 500. No window size and quantile value combination gave a model 
with R
2
 better that 72% (Table 3.6). These R
2
 values however were better than that 
obtained (69.8%) when no preprocessing was applied to the data. These suggest that 
baseline correction, at least on its own, will improve model quality of the models built 
with the spectra data. The optimal parameter setting for baseline correction was also 
found to be a window size of 500 and a quantile value of 0.1 (Table 3.6 in bold). 
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3.6.1.3. Alignment, Normalisation and Smoothing 
Table 3.7 shows the effect of alignment across a number of latent variables. Alignment 
of the spectra data was carried out along five m/z ratio peaks 6411, 6855, 7273, 7333, 
7869, 9061, 9218, 9532, 9736 which were found to be common among most of the 
spectra profiles. Results in Table 3.7 suggest that applying alignment on the data 
slightly improved the qualities of the PLS-DA models built using the mass spectra data, 
on average. This can be clearly seen from Fig. 3.21 (Table A.4, Appendix A). This 
suggests that using alignment may be necessary for this spectra data sets, at least on its 
own. 
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Table 3.8 shows results of the quality of PLS-DA classification models obtained after 
the data used to build the models was normalised at with varied parameter settings. The 
model evaluations were carried out at a fixed LV (LV 4). A 2
3
 full factorial design 
matrix (with no center points) was set up with two variables, rescaling and quantile 
value. Eight runs were carried out with the rescaling fixed at 100 and the quantile value 
was increased progressively from fixed at 0.1 to 0.6 at intervals of 0.1. A random design 
was subsequently set up and quantile values from 0.7 to 1 were evaluated against a 
fixed rescaling value of 100; whilst a fixed quantile value of 0.1 was evaluated against 
rescaling values of 20, 50 and 80. Results suggested that better models (R
2 
of 86% and 
RMSECV of 17.4%) were produced after normalisation, than when no preprocessing 
was performed on the data (R
2
 of 69. 8% and RMSECV of 65.4%). This suggests that 
data normalisation improves the quality of the PLS-DA models built with the mass 
spectra data. 
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Table 3.9 shows results of the quality of PLS-DA classification models obtained built 
with smoothed mass spectra data. Smoothing was performed with varied parameter 
settings. The parameter involved during smoothing was the smoothing span value (i.e. 
the segment size containing a specific number of m/z ratio data points). This was 
systematically changed from 10 to 100 at intervals of 5 units. The model evaluations 
were carried out at a fixed LV (LV4). 
 
As can be seen from the Table 3.9, span values of 20 and 25 produced better models, 
with an R
2 
of 72.2% and RMSECV of approximately 27% (indicated in bold in Table 
3.9). This also suggests that smoothing improves the quality of classification models. To 
conclude, results thus far suggest that evaluating the preprocessing methods in isolation 
remove undesired effects, increasing between class variations and hence the 
classification models as seen through the R
2 
and RMSECV. In the next section, the 
preprocessing methods were combined and evaluated together to verify if this will be of 
value. 
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3.6.1.4. Using all Preprocessing Techniques for the E. coli Spectra Profiles 
Tables 3.10 and 3.11 shows the effect of the spectra preprocessing techniques on the 
quality and performance of PLS-DA classification techniques obtained after the data 
used to build the models was preprocessed with all the techniques, with varied 
parameter settings. The model evaluations were carried out at a fixed LV (LV 4). A 2
4
 
full factorial design matrix (with 2 center points per block) was set up with four factors, 
i.e. baseline correction quantile value, baseline correction window size, normalisation 
quantile value and smoothing span value. All these factors were held at 2 levels (upper 
and lower levels).  
 
Eighteen runs were performed with baseline correction quantile value at 0.1-0.2, 
baseline correction window size at 300-500, normalisation quantile value at 0.1-1 and 
smoothing span value at 20-25. These intervals were those that gave optimal results 
(high R
2
 and low RMSECV) when the corresponding preprocessing techniques were 
used in isolation. A random design was subsequently set up with baseline correction 
quantile value at 0.1-0.2, baseline correction window size at 100-200, and normalisation 
quantile value at 0.1-0.2, evaluated against a fixed smoothing span value of 25. The 
qualities of the models were evaluated through the R
2
 and the RMSECV whilst the 
performance was evaluated against the root mean square error of prediction (RMSEP) 
and the R
2 
of prediction.  
 
As can be seen from the results (Tables 3.10 and 3.11, run order 21 and 24) the best 
models were obtained (with R
2
 of calibration 33.46%; RMSECV of 82.01%; R
2
 of 
prediction 89.19%; and RMSEP of 15.85%), when the baseline correction quantile 
value was at 0.1, baseline correction window size was set to 200, normalisation quantile 
value, 0.1 or 0.2,  and smoothing span value was at 25. These parameter settings were 
used as standard settings for the preprocessing approach applied to the E. coli mass 
spectra data. The standard preprocessing algorithm used for all spectra data sets can be 
found in Appendix A, Fig. A.1. 
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Fig. 3.22 shows the main effects and interaction plots for the preprocessing techniques 
with output being the RMSEP. The latter was used because prediction error is an 
absolute measure. Furthermore, using a parameter which test for model performance 
will help increase confidence on conclusions drawn with respect to model quality, and 
hence the preprocessing method.  
 
A seen in Fig. 3.22, the main effects plot suggests that all the preprocessing techniques 
are significant, with baseline correction quantile value and smoothing span value being 
the most significant preprocessing techniques affecting the model performance. This 
goes to support the earlier view that all these techniques were essential for 
preprocessing the spectra data. The main effects for average RMEP are maximised 
when baseline correction quantile value was set at 0.2 and smoothing span value to 20.  
 
From the interaction plots, the following interactions could be observed;  
 baseline correction window size and normalisation quantile value;  
 smoothing span value and normalisation quantile value;  
 baseline correction window size and smoothing span value; and  
 baseline correction window size and quantile value.  
 
At baseline correction window sizes of 300 or 500, model performance are increased 
(with lower average RMSEP) when the baseline correction quantile value is reduced 
from 0.2 to 0.1, and when the smoothing span value is increased from 20 to 25. At 
baseline correction window sizes of 300 or 500, model performance is increased when 
the normalisation quantile value is increased from 0.1 to 1. At normalisation quantile 
values of 0.1, 0.2 or 1, model performance is improved when the smoothing span value 
is increased from 20 to 25. At baseline correction quantile value of 0.2, model 
performance is improved when the normalisation quantile value is increased from 0.1 to 
1. However the gain is not as large as simply setting the baseline correction quantile 
value at low levels of 0.1. These interactions prove the notion that looking at one 
preprocessing technique in isolation from the others may be of limited value, an 
argument which was stressed by Baggerly et al, (2003). The factorial design enabled the 
incorporation of the possibility of interactions between the different preprocessing 
techniques whilst helping to evaluate the relative importance of the individual methods.  
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3.7. Preprocessing Studies for MALDI-ToF data generated from 
Monoclonal Antibody Producing CHO cell line Spectra Profiles 
3.7.1. Using all Preprocessing Techniques for the CHO Cell Line Spectra Profiles 
The procedure described in section 3.6 was repeated for the CHO cell line spectra data 
sets. All the preprocessing techniques were evaluated for the CHO cell line spectra data. 
The qualities and performances of the constructed models using different preprocessing 
techniques/parameters were assessed. Factorial and random designs was used with 
different parameters of the preprocessing techniques defining the design variables and 
the PLS-DA RMSEP and R
2 
of prediction as the response variables to determine the 
optimal combination.  
 
Tables 3.13 shows the effect of the spectra preprocessing techniques on the quality and 
performance of PLS-DA classification techniques obtained after the CHO cell line 
spectra data used to build the models was preprocessed with all the techniques varying 
the parameter settings. The model evaluations were carried out at a fixed LV (LV 5). A 
24 full factorial design matrix (with 2 centre points per block) was set up with four 
factors, i.e. baseline correction quantile value, baseline correction window size, 
normalisation quantile value and smoothing span value. All these factors were held at 2 
levels (upper and lower levels).  
 
Eighteen runs were performed with baseline correction quantile value at 0.1-0.2, 
baseline correction window size at 300-500, normalisation quantile value at 0.1-1 and 
smoothing span value at 20-25. These intervals were those that gave optimal results 
(high R
2
 and low RMSECV) when the corresponding preprocessing techniques were 
used in isolation. A random design was subsequently set up with baseline correction 
quantile value at 0.1-0.2, baseline correction window size at 100-200, and normalisation 
quantile value at 0.1-0.2, evaluated against a fixed smoothing span value of 25. The 
qualities of the models were evaluated through the R
2
 and the RMSECV whilst the 
performance was evaluated against the root mean square error of prediction (RMSEP) 
and the R
2 
of prediction.  
 
As can be seen from the results (Tables 3.12, run order 20) the best models were 
obtained (with R
2
 of calibration 48.5%; RMSECV of 46.2%; R
2 
of prediction 33.5%; 
and RMSEP of 50.3%), when the baseline correction quantile value was at 0.2, baseline 
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correction window size was set to 100, normalisation quantile value, 0.1, and smoothing 
span value was at 25. These parameter settings were used as standard settings for the 
preprocessing approach applied to the CHO cell line mass spectra data. The standard 
preprocessing algorithm used for all spectra data sets can be found in Appendix A, Fig. 
A.2. 
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Table 3.12: Design matrix showing the influence of different preprocessing 
techniques/parameter settings on the performances and qualities of PLS-DA models 
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3.8. Summary 
In this chapter, mass spectrometry was introduced as an important ‘omics’ tool. In 
particular, the capabilities and advantages of the MALDI-ToF mass spectrometry 
platform was explored. The relative ease of operation of MALDI coupled with ToF 
detection and its characteristic generation of mostly singly charged peptide and protein 
ions makes a useful mass spectrometry technique. Ions are generated from high-mass 
and non-volatile protein molecules through laser irradiation. A key aspect of MALDI is 
the use of an energy absorbing matrix which can co-crystallise with the analyte 
preventing decomposition of the latter due to the laser energy. Gas phase protein 
molecular ions produced by the matrix-analyte co-crystal traverse a field-free flight tube 
and are then separated according to their m/z ratio. MALDI-ToF was used for data 
analysis in this thesis because of the advantages it has such as high sensitivity, little or 
no fragmentation, widespread use and predominance of singly charged molecules as 
MALDI uses a soft ionisation approach. The fact that mostly singly charged molecular 
ions (with the mass equal to m/z ratio) are generated from the instrument is a key 
advantage as it enables the direct determination of the mass of the protein molecular ion 
and hence protein molecules. This offers the opportunity for rapid biomarker discovery 
as the experimental molecular weight of MALDI molecular ions can be matched against 
sequence molecular weight of organisms with sequenced genomes, directly identifying 
the protein (chapters 6 and 7).  
 
However, before any data mining is carried out on mass spectra data for biomarker 
identification, the raw spectra profiles have to be preprocessed. Preprocessing serves to 
reduce the spectral noise, reduce the amount of data, and ensure the spectra comparable. 
It includes a number of techniques including resampling, baseline correction, alignment, 
normalisation smoothing, and peak identification. Studies have shown that these 
preprocessing techniques are interrelated, and several combinations of the different 
techniques may have to be tested to identify an appropriate preprocessing approach 
(Baggerly et al., 2004). A review of the applications of the application of preprocessing 
on mass spectra data was provided, emphasising the importance of preprocessing. 
 
In this chapter, preprocessing studies were carried out using the MALDI-ToF mass 
spectra profiles generated from E. coli cells and CHO cell lines. A quantitative 
assessment of the impact of different combinations of preprocessing techniques on the 
     MALDI-ToF Mass Spectrometry  
 
87 
 
mass spectral data was carried out by factorial designs with the parameter settings of the 
various preprocessing techniques used as factors, and root mean square error of 
prediction (RMSEP), RMSE cross validation (RMSECV), R
2 
of prediction and 
calibration as the response. After combining all the preprocessing techniques, the 
combinations that gave favourable responses for the RMSEP and R
2
 of prediction were 
used as the preprocessing procedures for the E. coli cell spectra profiles. Moreover, 
identification of protein biomarkers from the reprocessed spectra profiles, consistent 
with those already described in the literature further helped validate the preprocessing 
methods/parameters combination used (chapter 6 and 7). The next chapter explores 
proteomic profiling for biomarker discovery as well as some important mass 
spectrometry based techniques. It focuses on intact-cell MALDI-ToF mass spectrometry 
(ICM), the technique that was used for analysing the samples in this thesis. 
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4. Protein Profiling for Biomarker Discovery 
4.1. Overview 
The previous chapter introduced the technique of mass spectrometry with a description 
of MALDI-ToF MS which is the main analytical technique used in this thesis. It also 
described the importance of pre-treatment of the high dimensionality mass spectra data 
generated from the MALDI, a number of preprocessing techniques, substantiated by 
examples using suitable mass spectra data from E. coli cells at different growth phases 
as well as from the IgG monoclonal antibody producing CHO cell lines during 
culturing. 
 
This chapter describes the concept of proteomic biomarker discovery and introduces the 
top-down proteomics based approach of ‘intact-cell’ MALDI-ToF MS (ICM-MS). The 
application of ICM-MS for the analysis of microorganism and mammalian cell line is 
given. The chapter also explores the potential advantages and usefulness of ICM-MS 
and internet-accessible protein databases for rapid biomarker profiling in the area of 
mammalian cell culture in biopharmaceutical bioprocessing. Finally the chapter 
concludes with a literature review on the applications of the application of ICM-MS on 
both bacterial and mammalian cells. 
 
4.2. Introduction 
Recent advances in genomics with the sequencing of the human genome (Venter et al.,, 
2001) and many other species including E. coli (Blattner et al., 1997), mouse 
(Waterston et al., 2002), and rat (Gibbs et al., 2004) are providing increasing 
knowledge in terms of the fundamental genetic code that characterises signal 
transduction pathways, and the control of important cellular events like growth, 
differentiation, and cell death. Although gene-related-information is of value, evidence 
within the context of clinical research suggests that analysing genome sequences alone 
provides insufficient indicators for the development of new therapies to fight human 
disease. Potentially of greater value will be to have knowledge of global patterns of 
protein content and activity and how these are altered during development or in 
response to disease. This type of information will be required to facilitate the discovery 
of novel drug targets and new therapies (Gygi et al., 1999). 
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Contrary to genomic studies, the analysis of proteomes is significantly more challenging 
and complicated mainly because the proteome is dynamic and is in constant flux. Other 
factors such as alternative splicing of the respective mRNAs, and posttranslational 
modifications can result in important functional differences in proteins of higher 
eukaryotes (Wery, 2012). The term proteome refers to all proteins expressed by a cell, 
tissue or a body fluid and is thus a complex mixture. Proteomics can be defined as ‘the 
systematic analysis of protein populations and the protein complement of cells, 
including the concurrent identification, modification, quantification, and localisation of 
large numbers of proteins in a functional context’ (Pothur et al., 2001). Among the 
many vital functions they perform, proteins catalyse a variety of chemical reactions, 
support a range of skeletal structures, control membrane permeability, modulate the 
concentration of metabolites, and control gene expression. Thus information at the level 
of the cellular proteome is essential for determining which proteins or groups of 
proteins are responsible for a specific function or phenotype in cells. This could be in 
relation to health and diseases, as in clinical proteomics, or cell systems involved in the 
production of a therapeutic protein in bioprocessing.  
 
Protein profiling, a sub-discipline of proteomics, has provided significant insight into 
biological events such as transcription and translation. It is the generation of extended 
protein expression data sets for analysing changes in global protein expression patterns 
in biological systems as a function of developmental, physiological, and disease 
processes. Protein profiling can promote understanding of aspects of a disease such as 
pathogenesis, improved early detection, staging, therapeutic monitoring and prognosis 
(Bakry et al., 2011). In clinical proteomics, biomarkers are among the important tools 
critical to understanding these disease aspects. 
  
4.3. Protein Biomarker Discovery 
Biomarkers can be defined as biological molecules that correlate to a specific biological 
or pathological state, pharmacologic response or a therapeutic intervention.  As 
advances in the fields of genomics and proteomics continue to contribute to a wide-
range of scientific disciplines (e.g. industrial manufacture of therapeutic proteins) 
through new technologies, the field of biomarker discovery, development and 
application has become an area of considerable research focus and activity.  
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The discovery of biomarkers can be carried out through the use of a variety of 
approaches depending on the nature of the biomarker involved. Approaches can range 
from transcriptional profiling and DNA methylation studies which have shown strong 
potential for biomarker discovery in cancer, to metabolomic approaches as 
demonstrated for metabolic disease, drug and toxicity studies (Rifai et al., 2006). 
However, with protein domains being the most affected entities during a pathological 
condition, protein biomarkers have become one of the most valuable classes of 
biomarkers over the past 100 years. As a consequence, proteomic biomarker discovery 
studies have become commonplace.  
 
In the context of clinical proteomics, protein biomarkers serve as important tools in 
terms of acting as an early indicator of a disease, for the monitoring of disease 
progression, and for assisting with disease detection. Protein biomarkers are often low-
molecular-weight proteins and their secretion and appearance in the bloodstream is 
triggered by the onset and progression of a disease process and their prominence has 
made them the cornerstone of medical care (Frank and Hargreaves, 2003). Blood 
biomarker measurements can provide indicators relating to the source of patient 
symptoms such as abdominal pain (transaminase biomarkers - hepatitis, alkaline 
phosphatase - biliary disorders, and human chorionic gonadotropin (β-hCG) - 
pregnancy) or chest pain (troponin biomarkers - heart attack). The demonstrated success 
of biomarkers in terms of impacting the prognosis of numerous patients and could 
providing insights into the appropriate patient therapy in situations where immediate 
treatment is necessary; the development of more and better therapeutic and diagnostic 
biomarkers has now become a priority area in the clinical sciences (Paulovich et al., 
2008). 
 
4.3.1. Biomarker Discovery Pipeline 
As reviewed in Rifai et al. (2006), the mass spectrometry-based biomarker development 
pipeline (Fig. 4.1) in clinical research usually consists of several phases. Discovery or 
identification is a step that involves the definition of differential protein expression 
between biological states. Biomarker discovery or identification is usually carried out 
using a series of proteomic technologies including gel-based mass spectrometry (MS) 
(e.g. two-dimensional polyacrylamide gel electrophoresis with matrix assisted laser 
desorption ionisation time of flight MS; 2D-PAGE/MALDI-ToF-MS), or gel-free MS 
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approaches, i.e., MudPIT (multidimensional protein identification technology) or ‘shot-
gun proteomics’. An example of ‘shot-gun proteomics’ is liquid chromatography with 
electrospray ionisation MS; LC/ESI MS. Sample systems used in discovery include 
model systems (e.g. mouse models or cell lines) or materials of human biological origin, 
and usually consist of a binary comparison between diseased and normal tissues. The 
outcome of the discovery phase is a compiled list of specific proteins differentially 
expressed between the normal and diseased states. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in Fig. 4.1, the next phase in biomarker development is qualification. 
Qualification confirms the differentially expressed candidate biomarkers, i.e., it links 
the biomarkers with a biological state. Qualification may also serve to confirm the 
candidate biomarkers in comparisons of diseased and normal human samples, if 
discovery was not initially performed in such samples. Discovery and qualification are 
mainly involved in verifying that the candidate biomarkers are consistently associated 
with the disease. Principally, they both demonstrate the sensitivity of a candidate 
biomarker (the likelihood that a diseased sample will test positive) over specificity (the 
likelihood that an unaffected sample will test negative). 
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Figure 4.1: Process flow for protein biomarker development 
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Qualification is followed by the verification step, which serve to determine if there is 
sufficient evidence for potential clinical utility of a given candidate biomarker to 
warrant further investment in that candidate for clinical validation studies. Hundreds of 
human samples are involved, where factors such as environmental, genetic, biological 
and variation in the population are tested, to confirm the sensitivity and specificity of 
the biomarkers. Biomarkers which perform well under verification are taken forward to 
clinical validation. This stage involves the use of quantitative methods on large 
populations of samples to confirm that the candidate biomarkers have clinical utility, 
i.e., the biomarker candidates are evaluated in clinical trials in a context most relevant to 
their eventual clinical application.  If not performed during the verification phase, 
immunoassays are used to assess the diagnostic abilities of the biomarkers, followed by 
assessment of performance characteristics such as reproducibility and accuracy (e.g. the 
ability to be accurately used as a disease indicator). Successfully validated biomarkers 
are then selected for commercialisation. 
 
4.3.2. Overview of Proteomic Approaches for Biomarker Discovery 
Currently, protein biomarker discovery is undertaken by one of two approaches (Fig. 
4.2), the analysis of intact proteins (top-down proteomics) and the analysis of peptide 
mixtures from digested proteins (bottom-up proteomics). Proteomic studies in the past 
have always been based on a trade-off between throughput (top-down proteomics) and 
resolution (bottom-up proteomics) (Dalmasso et al., 2009). These two proteomic 
approaches are briefly described in the subsequent sections. 
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4.3.3. Bottom-up Proteomics 
Bottom-up proteomics, also known as ‘shot-gun’ proteomics, involves mass 
spectrometry analysis of purified proteins, or complex protein mixtures, that have 
initially undergone enzymatic digestion, using enzymes such as trypsin (Fig. 4.3). 
Protein mixtures are treated with a proteolytic enzyme (e.g., trypsin) to fragment 
proteins into peptides. The resulting peptides can be subjected to either mass 
spectrometry (MS) or MS/MS for protein identification. Proteins purified by employing 
gel electrophoresis or chromatography containing only one or a few proteins are 
subjected to MS. In MS, the samples are ionised in the ionisation chamber, analysed by 
m/z ratio in the mass analyser, and detected by the ion detector (Fig. 4.3). 
Relative quantification 
and identification
Biological samples
LC-MS/MS or LC-MALDI 
MS/MS Analysis
Mass spectrometric 
profiling
Sample preparation 
(optional depletion, 
tagging and labelling)
Biological samples
Enzymatic digestion
Chromatographic 
separation
Selected biomarker 
cadidates identified
Statistical significant 
candidate biomarkers 
selected based on 
relative quantification
Bottom-up approach to 
proteomic profiling
Top-down approach to 
proteomic profiling
Figure 4.2: General workflows for bottom-up and top-down proteomic profiling 
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Alternatively (Fig. 4.3), if the analysis involves a complex protein mixture, MS/MS (or 
tandem MS) is used. In MS/MS (or tandem MS), peptides are fragmented in the 
collision cell at their peptide bonds before entering the second MS. Better sample 
resolution can be achieved by processing proteins/peptides before running MS. This is 
achieved by 2-dimensional gel electrophoresis (2D-GE) and gel purification of protein 
bands before tryptic digestion. The digested product may contain hundreds of thousands 
of peptides, and may require separation in liquid chromatography (LC) columns or 
capillary electrophoresis (CE) before MS analysis (Wehr, 2006). Examples of some 
quantitative shotgun proteomic technologies are stable isotope labelling by amino acids 
in cell culture (SILAC), isotope-coded affinity tagging (ICAT) and isobaric tags for 
relative and absolute quantification (iTRAQ) technology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Schematic diagram showing steps involved in bottom-up proteomics 
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The main advantage of bottom-up proteomics is its ability to achieve high resolution 
proteomic separations, for example, HPLC provides high-resolution separations of 
proteolytic protein products. The approaches are amenable to automation, with 
automated on-line nano-scale reversed-phase LC–ESI–MS–MS being widely used for 
bottom-up proteomics (Wehr, 2006). The identification of proteins from complex 
proteolytic mixtures such as cell lysates has been most successfully carried out using the 
bottom-up strategy using on-line multidimensional capillary HPLC–MS-MS (Link et 
al., 1999).  
 
Bottom-up approaches have several practical limitations. They are generally time-
consuming, as an on-line multidimensional LC–MS-MS proteomic analysis using ion-
exchange coupled to reversed-phase columns have run times of up to 15 hours or more. 
Furthermore, as each protein in the samples is reduced to multiple individual peptides, 
there is an overall increase in complexity during the analysis. This reduction into 
individual peptide leads to loss of some information concerning specific proteins and so 
there is no thorough coverage of the protein sequence. This limited sequence coverage 
and fragmentation process commonly used during bottom-up approaches leads to a loss 
of information about posttranslational modifications (PTMs) (phosphorylation, 
glycosylation, and methylation), which are potential biomarkers in clinical proteomics. 
This is because smaller proteins (below 30 kDa) and peptides have fewer proteolytic 
cleavage sites and do not generate enough peptides for confident identification PTMs. 
Other problems may include the masking of low-abundance peptides by high-
abundance species in the generated spectra, leading to a loss of information about low-
abundance peptides (Wehr, 2006) 
 
4.3.4. Top-down Proteomics 
Top-down proteomics involves separating intact proteins from complex mixtures using 
conventional separation techniques such as liquid chromatography or 2-DE followed by 
differential expression analysis using spectrum analysis (such as MALDI or ESI). The 
generated intact molecular ions are then subjected to gas-phase fragmentation by 
MS/MS, for subsequent bioinformatics data analysis through database searches 
(Dalmasso et al., 2009). Top-down proteomics is essential for the identification of small 
proteins with MWs below 20 kDa. Examples of top-down proteomic techniques are, 
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fourier-transform ion cyclotron resonance (FT-ICR), and surface enhanced laser 
desorption ionisation time-of-flight mass spectrometry (SELDI-ToF MS). 
 
There are two major advantages of the top-down approach. First, there is the possibility 
to gain access to the protein sequence and detect the native molecular mass (MW) of the 
protein; as well as locating and characterising PTMs. Secondly, it is less time 
consuming compared to the bottom-up approaches due to a simplified sample 
preparation procedure and the absence of time-consuming protein digestion that is 
required for bottom-up approaches. The absence of multiple digested peptides means 
there is an overall reduction in the complexity of the samples to be analysed (Dalmasso 
et al., 2009). 
 
Top-down proteomics is a relatively new field and is not as widespread as bottom-up 
proteomics. Limitations of the approach include the fact that it is restricted to isolated 
proteins or simple protein mixtures because its output is a complex spectra which 
comprises mainly multiply charged protein ions. Moreover, the fragmentation behaviour 
of the latter ions is not well understood. Secondly, the favoured FT-ICR instrumentation 
in top-down proteomics is expensive to purchase and operate. Finally, there are fewer 
bioinformatics tools for top-down proteomics compared with those for bottom-up 
proteomics making protein identification more challenging (Wehr, 2006). 
 
4.3.5. Top-down Proteomics without digestion: ‘Intact-cell’ MS by MALDI-ToF 
MS 
The development of a new MS-based top-down protein profiling technique has created a 
new wave of excitement amongst microbiologists as well as the biomarker discovery 
community. This approach is called intact- or whole-cell MALDI-ToF MS. The power 
of MALDI-ToF MS in protein profiling resides in its minimal sample preparation as 
well as rapid computer-assisted data handling. It should be emphasized that this 
approach differs from classical proteomics based-approaches. The latter may either 
employ 2-DE, followed by proteolytic digestion, and extraction prior to MALDI-ToF 
MS analysis (top-down proteomics); or the digested sample is subjected to clean up 
prior to tandem MS analysis (LC-ESI-MS/MS) (bottom-up proteomics). 
 
In intact-cell MALDI-ToF MS (ICM), the word “intact” literally means that the cell 
samples to be analysed are not treated or processed in any way specifically for the 
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removal or isolation of any cellular components. In “intact-cell” analysis, the cells are 
manipulated only as necessary to transfer them into the mass spectrometer for analysis. 
The cells are usually applied to the MALDI target plate along with a matrix compound 
and solvents in which the matrix has been dissolved. However, intimate contact 
between cells, matrix and matrix solvents means that osmotic pressure may result in 
stress on the cellular membrane and hence cell disruption. Moreover, in the case of 
bacteria cells, suspension of cells in solvents to minimise exposure to the organisms in 
the laboratory may lead to the disruption of the cells. Because none of these steps are 
intended to disrupt cells, and no steps are added to isolate proteins or other analytes, the 
technique is called “whole-cells” or “intact cell” MALDI analysis to differentiate it 
from procedures where additional steps are included in the procedure to deliberately 
disrupt cellular membranes or separate/recover analytes from the cellular material 
(Wilkins and Lay, 2006). Consequently, this techniques has been rapidly exploited by 
microbiologists for the investigation of microorganisms. 
 
4.3.5.1. Intact-cell MALDI-ToF (ICM) MS-based Biomarker Identification in 
Microorganisms  
MALDI-ToF MS analysis of bacterial whole cell proteins, as well as viruses, fungal 
vegetative cells, and spores, is now well established as reviewed by Lay, (2001); and 
Fenselau and Demirev (2001). For the analysis of bacteria through ICM, one proposed 
approach has been the rapid identification of bacteria (Holland et al., 1996). 
Identification of bacteria is based on the direct comparison of whole cell spectra 
considered to be the bacterial protein fingerprint, to reference spectra. This has been 
made possible by the creation of a bacterial fingerprint library of mass spectra from a 
wide range of known bacterial species (Mazzeo et al., 2006).  
 
A bioinformatics approach for microorganism identification and characterisation which 
does not involve the use of a fingerprinting library has also been used. This approach is 
based on matching a set of protein biomarker signal ion molecular weights (MWs) in 
the spectrum with those of sequence-derived theoretical MWs of proteins (Demirev et 
al., 1999; Fenselau and Ryzhov, 2001), to identify the protein biomarker signal ions. 
This is a consequence of the availability of protein biomarkers of bacteria in compiled 
internet-accessible protein databases of microorganisms with completely sequenced 
genomes (http://www.uniprot.org/uniprot/). 
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4.3.5.2. Bioinformatics and Internet Accessible Protein Databases 
Bioinformatics is the storage, organisation and analysis of huge amounts of biological 
data using computational tools and information technology. Such data are typically 
generated in the form of sequences and structures of proteins and nucleic acids.  
Genome sequencing of organisms has generated an exponential growth in biological 
data compiled in databases that are structured, searchable and up-to-date. Protein 
databases in particular have become a crucial part of modern biology. One of the first 
steps in the study of a new protein usually involves searching protein databases. 
Information about the relationship between proteins within a genome or across different 
species can be obtained by comparing with different proteins or protein families, 
offering much more valuable information than when studying an isolated protein due to 
coevolution (evolution of two or more interdependent proteins, each adapting to 
changes in the other). Since cellular proteins are connected to each other (through 
pathways and interaction networks), comparing proteins can expose functional 
interactions between molecules in the cell, generating insights into biological processes 
of interactions important for cellular function (Tillier and Charlebois, 2009). An 
example of such a protein database is the UniProt Knowledgebase (UniProtKB). 
 
4.3.5.3. UniProtKB/Swiss-Prot and UniProtKB/TrEMBL Protein Databases 
In 2002, the Swiss Institute of Bioinformatics (SIB), the European Bioinformatics 
Institute (EBI) and the Protein Information Resource (PIR) group at the Georgetown 
University Medical Center and National Biomedical Research Foundation in the U.S, 
joined forces to create what is known as the UniProt consortium. The mission of 
UniProt is to provide the scientific community with a single, comprehensive, high 
quality and freely accessible protein sequence database, UniProtKB (www.uniprot.org). 
The UniProt Knowledgebase (UniProtKB) is the central access point and consists of 
two sections: UniProtKB/Swiss-Prot, a manually annotated and reviewed section; and 
the UniProtKB/TrEMBL, an in-silico annotated section which is not reviewed. Both 
databases provide sequences and theoretical MWs of 'complete proteome sets', which 
are the entire set of proteins thought to be expressed by organisms. The bulk of the 
UniProt complete proteome sets are derived from the translation of completely 
sequenced genomes of organisms, and normally includes sequences that are derived 
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from extra-chromosomal elements such as plasmids or organellar genomes in organisms 
(www.uniprot.org).  
 
The sequencing of organisms such as E. coli (Blattner et al., 1997), mouse (Waterston 
et al., 2002), rat (Gibbs et al., 2004) and human (Lander et al., 2001; Venter et al., 
2001) genomes, with their eventual placing in the UniProt databases, has provided the 
possibility of applying the novel bioinformatics approach in protein profiling studies for 
biomarker discovery and identification in these organisms. Initiatives to completely 
sequence the CHO cell genome (Hammond et al., 2011; Xu et al., 2011), implies that 
the  bioinformatics approach could also be used for the proteomic profiling of CHO 
cells. Recently, the complete sequencing of the CHO genome has materialised into 
sequence-derived theoretical molecular weights (MWs) of CHO proteins becoming 
increasingly available in compiled internet accessible protein databases such as the 
UniProtKB database (http://expasy.org/proteomics, 2012). The advantage of requiring 
minimal sample preparation with MALDI-ToF MS, along  with  the production of 
singly charged ions, and the ease with which biomarker signal assignments can be 
sought from internet accessible databases raises the  possibility for the rapid 
identification of biomarkers for industrially relevant production platforms such as CHO. 
With the importance of the CHO cell platform for the commercial production of 
biopharmaceutical therapeutic products, this approach could be an asset for the 
biotechnology industry. 
 
4.3.5.4. Applications of Intact-cell MALDI-ToF MS (ICM) for the Analysis of 
Microorganisms 
It is now well-established that MALDI-ToF can be used to identify biomolecules above 
4kDa. These biomolecules are readily desorbed from unprocessed microorganisms and 
are intact protein ions (Ryzhov and Fenselau, 2001). Demirev et al., (1999) showed that 
the proteins of prokaryotic microorganisms have the propensity to fall in the range 
4±15kDa MALDI and this is supported in the literature using experimental evidence 
(Demirev et al., 1999; Ryzhov and Fenselau, 2001; Dieckmann et al., 2008; Ilina et al., 
2009; Christner et al. 2010; Hotta et al., 2011; Wang et al., 2012).  
 
In the last few years MALDI-ToF MS has been increasingly applied for the 
identification using the ‘fingerprint’ matching approach, a method that was first 
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introduced by Holland et al., (1996). More recently, MALDI-ToF MS has been applied 
clinically for microbiological diagnostics. Wang et al. (2012) applied the technique for 
the identification of 65 Streptococcus pyogenes isolates, a gram-positive pathogen, 
obtained from patients. ‘Intact cell’ measurements obtained using MALDI were 
matched with reference spectra found in the MALDI Biotyper software through a 
pattern recognition algorithm. This ‘fingerprint’ matching facilitated the isentification of 
61 of the 65 S. pyogenes isolates with 93.85% accuracy. In a similar study involving 
cilinical proteomics, Ilina et al. (2009) sought to identify and categirise the genus 
Neisseria into its pathogenic and non-pathogenic subtypes. Human pathogens, Neisseria 
meningitidis and Neisseria gonorrhoeae, as well as several nonpathogenic Neisseria 
species was profiled via MALDI and visual inspections coupled with ‘fingerprint’ 
matching using the MALDI Biotyper software successfully distinguished the pathogenic 
from the the non-pathogenic Neisseria isolates.  
 
Several other clinically relevant studies have used the MALDI technique for the 
identification, diagnosis and hence earlier treatment of bloodstream bacterial infections 
mainly through the MALDI Biotyper software. Vlek et al. (2012) directly profiled a 
suspension of bacteria and blood cell samples for Methicillin-resistant Staphylococcus 
aureus and vancomycin resistant enterococci to allow for earlier implementation of 
appropriate antimicrobial treatments. In another of such studies aimed at improving the 
clinical outcomes of bloodstream infections, Christner et al. (2010) used ‘fingerprint’ 
matching to reference spectra to identify aerobic and anaerobic bacteria in culture broth, 
providing identification rates as hiog as  87% with mismatching mostly resulting from 
insufficient bacterial numbers. 
 
A bioinformatics-based approach for microorganism analysis and identification applies 
only to microorganisms with sequenced genomes. It exploits the wealth of information 
contained in prokaryotic genome and protein biomarker sequences in internet-accessible 
databases like UniProtKB or SwissPROT and uses the fact that the majority of observed 
biomarkers above m/z ratio 4000 in MALDI spectra of intact organisms are proteins. 
This approach for microorganism identification was first introduced by Demirev et al. 
(1999), who analysed B. subtilis and E. coli, two organisms with completely sequenced 
genomes. The spectra m/z ratio peaks or signal ions of the microorganisms were 
tentatively assigned to protein biomarkers, by matching experimental spectra MWs 
against theoretical MWs for the protein biomarkers based on genome sequences in 
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internet-accessible protein databases. Subsequent ranking of the organisms 
corresponding to matched ions resulted in the identification of the microorganism.  
 
To further explore the bioinformatics aoproach, a second study was carried out by 
Ryzhov and Fenselau (2000). In the latter study, various features of the proteins rapidly 
desorbed by MALDI from intact E. coli K-12 cells, mass spectra m/z ratio ion peaks 
were also matched and correlated to protein biomarkers found in internet-accessible 
databases.  Forty m/z ratio peaks observed in the mass range 4-20kDa, and the matched 
proteins were analysed for hydrophobicity, basicity, copy number and location within 
the cell. It was shown that the bulk of matched proteins originating from the cytosol, 
were ribosomal, which are abundant within the cell, and are basic in nature with 
medium hydrophilicity.  
 
More recently, another bioinformatics-based approach has been applied for the 
identification of the genus Bacillus (Hotta et al., 2011). MALDI-ToF MS analysis of 
ribosomal proteins as biomarkers i.e. S10, S14, S19, L18, L22, L24, L29, and L30, 
coded in S10 and spc operons successfully distinguished Bacillus subtilis subsp. subtilis 
from B. subtilis subsp. spizizenii. Identification was possible by matching the 
experimental mass spectrum of the ribosomal protein biomarkers against the in silico–
predicted masses of the genome-sequenced Bacillus strains. In another recent study, 
Dieckmann et al. (2008) identified and classified various Salmonella subspecies, i.e. 
Salmonella enterica subsp. enterica, S. enterica subsp. salamae, S. enterica subsp. 
arizonae, S. enterica subsp. diarizonae, S. enterica subsp. houtenae, and S. enterica 
subsp. indica, and Salmonella bongori, using ‘intact cell’ MALDI analysis, based on 
matching 200 spectra protein biomarker peaks. These spectra biomarker peaks with 
masses corresponding mainly to abundant and highly basic ribosomal proteins were 
matched to biomarker masses of Salmonella genome sequence data in internet 
accessible protein databases. 
 
4.3.5.5. Applications of Intact-cell MALDI-ToF MS (ICM) for the Analysis of 
Mammalian cells   
‘Intact-cell’ MALDI-ToF MS (ICM-MS) raises many possibilities for the analysis of 
complex cellular systems like those of mammalian cells. Biomarker profiles have been 
obtained from whole mammalian cells of neuronal origin (Li et al., 2000; van Veelen et 
al., 1993) and tissue sections have been profiled (Chaurand et al., 2006; Chaurand et al., 
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2007; Crossman et al., 2006; Khatib-Shahidi et al., 2006; Reyzer et al., 2007). 
Differentiation between human (K562 and GM15226) and rodent (BHK21) mammalian 
cell types through their protein profile ‘fingerprints’ (Zhang et al., 2006), as well as 
between monocytes, T lymphocytes and polymorphonuclear leukocyte immune cells 
(Ouedraogo et al., 2010) have also been carried out using ICM-MS. These applications 
of ICM-MS in bacterial and mammalian cell protein profiling, demonstrate an outcome 
of the approach that could be useful for mammalian cell culture (MCC) in 
bioprocessing. 
  
Despite the numerous applications of ICM-MS to bacteria and mammalian cells, there 
have been relatively few studies that have applied this approach to MCCs in 
bioprocessing. ICM-MS has been used in profiling insulin/glucagon-producing 
pancreatic islet α- and β-cells (Buchanan et al., 2007); detection of apoptosis in 
mammalian cells (Dong et al., 2011); and characterisation of batches of monoclonal 
IgG-producing CHO cell lines (Feng et al., 2010; Feng et al., 2011). The 2006 work 
from Zhang’s group is an example of a MALDI approach where minimal sample 
pretreatment is involved (Zhang et al., 2006). The paper described a fast and simple 
approach to cellular protein profiling in which mammalian cells were lysed directly in 
the MALDI matrix 2,5-dihydroxybenzoic acid (DHB) and mass analysed using 
MALDI-ToF MS. Similar to the ‘fingerprint’ approach for microorganism 
identification, a unique MALDI mass spectral ‘fingerprint’ was generated in this 
analysis, to demonstrate that it was possible to differentiate between several different 
mammalian cell lines.  
 
Buchanan et al., (2007) applied ICM-MS in a direct analysis to cells from two cell lines 
representative of pancreatic islet α- and β-cells and acquired data in the 2000–20000 m/z 
ratio range.  They identified the expected secretory products (i.e. insulin and glucagon) 
from these intact cultured endocrine cells. Moreover, mass consistent with a protein 
oxyntomodulin was visualised in the cultured α -cells, a finding that had not been 
previously reported.  
 
A recent study conducted by Feng et al., (2010) has clearly demonstrated how 
biomarker profiling by ICM could be exploited to screen cultured mammalian cell lines 
in bioprocessing. They succeeded in distinguishing viabilities of CHO cells through the 
different ‘fingerprints’ of mass spectra after rapid and simple cell pretreatments. A 
                                                                               Protein Profiling for Biomarker Discovery  
 
104 
 
chemometric method (PLS) was used to discriminate between these cell lines with 
different productivities. As a follow-up of this work, the latter group more recently used 
PLS-DA to model spectra data sets obtained from another batch of monoclonal IgG-
producing CHO cell lines (Feng et al., 2011). In both studies mass spectra peaks from 
the spectra generated were identified, and hypothesised as being associated with 
potential protein biomarkers which can be correlated to the productivity of the cell lines. 
 
4.4. Summary 
In this chapter a brief introduction to biomarker discovery was presented with particular 
emphasis on protein biomarker discovery, as well as the biomarker discovery pipeline in 
clinical research. Moreover, an overview of MS-based has associated advantages and 
drawbacks.  
Several key points are as follows: 
 The main advantage of bottom-up proteomics approaches is the ability to 
achieve high resolution separation, the approaches are amenable to automation, 
and there is the availability of sophisticated quantitative proteomic technologies. 
 The limitations of bottom-up proteomics are that they are generally time-
consuming, the samples to be analysed are usually complex, and there is a lack 
of complete coverage of the protein sequence during analysis.  
 The advantages of the top-down approach is the direct determination of the 
MWs of the proteins, the simplified sample preparation procedure and it is less 
time-consuming. 
 The limitations of top-down proteomics is that it is relatively novel, generates 
high dimensionality data which is difficult to analyse, and there are fewer 
bioinformatic tools available for top-down proteomics for protein identification. 
 ICM-MS can be applied for the identification of microorganisms through two 
main approaches: a ‘fingerprint’ approach through direct comparison of intact-
cell spectra considered to be a bacterial protein fingerprint to reference spectra; 
and a bioinformatics approach, by matching a set of experimental protein 
biomarker MWs in the mass spectra with those of sequence-derived theoretical 
MWs of proteins in databases. 
 
The bioinformatics approach to microorganism identification through ICM has been 
widely applied in the field of microbiology as discussed in this chapter. The rapidity and 
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minimal sample preparation advantage of ICM, as well as the usefulness of internet-
accessible protein databases demonstrates aspects of this approach that could be useful 
in rapid biomarker profiling for mammalian cell culture in bioprocessing as well as the 
rapid sorting of important protein biomarkers. A number of studies have already been 
reported in terms of mammalian cell lines. Feng’s research group (Feng et al., 2010; 
Feng et al., 2011) in particular has successfully demonstrated the discrimination of 
monoclonal antibody producing CHO cell lines using ICM and PLS-DA. However, they 
did not use internet-accessible databases to identify protein biomarkers, an aspect that is 
explored and applied in this thesis. 
 
‘Intact-cell’ MS by MALDI-ToF MS is a top-down-based proteomic approach and 
produces high throughput proteomic mass spectra data with high dimensionality. 
Preprocessing plays an important part in reducing the dimensionality of such 
multivariate mass spectra data sets as discussed in chapter 3. Even after performing 
preprocessing that reduces the dimensionality (number of m/z ratio values), such 
reductions are usually insufficient, hence chemometric techniques have to be applied to 
the data to further reduce the dimensionality of the data, mine the data, help classify the 
samples and identify protein biomarkers. The next chapter introduces multivariate data 
analysis techniques, including principal component analysis (PCA) and partial least 
squares discriminant analysis (PLS-DA), the algorithm primarily used in this thesis 
(PLS-DA). It also presents some results on the application of PLS-DA to data for a 
greater understanding of how this technique performs with respect to biomarker 
discovery/identification and classification. 
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5. Partial Least Squares –Discriminant Analysis (PLS-DA) Scores and 
Loadings Plots 
5.1. Overview 
The objective of this chapter is to give a general introduction to and to discuss the 
multivariate data analytical techniques considered in this thesis, principal component 
analysis (PCA), partial least squares (PLS) and PLS –discriminant analysis (PLS-DA). 
These methods are appropriate for analysing high dimensional data sets such as mass 
spectra where the objectives are to obtain an overview of the data (PCA), data 
modelling (PLS) or classification (PLS-DA). PCA is a multivariate projection method 
that is designed to extract the systematic variation in a multivariate data set X. A brief 
introduction to PCA including its mathematical basis is provided. PLS is an extension to 
PCA and is used to develop a model between two blocks of variables, X and Y. A brief 
description of the PLS technique will be given followed by the associated algorithm. 
Particular attention will be given to PLS-DA as it forms a core aspect in terms of the 
mass spectra data analysis since it is used for classification and the eventual 
identification of biomarkers. A detailed explanation of the PLS-DA algorithm is given 
followed by a review of the application of PLS-DA method to other mass spectra 
studies. The chapter concludes with the results of where PCA and PLS-DA were used to 
analyse MALDI-ToF mass spectra data generated from cell lysate samples of E. coli K-
12 cells during different growth phases. This is to demonstrate specifically how the 
scores and loadings plot for the PLS-DA model can be easily interpreted and utilised to 
subsequently identity biomarkers. 
 
5.2. Introduction 
The term chemometrics was first introduced in 1971 to describe the application of 
mathematical, multivariate statistical and other logic-based techniques in the field of 
chemistry, in particular analytical chemistry. The application of chemometrics has 
found considerable success in three areas, (a) calibration and validation of biological 
measurements (multivariate calibration); (b) optimisation of chemical measurements 
and experimental procedures; and (c) extraction of chemical information from analytical 
data (classification, pattern recognition, clustering) (Haswell, 1992).  
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Mass spectra-based proteomic experiments for biomarker discovery typically comprise 
a data generation stage, a data preprocessing step (described in section 3.4) and a data 
analysis phase that may include data mining, pattern extraction and peptide or protein 
identification. The raw MS data has two basic characteristics that serve to guide the 
mining technology to be applied; firstly, the quality of the mass spectra data and 
secondly the issue of high-dimensionality (Hilario and Kalousis, 2008). Preprocessing 
addresses the problem of quality and transforms the MS data into a representation that is 
then ready to be mined.  
  
A mass spectrum typically comprises thousands of m/z ratios and since the sample size 
(e.g. the number of patients) is relatively small, this results in a so-called ‘high 
dimensionality small sample problem’. This data structure is the feature of microarray 
and MS data and suffers from the ‘curse of dimensionality’, i.e. the number of samples 
needed to describe a (discrimination) problem increases exponentially with the number 
of dimensions (variables). (Smit et al., 2007). To solve the high-dimensionality 
problem, it is important to use techniques that are capable of selecting a small number 
of discriminative variables from the thousands of variables in the spectrum. 
 
5.3. Multivariate Projection Methods and Dimensionality Reduction 
There are two approaches to overcome the high-dimensionality problem: variable 
selection or variable transformation. Variable selection is the extraction of a small 
subset of variables (m/z ratio peak selection) whilst variable transformation is the 
creation of new latent variables which express relationships between the original 
variables by applying a mathematical transformation (Fig. 5.1). Fig. 5.1(a) indicates 
how variable selection deletes some of the variables (X1 and X4) from the model, and 
Fig. 5.1(b) shows how in variable transformation all x–variables and transformed into 
linear combinations t1 and t2 which are related to y in a regression equation. 
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A number of variable selection methods have been reported in the literature, including 
the t-test (Wu et al., 2003), the X
2
-performance through neural-network analyses 
(Rogers et al., 2003) and the Wilcoxon test (Kozak et al., 2003). The benefits of 
variable selection are that it is simple and fast to apply, and the results are interpretable. 
Variable selection procedures reduce the size of the original variables by removing 
potentially uninformative variables. The output is a list of variables that contain 
potentially useful information (Hilario and Kalousis, 2008). 
  
However, information contained in the data may be removed when variable selection is 
used to identify uninformative variables if interactions and correlations between 
variables are ignored. Variable transformation methods have the ability to handle the 
large amounts of data contained within the spectra data sets and overcome the issue of 
high-dimensionality. Unlike variable selection, such methods use all the variables 
included in the original data set. The data are projected onto a lower dimensional sub-
space, and new components are attained that provide information underlying the 
structure of the data. Two of these are principal component analysis (PCA) (Pearson, 
1901; Hotelling, 1933) and partial least squares analysis (PLS) (Wold et al., 1984).  
 
Supervised methods such as PLS use the class information to construct new components 
whilst for unsupervised methods, PCA, no class information is utilised (Eriksson et al., 
(a) 
(b) 
Figure 5.1: Conceptual illustration of the differences between variable 
selection and variable transformation (adapted from Naes et al., 2002) 
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1999). During multivariate data analysis of spectra data, an overview of the information 
contained in the data is usually carried out using PCA, with classification techniques 
later applied to identify those proteins considered as significant, and which can then be 
categorised and used as potential biomarkers. PLS is the method that is used in 
regression modeling between two data matrices (X and Y), with the aim of predicting Y 
from X for new observations. 
  
5.4. Principal Component Analysis  
5.4.1. Theory of Principal Component Analysis 
Principal component analysis (PCA) is the method used by chemometricians for data 
compression, information extraction and preliminary visualisation of observations or 
samples (Hilario et al., 2004; Hilario and Kalousis, 2008). PCA’s main function is the 
reduction of the high-dimensionality of the multivariate data to a few dimensions that 
capture the main source of variability in the data. The new space is defined in terms of 
principal components (PCs) that are a linear combination of the original variables.  
 
The weights of the individual variables in the principal components are termed loadings. 
They are useful for identifying the important variables in individual PCs, and also 
contain information on how the variables relate to each other. Scores are the coordinates 
of the original data in the new space and contain information on how samples relate to 
each other with groups of samples indicating similar behaviour (Lee et al., 2003). 
  
5.4.2. The PCA Algorithm 
There are a number of PCA algorithms, including non-iterative partial least squares 
(NIPALS), the power method (POWER), singular value decomposition (SVD) and 
eigenvalue decomposition (EVD). The EVD algorithm is briefly described in this thesis. 
According to this algorithm, PCA is based on the eigenvalue decomposition of the 
covariance or correlation matrix of the original data (Wise et al., 2005). For a given data 
matrix X with m rows and n columns, the covariance matrix of is defined as: 
 
                                                                               
   
   
                                     (5.1)                                   
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provided that the columns of X have been “mean centred”. If the columns of X have 
been “autoscaled”, equation 5.1 gives the correlation matrix of X. PCA decomposes the 
data matrix X as the sum of the outer product of vectors ti and pi: 
                                                              
       
          
                        (5.2) 
In equation 5.2, the ti vectors are known as score vectors while the pi vectors are known 
as the loading vectors. Equation 5.2 can be written in the following matrix form: 
                                                                                                                          (5.3) 
where T = [t1 t2 ... tm]
T
 is the score matrix and P = [p1 p2 ... pm]
T
 is the loading matrix. In 
the PCA decomposition, the pi vectors are the eigenvectors of the covariance matrix; 
    
                                                                                                                     (5.4) 
where λi is the eigenvalue associated with the eigenvector pi.  
 
The PCs are arranged in descending order based on the eigenvalues: λ1 ≥ λ2 ≥ ... ≥ λm 
i.e. the first PC explains the greatest amount of variability with the second PC 
explaining the next greater amount variability in X. As many PCs as variables, if m > n, 
can be calculated but the majority of the variability will be captured in the first few PCs. 
 
Therefore the PCA decomposition of X, can be represented as: 
                                                
       
          
                             (5.5) 
where E is the residual matrix. In practical applications k must be less than or equal to 
the smaller dimension of X, i.e. k ≤ min {m, n}. Since E typically contains noise, it has 
the effect of noise filtering and will not cause any significant loss of useful information.  
 
In this thesis, PCA was first applied to the mass spectra data sets during this project to 
help identify the major factors that may be useful in terms of differentiating between 
samples. 
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5.5. Partial Least Squares Analysis 
Partial least squares (PLS) was first introduced by Herman Wold and co-workers, as a 
method for modeling data sets in terms of chains of matrices, known as path models. 
Wold then developed NIPALS (Non-linear Iterative Partial Least Squares) algorithm, an 
efficient way of estimating the parameters in the path models. The acronym PLS 
(Partial Least Squares) was thus used to refer to these models (Wold, 2001).  
 
The goal of PLS is to relate two sets of variables, predictor variables, X-block, and the 
response variables, y-block (PLS1). In this thesis, the y-block is a vector but the 
algorithm can be generalised to the case where Y is a matrix, PLS2.  The basis of the 
algorithm is: 
                                                                 (5.6) 
                                                                  (5.7) 
where q and f  are the loadings and residual vectors of the response variables. T, P and 
E are the scores, loadings and residual matrices of the response variables respectively. 
The dimensions of T, P and q are M × A, A × N and N × J (J = 1), where A is the 
number of PLS components (latent variables) retained in the model. The PLS scores are 
orthogonal (as in PCA) and each latent variable (LV) is obtained by maximising the 
covariance between y and the X-variables. Fig. 5.2 is an illustration of the principles of 
PLS1. The PLS1 algorithm can be found in Fig. C.1, Appendix C.  
Figure 5.2: An illustration of the principles of PLS1 (adapted from Brereton, 2000) 
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5.6. Partial Least Squares - Discriminant Analysis (PLS-DA) 
PLS-DA is a variant of PLS regression that is used for classification. PLS-DA is used in 
this thesis as it has a number of advantages over other commonly used classification tools 
such as soft independent modelling of class analogies (SIMCA), linear discriminant 
analysis (LDA), canonical correlation analysis (CCA), support vector machines (SVMs) 
and quadratic discriminant analysis (QDA).  
 
In contrast to PLS-DA, SIMCA computes PCA submodels that captures variation within 
a class but it does not identify directions in the data space that directly discriminate 
between classes. The major classification advantage of PLS-DA is that it can handle the 
situation where the number of variables exceeds the number of samples (high-
dimensionality). Overfitting may occur where such models may be describing noise rather 
than the underlying variability in the data set (Barker and Rayens, 2003). Techniques 
such as SVMs are more suited for discrimination analysis as opposed to determining the 
influence of variables (Brereton, 2009). With PLS-DA however, there is the potential to 
determine the important variables which are responsible for discrimination, and hence 
enable the identification of biomarkers.  
 
In PLS-DA the prediction matrix, Y comprises the entries denoting the class with as many 
columns as classes and is termed a ‘dummy’ matrix. If there are two classes to be 
modeled, PLS-DA is based on the PLS1 algorithm, otherwise PLS2 algorithm is used 
where the number of class is greater than 2 i.e. C > 2 (where C = number of classes). 
Typically, ‘1’ denotes belonging to a class and ‘0’ not (Fig. 5.3). As shown in Fig. 5.3, 
the ‘dummy’ matrix contains ‘1’ and ‘0’ which describes class membership of samples in 
a calibration data set. The matrix has 3 columns (for 3 classes) such that 1
st
 column is ‘1’ 
and the others are ‘0’ for samples belonging to class one. In practice, the model does not 
predict either a ‘1’ or ‘0’ precisely, so a threshold value is set, say 0.7, above which a 
sample is assumed to belong to a class otherwise not (Wise et al., 2005).  
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In order to better define the threshold value for classes, a probabilistic version of PLS-DA 
has been developed (Pérez et al., 2009). In this version (used in this thesis), the 
distribution of calibration sample predictions ( ̂) obtained from a PLS model built for two 
or more classes to determine a threshold value which will best split the classes with the 
least probability for false classification for future predictions. If the calibration data 
contains more than two classes, the thresholds to distinguish each class are determined 
(Botella et al., 2009).  
 
The algorithm for the probabilistic PLS-DA version calculates the classification threshold 
based on a probability density function (PDF) with the mean and standard deviation of all 
the sample predicted responses,  ̂, for each class. It assumes that the predicted responses 
for samples for each class in the calibration data set are approximately normally 
distributed. An empirical PDF is then used to derive posterior probabilities based on 
Bayes Theorem and a threshold is defined, the value of  ̂ at which the posterior 
probabilities of both classes are equal. It is based on this threshold that a sample is 
assigned to a class. The probabilistic PLS-DA algorithm used in this thesis is described in 
detail in the following sections. 
 
5.6.1. Summary of PLS-DA Algorithm 
The algorithm started with the calculation of a PLS model (see PLS1 algorithm in Fig. 
C.1, Appendix C) for A latent variables (LVs) with spectra data sets (X-block) for 
calibration samples and y vector (Fig. 5.4). The PLS-DA algorithm applied performed 
classification on two classes at a time (C = 2), so the y vector contained ‘1’ and ‘0’ which 
describes class membership of calibration samples as belonging to class,    (the class of 
4
th
 sample 
belongs to 
class 2 
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7
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Figure 5.3: A ‘dummy’ matrix structure showing ‘1’ and ‘0’ denoting 
class of samples 
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interest) otherwise   . For a sample i (i = 1,2,3,…,m), the value predicted by the PLS 
model was,  ̂  , calculated from equation 5.8, where,    , were the regression coefficients 
of the PLS model for A LVs. With the y vector coding class membership, calibration or 
training samples with predicted values close to 1 were assigned to class,   , whilst those 
with predicted values close to 0 were assigned to class   . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The PLS-DA algorithm was as follows:  
Step 1: Predicted Responses of Samples 
For each training sample i (i = 1,2,3,…,m) the predicted response value,  ̂   was 
calculated: 
 ̂      
  ̂                                                         (5.8) 
where    is the column vector of n m/z ratios measured for that sample and,  ̂, is the 
vector of regression coefficients attained from the PLS model.  
Step 2: Gaussian Functions 
For each of the m training samples a Gaussian function centred at the predicted value,  ̂  , 
was calculated: 
    ̂  (
 
    √  
)    
 (
( ̅  ̂  )
    
)
 
                                  (5.9) 
 
1
st
 sample 
belongs to class 
of interest, 𝜔 . 
7
th
 sample does not 
belong to class of 
interest, hence belongs 
to class 𝜔 . 
Figure 5.4: A y vector structure showing ‘1’ and ‘0’ denoting 
class of samples 
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where SEPi is the standard error of prediction of the samples (i = 1,2,3,…,m),  ӯ is the 
known mean of predicted values ( for class    or   ), and  ̂   is the predicted value (Fig. 
5.5). The figure shows a plot of the potential functions,    ̂     (c = 1 or 0), as a function 
of the predicted value, which were the Gaussian functions centred at each   ̂    of samples 
of each class. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 3: Probability Density Functions (PDFs) 
The Gaussian functions of the training samples,   , belonging to class   , the class of 
interest, were averaged to obtain the probability density function (PDF) of the class. 
)ˆ(
1
)/ˆ(
11
1 yf
m
yp
cm
i
i

                                               (5.10) 
The procedure was repeated for the   training samples belonging to the class   . 
)ˆ(
1
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0
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0 yf
m
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m
i
i

                                               (5.11) 
where    ,    ̂     and   ,    ̂      are the number of samples and PDFs of class    
and class   , respectively (Fig. 5.6). Fig. 5.6 shows a plot of the PDFs,    ̂     (c = 1 or 
0), as a function of the predicted value. The PDFs were the averages of the Gaussian 
functions centred at each   ̂   of samples for the two classes,    and   . 
 
Figure 5.5: Calculation of the Gaussian functions for class 𝝎𝟏 and 
class 𝝎𝟎, centred at each  ?̂?𝒊  
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Step 4: Posterior PDFs 
Using Bayes theorem, the posterior PDFs were calculated: 
)ˆ(
)()./ˆ(
)ˆ/( 111
i
i
i
yp
Pyp
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
                                       (5.12) 
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i
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                                      (5.13) 
where     ̂     and    ̂     are the conditional probabilities while       and       
are the prior probabilities. Both the priors were estimated as the proportion of samples of 
each class in the training set, as the set was a representative of the total number of 
samples, m, that is: 
     ) =      and       ) =    , where m =      . 
The denominator of equation (5.12) and (5.13) was: 
                                ̂    =    ̂      .       +     ̂      .                                                 (5.14)          
 
 
 
Figure 5.6: PDFs for classes 𝝎𝟏 and class 𝝎𝟎 was calculated as the 
average the individual Gaussian functions for each class in Fig. 5.5 
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Step 5: Classification Threshold 
The value of  ̂ (predicted value) corresponding to the point where the two posterior 
probability functions (for class    and   ) are equal is identified as the threshold value, 
  , for the class of interest. The threshold value,   , for each class can then be used to 
classify the test samples (Fig. 5.7).  
 
Fig. 5.7(a) shows a plot of the PDFs,    ̂      multiplied by the prior probability       
(c = 1 or 0), as a function of the predicted value, whilst Fig. 5.7(b) shows a plot of the 
posterior probability,       ̂ , versus the predicted value. Fig. 5.7(b) also shows the 
point where posterior probabilities were equal, indicating the classification threshold. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
Figure 5.7: PDFs for classes 𝝎𝟏 and class 𝝎𝟎 and classification 
threshold for class 𝝎𝟏 
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Step 7:  Classification Rule 
The predicted,  ̂     , for a test sample was first calculated from equation 5.8, and 
the samples were then classified according to the following rules: 
 
Assign the sample to: class    if   ̂     >   ; otherwise assign to class   . 
 
A flow chart of the PLS-DA algorithm described above for the modelling of 
MALDI-ToF mass spectra data sets is shown in Fig.  5.8. 
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Figure 5.8: Flow chart of the PLS-DA algorithm for modeling of MALDI-ToF mass 
spectra data sets 
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5.6.2. Applications of the PLS-DA Algorithm 
5.6.2.1. MALDI-ToF Mass Spectra Data of E. coli K-12 Cells at Different Growth 
Phases  
The PLS-DA algorithm (described in section 5.6.1) was initially applied to MALDI-
ToF MS data obtained from E. coli cell samples to determine if such an approach could 
be used to distinguish between and characterise different growth phases. For the 
application of PLS-DA, the training data set consisted of a matrix, X, of E. coli culture 
MALDI spectra, comprising 7000 m/z ratio values measured for 300 samples, and a 
dependent variable vector, y (300 × 1) in which the class of each sample was coded as 
‘0’ or ‘1’ depending on whether it belongs to the class of interest or not. The PLS-DA 
algorithm performed classification on two classes at a time and the classes were defined 
as follows:   , class 1 represented the decline phase;   , class 2 represented the 
exponential phase; and   , class 3 represented the stationary phase. One of the classes 
was defined to be the one of interest, i.e. coded as ‘1’ and the other two were coded as 
‘0’ i.e. class   . 
 
5.6.2.2. MALDI-ToF Mass Spectra for IgG Monoclonal Antibody producing CHO 
Cell Lines 
MALDI-ToF mass spectra were generated from IgG monoclonal antibody producing 
Chinese hamster ovaries (CHO) cell lines. The PLS-DA algorithm was also applied to 
model the data to discriminate between high and low producer cell lines. For this data 
set, the training sample consisted of a matrix, X, the CHO cell line MALDI spectra, 
comprising 18092 m/z ratio values measured in 44 samples, and a dependent variable 
vector, y (44 ×1), in which the class of each sample was coded as ‘0’ or ‘1’ depending 
on whether it belongs to the class of interest or not. The classes were defined as follows: 
  , class 1 represented the high producer cell lines (Hs) whilst   , class 2 represented 
the low producer cell lines (Ls). 
  
5.6.3. PLS-DA Model Quality and Performance Evaluation 
5.6.3.1. Calibration 
After the application of PLS-DA the quality and performance of the models is assessed 
mainly through their ability to predict unknown response (y) values. This is even more 
important when selecting the number of latent variables (LVs), A, to include in the 
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model. It is important to select an appropriate number of LVs which guarantees good 
model quality and performance without overfitting i.e. when the model describes noise 
rather than the underlying variability in the data set. One measure used is the root mean 
square error of calibration (RMSEC) (Naes et al., 2002). It gives indication about the fit 
of the model to the calibration data set. It can be used to access the model quality and it 
is a measure of how well the model fits the data. It is the error of calibration and the 
smaller it is, the greater is the model quality. 
    
 
M
yy
RMSEC
I
i
ii


 1
2
ˆ
                                          (5.15) 
where iy  and iyˆ  are the actual and predicted value of the response for the ith 
calibration sample  respectively, and M is the number of calibration samples. 
 
5.6.3.2. Cross-validation 
Cross validation involves the removal of a subset of samples from the calibration set, 
and the construction of a model using the remaining samples, and the subsequent 
application of the resulting model to the samples withheld from the calibration set. This 
way the model is tested with samples that were not used to build the model (Naes et al., 
2002). The process is repeated for a number of subsets of the calibration data set. 
Estimation of the root mean square error (RMSE) based on this technique is the RMSE 
of cross-validation (RMSECV). The RMSECV is a measure of the model’s ability to 
predict samples that were not used to build the model. A good model compared to 
others is one that has the lowest RMSECV.  
 
5.6.3.3. Prediction Testing 
Prediction testing is an external validation technique based on splitting the samples into 
two, one set called the training or calibration set and the other called the test set. The 
prediction testing estimate is called the root mean square error of prediction (RMSEP). 
The latter is a RMSE assessment involving the use of a test set of samples that have 
known y-values. RMSEP is obtained when the model is applied to the test data.  
 
                                                                Partial Least Squares –Discriminant Analysis (PLS-DA)  
 
123 
 
5.6.3.4. Coefficient of Determination (R2) 
The coefficient of determination (R
2
) of a model is a measure of the goodness of fit of 
the model and can be used to assess the quality of the model. It lies between 0 to 1 and 
the quality of the model improves as R
2 
gets closer to 1. It is calculated as follows: 
 
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                                              (5.16)
 
where iy  and iyˆ  are the actual and predicted value of the response for the ith sample  
respectively;  is the average response for calibration (R
2
),  for validation (R
2
CV),  or for  
prediction (R
2
p); and M  is the number of samples. 
 
5.7. Review of the Applications of PLS-DA on Mass Spectra Data 
PLS-DA modelling has been applied in a number of areas of proteomic research and 
technology (Lee et al., 2003; Norden et al., 2005; Liley and Cupree, 2006; Pierce et al., 
2006; Feng et al., 2011). Lee et al. (2003) directly applied PLS-DA to address the high-
dimensionality problem involving a proteomic mass spectra data set comprising 60,000 
m/z ratio variables. The PLS-DA model performed well, reducing the data set to 545 
m/z ratio variables, and clearly identifying biomarkers that potentially contributed to the 
discrimination between normal and diseased specimens of cancer patients.  
 
In another biomarker identification study, Norden et al., (2005) applied PCA and PLS-
DA to mass spectra data from clinical urine samples. A number of peptide-biomarker 
fingerprints related to the diagnosis and progression of chronic obstructive pulmonary 
disease were identified. A similar approach was adopted by Liley and Dupree, (2006), 
to study plant organelles. Quantitative proteomic analysis using differential isotope 
tagging strategies coupled to non-gel-based LC-MS allowed proteins in different 
organelles to be discriminated between based on their differential fractionation in 
density gradients of the LC. PCA and PLS-DA scores plots showed clustering of 
proteins according to their subcellular localisation. 
 
PLS-DA was applied to linear mode MALDI-ToF mass spectra data to confirm the 
identification and presence of the microorganism Coxiella burnetti as a category B 
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bioterrorism agent in the U.S. (Pierce et al., 2006). The mass spectra data were 
preprocessed (normalisation, baseline-correction, filtering, and binarisation) prior to 
being modeled by PLS-DA using leave-one-out cross-validation. The model was 
validated by the prediction of unknown C. burnetii test samples resulting into a 100% 
sensitivity (proportion of actual C. burnetii samples correctly classified) and specificity 
(the proportion of non C. burnetii samples correctly classified), and successfully 
identifying five out of six strains of the microorganism. 
 
A recent study conducted by Feng et al., (2011) demonstrated how biomarker profiling 
by ‘intact cell’ MALDI-ToF mass spectrometry in combination with chemometrics 
could be exploited to screen cultured mammalian cell lines in bioprocessing. They 
succeeded in distinguishing viabilities of IgG-producing CHO cell lines through 
different ‘fingerprints’ of mass spectra for the CHO cells. PLS-DA was used to 
discriminate between the cell lines with different productivities. In this study, m/z ratio 
peaks from the spectra generated were identified, and hypothesised as being associated 
with potential protein biomarkers which could be correlated to productivity of the cell 
lines. 
  
5.8. Multivariate Data Analysis of MALDI-ToF Mass Spectra Data 
from E. coli K-12 Cell Lysate at Different Growth Phases Using 
PCA and PLS-DA 
The multivariate projection methods (PCA and PLS-DA) were applied to MALDI-ToF 
mass spectra data generated from cell lysate samples of E. coli K-12 cells at different 
growth phases. The application of PCA and PLS-DA to the spectral data was carried out 
using the MATLAB® software v.7.6.0.324 (R2008a, The MathWorks, Inc.) and the 
MATLAB® PLS Toolbox v.3.5 (Eigenvector Research, Inc.). 
 
5.8.1. Data Sampling 
The cell lysate sample preparations as well as MALDI-ToF analysis of the samples to 
generate the spectra data sets has been described in chapter 3.3.7.1. The data were first 
divided into a training and a test data set, for each group of spectra samples 
(exponential, stationary and decline phases) using simple random sampling. There is no 
generally accepted rule as to the proportion of samples to assign to the test and training 
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set (Brereton et al., 2009). In this application, 4/5 of the samples were placed in the 
training set whilst the rest were included in the test set. 
From a total of 120 exponential phase cell lysate spectra samples, 100 were selected as 
training samples and 20 as test samples. For the stationary phase samples, the split was 
100/16 training/test, and for the decline phase the split was 100/19 training/test. This 
gave a total of 300 spectra for training and 66 for testing. The data set was represented 
by three classes: class 1, decline phase; class 2, exponential phase; and class 3, 
stationary phase. The data sets were first preprocessed (section 3.6) and PCA was then 
applied to the preprocessed mass spectra. 
  
5.8.2. Results 
The results in this section are focused primarily on the interpretations of PCA and PLS-
DA scores and loadings plot to emphasise their importance in this work, and to 
specifically demonstrate how the PLS-DA scores and loadings are graphical 
representations that can easily be interpreted and subsequently used in biomarker 
identification.  
 
5.8.2.1. Interpretation of Principal Component Analysis Scores Plot 
Prior to sampling the data into training and test sets, PCA was applied to get an 
overview of the 355 preprocessed cell lysate mass spectra to identify any groupings and 
to determine if differences occur due to the growth phase. The first three principal 
components (PCs) were retained and these account for 93.36% of the variability (Table 
B.1 in Appendix B). The PC scores plots are shown in Fig. 5.9(a) and (b). The Samples 
are colour-coded according to their growth phase or class and the ellipse (blue dashed 
line) represents the 95% confidence region based on Hotelling's T
2
. The three-
component model shows clear evidence that class 2 (exponential phase samples) are 
separate from the other two classes along the second principal component (Fig. 5.9(a)). 
Separation between class 1 and 3 is not evident from the three PCs. These preliminary 
observations suggest that a major part of the spectral variation is related to the growth 
phase.  
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5.8.2.2. PLS-DA Model Quality and Performance 
The next step was to apply PLS-DA to the full preprocessed 300 calibration mass 
spectral profiles from the E. coli cell lysate. During PLS-DA model calibration, leave-
one-out-cross-validation (LOOCV). In practice, the cross-validation (CV) method used 
here can be termed a leave-class-out-cross-validation (LCOCV), a modified version of 
LOOCV, where all samples belonging to the same class were removed from the 
calibration data set and a sub-model based on the remaining samples was used to build 
the PLS-DA model and predict the left out samples.  
 
The process was repeated with all the 300 calibration data set until each of the three 
classes had been left out once. Since samples of the same class were replicates, LCOCV 
helped to avoid the ‘replicate sample trap’; where the presence replicates of the same 
physical sample in both the calibration and test data sets may lead to overly optimistic 
cross-validation results giving a biased estimate of the error rate (Hansen et al., 2009). 
A cross-validation was customised by creating a vector (Fig. B.1, Appendix B) and 
specifying how the cross-validation was to be performed. The validation residual 
variance, the RMSECV was then computed to help identify the number of LVs to 
retain. Fig. 5.10 shows a plot of RMSECV as a function of number of LVs. For the class 
2 samples (RMSECV 2), the error stabilises after 4 LVs whilst for the other two classes 
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Figure 5.9: PCA overview of 355 mass spectra data sets for E. coli cell lysate samples 
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(1 and 3) the RMSECV is a minimum for LV1. From Fig. 5.10, as the results were not 
conclusive 3 LVs were retained. 
 
 
 
 
 
 
 
 
 
 
 
The percentage of variance explained for the individual LVs and the individual and 
cumulative explained is reported in Table B.2 (Appendix B), for the 3 LVs. The 3-LV 
PLS-DA model captured 90.50% of the X-block variance and explained 85.25% of the 
Y-block variance of the training data set. From the results reported in Table B.3 
(Appendix B), the quality of this model was good, according to the values of R
2 
calculated both fitting (73.1% for class 1, 93% for class 2 and 67.2% for class 3) and in 
cross-validation (86.3% for class 3). Table B.3 shows that the quality of the model was 
good both in calibration and CV with a sensitivity (proportion of samples correctly 
classified that belong to the class being modeled), and specificity (proportion of samples 
correctly classified that do not belong to the class being modeled) of at least 92%. This 
suggests that the model had a good practical value.  
 
The same conclusions can be drawn from Fig. B.3 (Appendix B) representing the 
calculated versus the measured responses both in fitting and in prediction (using test 
sample). This suggests that all the useful information was taken into account by the 
model. The model was successfully validated using the test data sets, and results of the 
model performance are summarised in Fig. B.3 and Table B.4 (Appendix B). The 
successfully validation of the model means that the model parameters such as scores 
and loadings are valid. 
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5.8.2.3. Interpretations of PLS-DA Scores Plot  
The practical value of the model was demonstrated by its ability to discriminate 
between the three classes as shown in the scores plot (Fig. 5.11). A plot of the first two 
components (LV1 vs LV2) shows that the model concentrates most of the 
discriminating information into the second LV (Fig. 5.11(a)). Exponential phase (class 
2) samples appear quite distinct from the other two classes and have high positive 
scores along LV2 well separated from the other two classes with negative scores along 
the same LV. A few stationary phase samples however are borderline and have low 
positive scores. This observation is supported by a plot of scores on LV2 as a function 
of samples (Fig. 5.11(c)). A plot of LV2 vs LV3 (Fig. 5.11 (b) and (d)). shows that there 
is an indication of separation between stationary phase (class 3) and decline phase (class 
1) samples along LV3, with overlapping. Majority of class 3 samples have a positive 
score whilst their class 1 counterparts have a negative score (Fig. 5.11(b)). This 
observation is supported by a plot of scores on LV3 as a function of samples (Fig. 
5.11(d)). 
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Figure 5.11: PLS-DA scores plots for the 300 preprocessed calibration spectra data sets for 
cell lysate 
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5.8.2.4.   Interpretations of PLS-DA Loadings Plot 
The PLS-DA loadings plot for a specific LV potentially contains valuable information 
regarding the regions of the mass spectra (m/z ratio peaks or signal ions) that contribute 
to the ability of the PLS-DA model to distinguish between classes. There is a direct 
geometric link between the scores and the loadings plot of PLS-DA, so interpreting 
scores and loadings plot together could provide the possibility of identifying the mass 
spectra regions (from the loadings plot) that influence the behavior of samples in the 
scores plot.  
 
The loadings plot for LV2 and LV3 (Fig. 5.12) indicates which variable loadings 
(associated with m/z ratio signals in the MALDI data sets) that contain information that 
is causing the separation of the samples in the scores plot. The loadings describe the 
weighting coefficients for each m/z ratio signal ions (experimental MWs of proteins) 
with the magnitude of the variable loadings being indicative of how the expression of 
proteins varies with growth phase. In Fig. 5.12(a), it can be seen that variables 3578, 
3462 and 2679 have absolute loadings of large positive magnitude. Since the 
exponential phase cell samples have positive scores along LV2, this implies that these 
samples can be differentiated from the other two classes by these m/z ratio signal ions 
associated with variables of large positive loadings in the LV2 loadings plot. These 
signal ions potentially identify those proteins which are differentially expressed in cells 
during the exponential phase and are most likely to be biomarkers of the exponential 
phase. 
 
For the loadings associated with LV3 (Fig. 5.12(b)), the variables 3110, 2635 and 2293 
have loadings with large positive magnitude. Most stationary phase cell samples can 
thus be differentiated from decline phase samples by the presence of m/z ratio signals 
associated with variables with positive loadings in the LV3 loadings plot. These m/z 
ratio signal ions are indicative of those proteins which are differentially expressed in 
cells during the stationary phase. Variables 3639, 3095 and 2684 have loadings with 
large negative magnitude on the LV3 loadings plot (Fig. 5.12(b)), and since the decline 
phase cell samples have negative scores along LV3, they can be distinguished from the 
stationary phase cell samples by the differential expression of proteins associated with 
signals with positive loadings in the LV3 loadings plot.  
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To identify protein biomarkers through data base searches, PLS-DA loadings plots for 
LV2 and LV3 can be considered for further analysis.  The variables from the loadings 
plot are associated to m/z ratio peaks or signal ions, and since most of the m/z ratio 
signal ions are singly charged protonated protein (MH
+
) molecules, they represent the 
approximate MALDI experimental molecular weights (MWs) of the ionised proteins 
Figure 5.12: PLS-DA loadings plots on LV2 and LV3 
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expressed by the cells at the different growth phases. The MWs of protein ions can be 
used as search parameters and matched with sequence derived theoretical MWs of 
proteins in the UniProtKB/Swiss-Prot database (http://expasy.org/proteomics). Details 
of how the database searches are carried out as well as the identified protein biomarkers 
are explained in section 6.5 (chapter 6). The biological implications of such identified 
biomarkers are also given subsequently. 
 
5.9. Summary  
In this chapter an introduction to multivariate data analysis was given focusing on the 
dimensionality reduction techniques of PCA and PLS-DA. It has been proposed in the 
literature that these methods are more realistic for multivariate data analysis of data sets 
such as mass spectra because of their ability to handle large amounts of data by 
reducing the high-dimensionality, handling correlated variables, ability to handle 
missing data, and providing graphical representations that are informative and easily 
interpretable. PCA, PLS and PLS-DA were introduced including the underpinning 
theory. 
 
The probabilistic PLS-DA approach was explored and the PLS-DA algorithm used in 
this thesis was outlined. Applications of PLS-DA algorithm were demonstrated using 
MALDI-ToF mass spectra data obtained from E. coli cell samples to distinguish 
between and characterise different growth phases. A second application for the 
algorithm considered spectra from IgG monoclonal antibody-producing CHO cell lines.  
 
The chapter is concluded with results of an example where PCA and PLS-DA were 
applied to MALDI-ToF mass spectra data generated from cell lysate samples of E. coli 
K-12 cells at different growth phases. Results of the models were shown and 
interpreted. Scores plot (shows relationships among the samples as in PCA) were also 
shown and interpreted, in order to demonstrate how results from these multivariate 
projection methods are easily interpretable. PLS-DA loadings (parameters that also 
supply information related to the variables) were also explained and interpreted. The 
importance of using loadings plots for database searches for biomarker identification as 
well as how this is carried out is explained in section 6.4.3 (chapter 6). 
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6. CASE STUDY I: Biomarker Profiling Of E. coli Utilising the 
ICM, PLS-DA, and Protein Database Search Approach  
6.1. Overview 
In previous sections, the potential and applications of the methods of intact-cell 
MALDI-ToF MS (ICM-MS) (section 4.3.4.1), projection to latent structure – 
discriminant analysis (PLS-DA) (section 5.6), and protein database search (section 
4.3.4.3) in various areas of proteomics have been discussed. In this chapter, the 
approach of combining ICM-MS, PLS-DA, and protein databases search is applied for 
growth phase-associated protein biomarker profiling of E. coli K-12 cultures. This case 
study was going serve as a proof-of-concept study for applying this approach for 
biomarker profiling of IgG-producing CHO cell lines during bioprocessing discussed in 
chapter 7. 
6.2. Specific Aims of Chapter 
The purpose of this study is to serve as a proof-of-concept study for applying the 
approach (ICM-MS and PLS-DA along with a database search) for biomarker profiling 
of IgG-producing CHO cell lines during bioprocessing. In this study a ICM-MS and 
PLS-DA  along with a database search, is used to identify potential protein biomarkers 
associated with the different growth phases (exponential, stationary and decline) of 
unprocessed whole (or intact) E. coli K-12 culture.  
 
Biologically, it is expected that E. coli cultures at the three different phases of growth 
exhibit different metabolic profiles and hence different protein expression patterns so 
that unique proteins can be induced and differentially expressed by these cultures. It is 
anticipated that the latter protein expression patterns correlate with the growth phase of 
the culture, and hence between-class (exponential, stationary and decline phase classes) 
variability will be evident. The multivariate classification method (PLS-DA) is used to 
capture these differences and hence classify the E. coli cells. A database search (based 
on the bioinformatics approach of microorganism identification), by matching the 
MALDI spectra experimental molecular weights (MWs) to sequence-derived theoretical 
MWs of E. coli cells using internet accessible protein databases, was then carried out to 
identify potential growth-phase-associated protein biomarkers.  
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Figure 6.1 shows an overview of the various steps involved in biomarker profiling using 
ICM-MS, PLS-DA and protein database search used in this E. coli growth phase-
associated protein biomarker profiling model. It begins with preparation of the E. coli 
cell samples at different growth phases (section 6.1), the analysis of the samples by 
MALDI mass spectrometry, and preprocessing of the spectra data generated to remove 
to remove unwanted variation whilst preserving biological information. Sampling is 
carried out on the preprocessed data sets to separate the samples into training and test 
sets. The training set is overviewed using PCA to study initial trends and later analysed 
using PLS-DA, whilst the test sets are retained for external validation of the PCA and 
PLS-DA models built. PLS-DA scores and loadings plot are interpreted. The 
information from the scores and loadings plot is used for database searches to identify 
protein biomarkers.  
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Figure 6.1: An overview of the various steps involved in the growth phase-
associated protein biomarker profiling of E. coli K-12 cultures using ICM-MS, 
PLS-DA and protein database search 
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6.3. The Bacterial Growth Curve and Growth Measurements 
The growth of bacteria in culture comprises a number of phases, characterised by a 
variation in the growth rate (Monod, 1949). The following definitions are growth phases 
usually distinguished in a bacterial culture, assuming a genetically homogeneous 
bacterial population. In Fig. 6.2,  A is the lag phase of null growth rate (initial 
acclimatisation of cells to their new environment); B, the acceleration phase: growth 
rate increases; C, the exponential (logarithmic) phase: growth rate is constant (rapid 
growth as cell biomass increase linearly with time); D, the retardation phase: growth 
rate decreases; E is the stationary phase: null growth rate (nutrient becomes exhausted, 
rapid growth is halted); F. accelerated death phase; G, the logarithmic decline phase of 
negative growth rate negative (waste accumulates, cells die) (Stainier et al., 1987). It is 
not uncommon for one or several of these growth phases to be absent. For instance 
under suitable conditions of abundant nutrients, the lag and acceleration phases may 
often be suppressed.  It is also not uncommon to have very short retardation or 
stationary phases so that they are indiscernible (Monod, 1949). Thus some phases are 
usually ignored to give the main growth phases as lag, log, stationary and death phases. 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Schematic diagram of a bacterial culture growth curve 
showing the various growth phases 
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In this study, cells were grown in culture, and samples were prepared and MALDI-ToF 
mass spectra were recorded in a manner comparable with the previously reported 
studies (Saenz et al., 1999; Reilly et al., 1999; Holland et al., 2000; Harrington et al., 
2008). Samples were collected and analysed from the cultures at points in the three 
specific growth phases (exponential, stationary and decline phases). To determine the 
sample collection times (in hours), the bacteria was first grown in culture and the 
growth curve was determined. The predictable timing of growth along the growth curve 
ensured that samples (bacteria cell pellets) were collected at specific time points during 
the three growth phases (Fig. 6.3). This increased the likelihood that differences 
between identified proteins will be related to the progression from one growth phase to 
another. The specific points (indicated by the thick arrows) of the growth curve at which 
samples were collected for MALDI analysis are shown on Fig. 6.3. To quantify the 
amount of bacteria to be analysed in the MALDI, the wet/dry cell weights (mg/mL) and 
bacterial number through the viable cell counts (CFU/mL) were also determined. The 
next sections describe the materials and methods used in this study, followed by the 
results, discussions and conclusions drawn. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: Growth curve (optical density vs growth time) of E. coli 
K-12 grown in 200mL LB growth media 
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6.4. Experimental Section  
6.4.1. Materials 
This section outlines the materials used to carry out the laboratory experiments. Freeze-
dried stock cultures of E. coli K-12 strains ATCC 15223 were purchased from DSMZ 
GmbH, Germany. Acetonitrile/trifluoroacetic acid (ACN/TFA; 0.1%, v/v), absolute 
ethanol (Analytical grade reagent), glycerol (100% analytical grade reagent), 
hydrochloric acid (~36%), formic acid, and acetonitrile were obtained from Fisher 
Scientific, UK. Calcium chloride, disodium hydrogen phosphate, potassium dihydrogen 
phosphate, sodium chloride (Sigma Ultra, min 99.5%), were purchased from Sigma-
Aldrich Co., USA. Distilled water was obtained from a Milli-Q Plus purification system 
(Millipore Corporation, Bedford, MA, USA). Nutrient broth was purchased from Oxoid 
(Basingstoke, Hampshire, United Kingdom) and nutrient agar was obtained from 
Merck, Germany. Sinapinic acid and the MALDI-ToF calibrant (a protein mixture 
containing insulin, ubiquitin I, cytochrome C, and myoglobin) was purchased from 
Bruker Daltonics, GmbH, Germany. 
6.4.2. Culture Growth 
This section briefly describes how the bacteria were cultured. Glycerol stocks were 
prepared from the freeze-dried stock cultures of E. coli. A growing culture was used to 
inoculate a 100 mL Luria Bertani (LB) medium in an Erlenmeyer flask and grown 
overnight at 37
o
C in a shaker incubator set at 200 rpm. The volume required to produce 
an optical density at 600 nm (OD600) of 0.05 OD units was then used to inoculate three 
flasks of 100 mL LB medium. The OD600 of the cultures were measured with a 6705 
UV/Vis Spectrophotometer (JENWAY, Bibby Scientific Ltd, UK) at hourly intervals of 
incubation. 
 
6.4.3. Determination of Bacteria Numbers, Dry and Wet Cell Weights 
The bacteria was quantified using both standard plate counting on nutrient agar and by 
measuring the wet cell weight (WCW) and dry cell weight (DCW). Serial dilutions of 
bacterial culture were plated and incubated after which colonies were counted. For 
weight determination, ten 1 ml samples of culture were centrifuged at 17949 × g for 10 
mins in a bench-top centrifuge in pre-weighed tubes. The supernatants were carefully 
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removed by first pouring and then using stretched cotton wool swabs. The tubes 
containing cell pellets were then re-weighed both whilst wet and following drying, and 
the weight of the cell pellet was determined. Calibration curves determined from serial 
dilutions of the 12-hour culture using the bacteria numbers and weights were used to 
determine the amount of bacteria to be analysed by the MALDI. 
 
6.4.4. MALDI-ToF MS Analysis and Data Preprocessing 
‘In-tact cell’ sample preparation for MALDI analysis was carried out (on samples that 
had been stored at -70
o
C) as described in section 3.3.7.1. Previously, the calibration 
curves were used to determine the amount of ‘intact’bacteria cell pellets (approximately 
3.3 × 10
9
cells, 10.2 mgmL
-1
 (WCW), and 0.44 mgmL
-1
 (DCW)) to be analysed. All 
mass spectra were acquired with an Ultra Flex MALDI-ToF mass spectrometer (Bruker 
Daltonics, GmbH, Germany), located in the School of Biosciences, University of Kent, 
Canterbury, Kent, UK. The instrument parameters used as well as the analysis 
procedure has been described in section 3.3.7.1. Data preprocessing was carried out as 
described in section 3.6 using in-house scripts developed from MATLAB
®
 v.7.6.0.324 
(R2008a the MathWorks, Inc.) and functions from the Bioinformatics Toolbox of 
MATLAB
®
 (v 3.1, R2008a, Eigenvector Research, Inc.). Preprocessing studies was 
carried out as described in section 3.6, to find the appropriate combination of 
preprocessing techniques. 
 
6.4.5. Multivariate Data Analysis 
The application of multivariate data analysis (PCA and PLS-DA) to the spectral data 
was carried out as described in section 5.8 using the PLS Toolbox v.3.5 and MATLAB
®
 
software v.7.6.0.324 (Eigenvector Research, Inc.). The first step was to divide the mass 
spectra data into training and a test data set for each group of spectra samples 
(exponential, stationary and decline phases). The PLS-DA algorithm used in modeling 
this data set has been described in detail in section 5.6.1. 
 
Random sampling was undertaken and 80% of the samples were placed in the training 
set whilst the rest were included in the test set. For the exponential phase, 100 were 
denoted as training samples and 22 as test samples, with 100 training and 20 test 
samples for the stationary phase; and finally 100 selected as training set and 24 as test 
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set samples for the decline phase. This resulted in a total of 300 training samples and 66 
test set samples (from a total of 366 E. coli cell samples). PCA was then applied to the 
preprocessed mass spectral data sets to identify any groupings. 
 
6.5. Database Search 
The m/z ratio peak values (as experimental MWs) were submitted to a protein database 
search with the aim of assigning protein identities to mass spectra ion signals obtained 
from the PLS-DA modeling results. The searches were conducted using the MALDI 
mass spectra protein experimental MWs and the organism’s theoretical MWs found in 
the UniProtKB/Swiss-Prot database, which is the Expert Protein Analysis System 
(ExPASy) of the Swiss Bioinformatics Institute (http://expasy.org/proteomics).  With 
the query specified as E. coli K-12, the experimental MWs were matched to biomarker 
peaks contained in the Protein Knowledgebase (UniProt) and TrEMBL query form 
given in the database for the identification of the bacterial main biomarkers. Potential 
assignments from m/z ratio signal ions were possible for a number of m/z ratio values 
within the range 4 to 20kDa. 
 
6.6. Results and Discussions  
6.6.1. PCA Modeling of E. coli MALDI-TOF MS Data at different Growth Phases 
PCA was applied to the 366 preprocessed mass spectral for preliminary data 
visualisation. The objective of applying PCA was to determine if the growth phase is 
the trend that differentiates samples into classes. The scores of the first three principal 
components (PC1 vs PC2 and PC2 vs PC3), which account for 93.73% of the variability 
in the original data set are shown in Fig. 6.4 and the variance explained is summarised 
in Table 6.1.  
 
 
Principal 
component (PC)  
number 
Eigenvalue of 
covariance (X) 
% Variance captured 
for this PC 
Total % variance 
captured 
               1 1.36 × 10
5
 81.37 81.37 
2 1.71 × 10
4
 10.25 91.62 
3 3.53 × 10
3
 2.12 93.73 
Table 6.1: Results of PCA model for all 366 mass spectra data sets for intact cells 
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In Fig. 6.4, the ellipse (blue dashed line) represents the 95% confidence region for the 
two PCs based on Hotelling's T
2
. The samples are colour-coded according to their 
growth phase or class. The three-component model shows clear evidence of class 2 
(exponential phase culture samples) being separate from the other two classes along the 
second principal component (Fig. 6.4a). The representation also showed an indication of 
a difference between class 1 and 3 from the PC2 vs PC3 plot (Fig. 6.4b). These 
preliminary observations suggest that a major part of the spectral variation is related to 
the growth phase.  
 
 
 
 
 
 
 
 
 
6.6.2. PLS-DA Modeling of E. coli MALDI-TOF MS Data at different Growth 
Phases 
6.6.2.1. Latent Variable (LV) Selection 
The next step was to apply PLS-DA to the full preprocessed mass spectral profiles from 
the ‘intact’ E. coli cells. During PLS-DA model calibration, leave-class-out-cross-
validation (LCOCV), a modified version of leave-one-out-cross-validation was carried 
out. In LCOCV, all samples belonging to the same class were removed from the 
training data set and a sub-model based on the remaining samples were used to build the 
PLS-DA model and predict the left out samples. Cross-validation was customised by 
creating a vector (Fig. A.3, Appendix A) and specifying how the cross-validation was to 
be performed.  
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Figure 6.4: Principal component scores plot for 366 intact cell E. coli mass 
spectra data 
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Fig. 6.5 shows a plot of the root mean square error of cross-validation (RMSECV) for 
LCOCV as a function of number of the number of LVs and illustrates the impact of 
increasing the number of LVs under cross-validation conditions. The number of LVs 
was chosen to simultaneously maximise the percentage of explained systematic 
variation whilst achieving correlation with Y. Fig. 6.5 indicates that exponential phase 
(class 2) samples behaved differently from the other two classes. For the exponential 
phase samples, the lowest RMSECV of 0.6 was attained with two LVs, with the 
RMSECV leveling out after 3 LVs. The other two classes achieved their lowest 
RMSECV for LV1. As a rule of thumb, the appropriate LV should have a minimum 
RMSECV (Li et al., 2002). Based on these observations three LVs were retained for the 
subsequent model. The 3-LV model captured 86.62% of the Y-block of the training data 
set. 
 
 
 
 
 
 
 
 
 
 
 
 
6.6.2.2. Model Quality 
The model parameters are summarised in Tables 6.2 and 6.3, and Fig. 6.6. The 
percentage of explained and cumulative explained variance of the X and Y- variables are 
reported in Table 6.2 for the first six LVs. The results in the table suggest that three LVs 
was the appropriate choice or number of LVs. This is because starting from LV 6, the 
percentage variance captured on the Y-block gets gradually larger until LV 4 is reached, 
then there is a sudden jump up to LV 3 (Table 6.2). The 3-LV PLS-DA model captured 
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Figure 6.5: Root mean square error of cross validation (RMSECV) as 
a function of the number of LVs added to the PLS-DA model 
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86.7% of the Y-block variance and explained 93.2% of the X-block variance of the 
training data set under cross-validation.  
 
 
 
 
 
 
 
Table 6.3 shows the parameters that describe the quality of the model after calibration 
(Cal) and cross-validation (CV). The Table shows that the quality of the model was 
good both in calibration and CV with a sensitivity (proportion of samples correctly 
classified that belong to the class being modeled), and specificity (proportion of samples 
correctly classified that do not belong to the class being modeled) of at least 93%. 
Furthermore, the model had a low classification error over the three classes, with the 
highest value being 3.7% (class 1). R
2 
values calculated were high, both fitting (74% for 
class1, 90% for class 2 and 71% for class 3) and in cross-validation (81% for class 3). 
Latent 
variable 
(LV) 
number 
X-Block Y-Block 
% Variance 
captured for 
this LV 
Total % 
variance 
captured 
% Variance 
captured for 
this LV 
Total % 
variance 
captured 
1 81.18 81.18 32.36 32.36 
2 10.49 91.66 31.68 64.04 
3 1.56 93.22 22.60 86.65 
4 1.57 94.79 4.17 90.81 
5 0.60 95.39 3.39 94.17 
6 0.71 96.10 1.01 95.18 
Table 6.2: PLS-DA percentage variance explained by the LVs calculated 
for X and Y variables 
Modeled class 
Class 1 
(Decline phase) 
Class 2 
(Exponential phase) 
Class 3 
(Stationary phase)  
Sensitivity (Cal) 0.930 1.000 0.980 
Specificity (Cal) 0.995 0.990 0.936 
Sensitivity (CV) 1.000 1.000 1.000 
Specificity (CV) 0.505 0.955 0.005 
Classification 
error (Cal) 
0.037 0.005 0.042 
 Classification 
error (CV) 
0.248 0.023 0.498 
RMSEC 0.238 0.148 0.254 
RMSECV 0.773 0.599 1.038 
R
2 
Cal 0.745 0.904 0.708 
R
2
 CV 0.057 0.028 0.885 
Table 6.3: PLS-DA modeling results showing the quality of the model is good after 
calibration (Cal) and cross-validation (CV) 
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The high values of R
2 
in fitting (and the consequent small values of RMSEC (24% for 
class1, 15% for class 2, and 25% for class 3) show that the model is characterised by a 
large fitting ability. 
 
Fig. 6.6 shows the calculated Y versus measured Y in fitting and prediction for the PLS-
DA model after cross-validation. This figure also supports the assertion that the model 
is good. It represents the calculated versus the measured responses both in fitting and in 
prediction: no deviations can be identified along the y-axis in all three classes. This 
suggests that all the useful information is taken into account by the model. 
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Figure 6.6: PLS-DA calculated Y versus measured Y in fitting and prediction after cross-
validation 
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6.6.2.3. External Validation and Model Performance 
The model was successfully validated with the 66 test data sets (Table 6.4; Fig. 6.7) 
indicating that the PLS-DA model is informative in terms of class separation. Table 6.4 
shows that the model had a very high performance (95-100% sensitivity and 
specificity). Furthermore, the model had a low classification error over all the three 
classes, with the highest being 3.6% (class 3).  
 
During the PLS-DA model building stage (calibration), the algorithm utilises Bayesian 
statistics to make a decision as to whether a future unknown sample will belong to a 
given class or not. During prediction of a test set, samples associated with a Y-value 
(predicted value) above the decision line have a statistically significant probability of 
belonging to the target class; the samples associated with Y-values below the decision 
line have a statistically significant probability of not belonging to the target class.  As 
indicated in Fig. 6.7, the decision threshold shown in each case (middle dashed red line) 
is calculated using the distribution of predicted Y values obtained during model 
building. Misclassified samples have been labelled and coloured in pink.  
 
As indicated in Fig. 6.7, just one sample from class 1 (1di01) was misclassified falling 
below the decision threshold. This gave an excellent prediction sensitivity and 
specificity of 95.8% and 100% respectively. No class 2 samples were misclassified 
giving 100% prediction sensitivity and specificity. Only one class 3 sample (4si13) was 
Modeled class 
Class 1 
(Decline phase) 
Class 2 
(Exponential 
phase) 
Class 3 
(Stationary 
phase)  
Sensitivity 
(prediction) 
0.958 1.000 0.950 
Specificity 
(prediction) 
1.000 1.000 0.978 
Classification 
error 
(prediction) 
0.021 0.000 0.036 
RMSEP 0.228 0.156 0.228 
Prediction Bias -0.026 0.036 0.012 
R
2 
prediction 0.786 0.902 0.771 
Table 6.4: PLS-DA modeling results showing the performance of the 
model after external validation 
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misclassified giving an excellent prediction sensitivity and specificity of 95% and 
97.8% respectively. These results suggest that the model had an excellent performance 
and is valid. The successfully validation of the model means that the model parameters 
such as scores and loadings are valid. The model performance also validates the choices 
of the preprocessing methods/parameters used for the spectra data described in section 
3.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.6.2.4. Scores Plot 
The practical value of the model was demonstrated in its ability to separate the three 
classes as shown in the scores plot. Fig. 6.8 shows the resulting PLS-DA scores plot. A 
plot of the first two components (LV1 vs LV2) shows that the 3-LV model concentrates 
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most of the discriminatory information into the second LV (Fig. 6.8(a)), with the 
exponential phase cell samples (class 2) exhibiting differences from the other two 
classes. This observation is supported by a plot of scores on LV2 as a function of 
samples (Fig. 6.8(c)). A plot of LV2 vs LV3 shows separation between the stationary 
phase (class 3) and decline phase (class 1) cell samples (Fig. 6.8(b)), an observation 
supported by Fig. 6.8(d). Stationary phase samples have positive scores (found in the 
left quadrant) whilst decline phase samples have positive scores (found in the right 
quadrant) in LV3 (Fig. 6.8(b)). 
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Figure 6.8: PLS-DA scores plot for the E. coli calibration mass spectra data 
           CASE STUDY I: Biomarker Profiling of Escherichia coli  
  
 
148 
 
6.6.2.5. Loadings Plot 
The PLS-DA model uses whole m/z ratio regions (without variable selection) to 
differentiate between classes so it is possible to investigate which m/z ratio regions 
contributing towards the discriminatory ability of the model for classifying a given 
sample as class 1, 2 or 3, that is, decline, exponential and stationary phases respectively. 
The PLS-DA loadings plot for a specific LV potentially contains valuable information 
regarding the regions of the mass spectra (m/z ratio peaks or ion signals) that contribute 
to the ability of the PLS-DA representation to distinguish between classes. There is a 
direct geometric link between the scores and the loadings plot of PLS-DA.  
 
The loadings plot for LV2 and LV3 (Fig. 6.9 and 6.10) indicates which variable 
loadings (associated with m/z ratio ion signals in the MALDI data sets) that contain 
information which are causing the separation of the samples in the scores plot. The 
loadings describe the weighting coefficients for each m/z ratio ion signal (experimental 
MWs of proteins) with the magnitude of the variable loadings being indicative of how 
the expression of proteins varies with growth phase. In Fig. 6.9, it can be seen that 
variables 1702, 2271, 2344, 2729 and 3642 have loadings of large negative magnitude. 
Since the exponential phase cell samples have negative scores along LV2, this implies 
that these samples can be differentiated from the other two classes by these m/z ratio 
signals associated with variables of large negative loadings in the LV2 loadings plot. 
These ion signals potentially identify those proteins which are differentially expressed 
in cells during the exponential phase and are most likely to be biomarkers of the 
exponential phase.  
 
 
 
 
 
 
 
 
 
 
 Figure 6.9: PLS-DA loadings plot on LV2 
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For the loadings associated with LV3 (Fig. 6.10), the variables 1701, 2271, 2344, 2915 
and 3719 have loadings with large positive magnitude. Stationary phase cell samples 
can thus be differentiated from decline phase samples by the presence of m/z ratio 
signals associated with variables with positive loadings in the LV3 loadings plot. These 
m/z ratio signals are indicative of those proteins which are differentially expressed in 
cells during the stationary phase. Variables 2550, 2735, 3473 and 3528 have loadings 
with large negative magnitude on the LV3 loadings plot (Fig. 6.10), and since the 
decline phase cell samples have negative scores along LV3, they can be distinguished 
from the stationary phase cell samples by the differential expression of proteins 
associated with signals with positive loadings in the LV3 loadings plot. 
 
 
 
 
 
 
 
 
 
 
 
6.6.3. Protein Database Search for Database Search for the E. coli Cell Samples 
The PLS-DA loadings plots for LV2 and LV3 are now considered for further analysis.  
The variables from the loadings plot are associated to m/z ratio peak or signal ions 
(Table A.6 to A.8, Appendix A). Since most of the m/z ratio signal ions are singly 
charged protonated protein (MH
+
) molecules, they represent the approximate MALDI 
experimental MWs of the ionised proteins expressed by the cells at the different growth 
phases. Thus the m/z ratio signal ions (experimental MW of protein ions) were 
submitted to a protein database search to assign protein identities to them. The 
experimental MWs of protein ions were used as search parameters and were matched 
Figure 6.10: PLS-DA loadings plot on LV3 
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with sequence derived theoretical MW values in the UniProtKB/Swiss-Prot database 
(http://expasy.org/proteomics).   
 
A number of matches resulted in protein biomarkers which have been predicted in the 
organism's genome, and there is experimental evidence that these proteins are expressed 
in vivo at the different phases of growth (Yoon et al., 2003; Nystrom, 2004; Han and 
Lee, 2006). Table 6.5 summarises the results of the database search and shows the 
compiled results of the protein matches obtained for the three growth phases. If no 
match was found after the initial search, the search was repeated assuming N-terminal 
Methionine (Met) is lost (experimental MW with less than 131 Da). In prokaryotes, it is 
estimated that more than 50% of E. coli proteins undergo Met loss as posttranslational 
modification (PTM) (Hirel et al., 1989).  E. coli have been well studied and N-terminal 
Met excision PTM is reflected in the UniProt/SwissPROT databases which contains 
proteins with or without N-terminal Met (Gibson et al., 1997; Demirev et al., 1999).  
 
Most of the experimental MWs were matched with proteins in the mass range 4 – 20 
kDa.  Matches were not found for the majority of experimental MWs below 4 kDa. 
These MWs may represent the bacterial cell lipooligosaccharide and peptidoglycan 
molecules (Guo et al., 2002). Information relating to the synthesis of these non-protein 
biomolecules is not derived from the genetic code and hence would not be found in the 
protein database. MWs less than 4 kDa may also partly be a combination of abundant 
matrix-related ions since most of the currently used matrices have MWs less than 3 
kDa. They may also act as their own matrices, producing a variety of matrix-related ions 
during laser ionisation (Ochoa et al., 2005). Thus any assignment to m/z ratio ion 
signals below the 4 kDa region is tentative, and necessitates further conclusive 
evidence. Such assignments were therefore excluded. 
 
6.6.4. SwissPROT/TrEMBL Protein Molecular Weight Distribution for E. coli 
K-12, MALDI Mass Accuracy and Biomarker Identification 
Biomarker assignment and identification was based on several factors. Biomarker 
identification was based on m/z ratio values or experimental MW ranges can correspond 
to variable count ranges in the PLS-DA loadings plot. An average experimental MW is 
assigned to a protein biomarker if it falls within this range and matches the theoretical 
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MW of the protein biomarker based on the mass accuracy of linear mode MALDI-ToF 
MS instrument. The assigned proteins to take into account the mass accuracy in the 
linear mode MALDI-ToF which is 100 ppm, i.e., for all the assigned proteins, 
experimental MW masses was within 0.01% of their theoretical MWs (+/- 1 mass unit 
for 10,000 MW protein). Tables A.9 to A.11 (Appendix A) shows variable count ranges 
and their experimental MW ranges as well as the average experimental MWs (within 
the latter range) matching theoretical MWs for the all the protein biomarkers shown in 
Table 6.5. 
 
Secondly, assignments took into consideration the molecular mass distribution of 20653  
protein sequences (providing theoretical MWs) of E. coli K-12 proteins derived from 
genomic open reading frame as well as nongenomic entries found in the 
SwissPROT/TrEMBL database. The molecular mass distribution of known E. coli K-12 
proteins (Fig. 6.11) has a peak centered around 12 kDa. Fig. 6.11 shows the molecular 
mass distribution (in bins of 1 kDa) of E. coli K-12 proteins deposited in the 
SwissPROT/TrEMBL sequence database. Fig. 6.11 suggest that many E. coli K-12 
proteins have masses in the range of mass range 4 – 20 kDa. Therefore, it may be also 
expected that unique combinations of protein masses in the mass range from 4 to 20 
kDa can serve as protein biomarkers for E. coli K-12 (Arnold and Reilly, 1999; Ryzhov 
and Fenselau, 2001). For example most experimental MWs were assigned to ribosomal 
proteins because the latter are highly abundant in growing cells (almost half of the cell 
mass), relative to other cytosolic proteins and most have MWs of less than 20kDa. 
Moreover, ribosomal proteins are very basic, and basic proteins are more amenable to 
protonation during MALDI analysis. Experimental MWs that did not match ribosomal 
proteins were assigned to other abundantly produced non-ribosomal cytosolic proteins 
which are basic, and expressed at the different growth phases based on evidence from 
the literature (Arnold and Reilly, 1999; Ryzhov and Fenselau, 2001). 
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Figure 6.11: Molecular weight (MW) distribution (in bins of 1 kDa) of 20653 
E. coli K-12 proteins deposited in the SwissPROT/TrEMBL sequence database 
 
The full explanation of superscript letters assigned to column titles in Table 6.5 are as 
follows:    
a
Experimental MWs were the m/z ratio ion (MH
+
) signals associated to the variables 
(associated to m/z ratio ion signals in the MALDI data set) from the PLS-DA loadings 
plot.  
b
The intensity of the variables ( m/z ion signals) 
 
is the magnitude of their loadings in 
the loadings plot. High: intensity ≥ ±0.1 units; medium: intensity ≥ ±0.05 and ≤ ±0.1 
units; low: intensity between 0 and ±0.05 units.  
c
Theoretical sequence MWs were calculated using the Compute pI/MW tool 
(http://web.expasy.org/compute_pi/). Assigned proteins took into account the mass 
accuracy in the linear mode MALDI-ToF which is 100 ppm, i.e., for the proteins, 
experimental MW masses should be within 0.01% of their theoretical MWs (+/- 1 mass 
unit for 10,000 MW protein).
  
d
MWs of the proteins described in previous studies using MALDI-TOF analysis of E. 
coli K-12.   
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ef
MW from studies by Arnold and Reilly (1999); and Ryzhov and Fenselau (2001) 
respectively. Proteins in bold with ‘none’ as paper match are proteins identified that 
were not reported in previous E. coli culture MALDI studies.  
g
Protein names, description, PI, accession numbers and remarks were from ExPASy 
Proteomics Server (http://www.uniprot.org/uniprot/ ). 
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6.6.5. Identification of Growth Phase-associated Biomarkers 
As seen in Table 6.5, most of the database matches identified corresponded to 
intracellular proteins of the bacteria suggesting that the E. coli cells from the culture 
were lysed releasing intracellular contents. Cell lysis may have occurred as a result of 
the sample preparation procedure as a consequence of the organic solvents used or 
possibly during the storage and freeze-thawing of the cell pellets at -70
o
C prior to the 
MALDI analysis. The majority of protein matches corresponded to ribosomal proteins 
in the 50S and 30S subunits. This outcome was expected since ribosomal proteins have 
a high abundance of up to 45% of the total mass of E. coli cells and these proteins make 
up to 21% of the cell’s protein content (Ryzhov and Fenselau, 2001; Ochoa et al., 
2005). Previous MALDI studies on whole E. coli cultures have also matched several 
m/z ratio peaks to ribosomal proteins (Ryzhov and Fenselau, 2001; Jones et al., 2003; 
Ochoa and Harrington, 2005). Ribosomal proteins are basic (that is, pI greater than 9), 
and basic proteins are more amenable to MALDI analysis because they can easily be 
protonated as they comprise many basic functional groups (Ochoa and Harrington, 
2005).  It is interesting to observe that exponential phase cultures had more ribosomal 
protein matches than the other phases with the number of ribosomal protein matches 
dropping from the exponential to the decline phase. The predominance of ribosomal 
proteins in actively growing cells has previously been reported (Saenz et al., 1999; 
Harrington et al., 2008). This trend is in keeping with the biology of these cultures since 
during the exponential phase, cultures are metabolically at their maximum, actively 
growing and protein synthesis is higher than in the other phases. At later growth phases, 
cultures are less metabolically active and grow less so it is not necessary to retain a high 
level of ribosomes (Reilly et al., 1999). This suggests that ribosomal proteins may serve 
as biomarkers for exponential phase E. coli cultures.   
 
Several proteins reported in other research studies as stationary phase proteins were also 
identified in the stationary phase samples (Table 6.13). Amongst these are the nucleoid-
associated proteins (NAPs), IhfA and Dps;  the DNA-binding morphogene (BolA);  
lipoproteins OsmY and OsmB; the glycogen synthesis protein (GlgS); and the 
bacteriocin MccB17 (Connell et al., 1987; Aldea et al., 1989; Jung et al., 1989; Yim 
and Villarejo, 1992; Hengge-Aronis and Fischer, 1992; Azam et al., 1999). Hence these 
proteins could be considered as potential stationary phase biomarker candidates. 
Identified proteins also indicated that a high number of toxin-antitoxin (TA) loci-
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associated proteins (TALAPs) were present in decline phase samples, ChpS antitoxins; 
antitoxin YefM, DinJ, RelB, RelE, and mRNA interferase. The presence of TALAPs is 
in keeping with the concept of either an increased culture die-off or increased culture 
stasis from the exponential to the decline phase (Aizenman et al., 1996; Pedersen et al., 
2002). TALAPs are most likely to be biomarkers of the decline growth phase.  
 
Since MALDI-MS produces mostly singly charged ion protein or peptide fragment, the 
MW of the molecular ion and hence protein can be directly determined, hence 
identification of the protein. However, since information from MW of the proteins is not 
sufficient to identify them (because of matrix effect, post-translational modification, and 
mass errors) protein identifications through database search in this project were 
tentative pending further analysis. Proteins identified in this project have been reported 
in other research studies (Reilly et al., 1999; Guo et al., 2002; Jones et al., 2003; Ochoa 
et al., 2005; Harrington et al., 2008).  
6.7. Summary 
Within this chapter, it is shown that PLS-DA is a potentially powerful tool for 
extracting systematic variation pertaining to biological effects of spectra data generated 
using intact-cell MALDI mass spectrometry (ICM-MS) method. The proposed approach 
has enabled the investigation and potential identification of the biological factors 
involved in a bacterial culture and the biomolecules contributing to the main trends of 
such biological factors. The PLS-DA has indicated that the spectra of bacterial cell 
samples from the exponential, stationary and decline growth phases exhibit differences 
due to differentially expressed proteins which can be identified from examining the 
PLS-DA loadings plot (that is, m/z ratio values) in conjunction with protein database 
search. Proteins such as ribosomal proteins are predominantly expressed during the 
exponential phase cultures since they are actively growing. This and other studies have 
indicated that these are potential biomarkers for cultures in the exponential phase. Other 
proteins previously identified in the literature were found to be differentially expressed 
in both the stationary and decline phases. The minimal sample pretreatment 
requirements for ICM which reduces sample processing time, the straight forward 
interpretability of the PLS-DA results, and the availability of internet accessible 
proteomic databases provide the potential to easily and rapidly identify biomarkers. 
This rapid identification of biomarkers demonstrates one aspect of this approach that 
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could be useful for biomarker profiling in mammalian cell culture. This approach could 
also serve as a valuable tool in process development in the bioprocessing industry to 
enhance cell growth by facilitating the selection of high producing cell lines based on 
identified biomarkers, as well as identify potential targets for cell engineering. This is 
described in the subsequent chapter (chapter 7). 
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7. CASE STUDY II: Biomarker Profiling Of Cultured Intact 
Mammalian Cell Lines Utilising the ICM, PLS-DA, and Protein 
Database Search Approach 
7.1. Overview 
In chapter 6, the application of the approach utilising intact-cell MALDI-ToF MS 
(ICM-MS), projection to latent structure – discriminant analysis (PLS-DA), and 
database search was demonstrated in the study of protein biomarker profiling, using an 
E. coli growth-phase-associated protein biomarker model. This case study acted as a 
proof-of-principle study for the ICM, PLS-DA and protein database search approach. 
The case study demonstrated that if between-class (exponential, stationary and decline 
phase classes in this case) variabilities exist in spectra data, PLS-DA is used to capture 
these differences and hence classify the samples based on these variabilities. The results 
obtained from the proof-of-concept study suggest that this approach was successful in 
identifying protein biomarkers. 
  
In this chapter, the approach is applied in biomarker profiling of IgG-producing CHO 
cell lines during bioprocessing. It is hoped that a between-class variability (based on the 
cell line productivity) will exist within the CHO cell line spectra data so that PLS-DA 
can be used to classify the samples and identify potential protein biomarkers which are 
associated to the CHO cell line productivities. 
 
7.2.  Introduction 
‘Intact-cell’ MALDI-ToF MS (ICM-MS) raises many possibilities for the analysis of 
mammalian cells (Chaurand et al., 2006; Chaurand et al., 2007; Crossman et al., 2006; 
Khatib-Shahidi et al., 2006; Reyzer et al., 2007). These applications have been 
discussed in section 4.3.4.5 (chapter 4). Despite the application of ICM-MS to bacteria 
(section 4.3.4.4) and mammalian cells, there have been relatively few studies that have 
applied this approach to mammalian cell cultures (MCCs) in bioprocessing (Buchanan 
et al., 2007; Feng et al., 2010; Dong et al., 2011; Feng et al., 2011). The few 
applications that exist in the literature (to the best of the author’s knowledge) have also 
been discussed in section 4.3.4.5 (chapter 4). 
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7.3. Specific Aims and Contributions of the Chapter  
In a recent application Feng et al., (2010) applied ICM-MS to a batch of CHO cell lines 
producing the monoclonal antibody, IgG. The mass spectra data sets obtained were 
modeled using PCA and PLS, discriminating between the cell lines (high/low 
producers) based on different expressed recombinant proteins (different productivities). 
As a follow-up to this work, the group more recently used PLS-DA to model spectra 
data sets obtained from another batch of monoclonal IgG-producing CHO cell lines 
(Feng et al., 2011). In both studies mass spectra peaks of potential protein biomarkers 
associated with productivity were identified using the multivariate data analysis 
approaches of PCA, PLS and PLS-DA. Whilst these two studies represent an important 
step forward towards pattern-based biomarker profiling of mammalian cell culture 
(MCC) in bioprocessing, no attempts were made by the experimenters to provide the 
mass spectra peak assignments that were obtained to potential protein biomarkers. 
  
In this chapter, ICM-MS combined with PLS-DA was used to distinguish between cell 
lines in terms of productivities (high/low producers; Hs/Ls). Protein database searches 
were then used to identify potential biomarkers associated with productivity, and whose 
differential presence may be useful in classifying between the two cell line classes. 
Furthermore, biological interpretations as to the presence of such protein biomarkers 
will be provided. The presence of such biomarkers may then be used as a basis for 
predicting cell line productivities; provide insight into biological mammalian cell lines 
used during bioprocessing; and may give indications to potential genetic engineering 
targets that may be exploited to engineer batter cell lines. 
 
Figure 7.1 shows an overview of the various steps involved in using ICM-MS, PLS-DA 
and protein database searches for the biomarker profiling of IgG monoclonal antibody-
producing CHO cell lines. It begins with preparation of the CHO cell samples, the 
analysis of the samples by MALDI mass spectrometry, and preprocessing of the spectra 
data generated to remove unwanted variation whilst preserving biological information. 
Sampling is then carried out on the preprocessed data sets to separate the samples into 
training and test sets. The training set is overviewed using PCA to study initial trends 
and later analysed using PLS-DA, whilst the test sets are retained for external validation 
of the PCA and PLS-DA models built. PLS-DA scores and loadings plot are then 
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interpreted. The information from the scores and loadings plot is used for database 
searches to identify protein biomarkers. 
 
Figure 7.1: An overview of the various steps involved in the growth phase-
associated protein biomarker profiling of IgG monoclonal antibody-producing 
CHO cell lines using ICM-MS, PLS-DA and protein database search 
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7.4. Experimental Section  
7.4.1. Chemicals 
This section outlines the chemicals used in this project, as provided by collaborators at 
the School of Bioscienes, University of Kent, to carry out the laboratory experiments. 
Acetonitrile/Trifluoroacetic Acid (ACN/TFA; 0.1%, v/v), Sinapinic acid (SA); Sucrose 
(>99.5%, Sigma Aldrich UK); Phosphate buffer saline (PBS) - Oxoid tablets (made up 
as directed, filter-sterilised and stored at 4
o
C); and the MALDI-TOF calibrant (a protein 
mixture containing insulin, ubiquitin I, cytochrome C, and myoglobin) were purchased 
from Bruker Daltonics, GmbH, Germany 
 
7.4.2. Cell Culture 
This section presents information about the cell line used in this project, as provided by 
collaborators at the School of Bioscienes, University of Kent. Immunoglobulin G (IgG1 
and IgG4) monoclonal antibody expressing mammalian cell lines (concealed identity) 
were generated in-house (Lonza Biologics, Slough, UK) through methothrexate 
amplification. Cell line suspensions of varying productivities were cultivated in a 96 
deep well plate (96DWP), 24 well plate, and bioreactor. The cell line culture time was 5 
days after which exponential phase cells were harvested for analysis. At the 96DWP 
scale of production, cell lines were attributed to a high or low class based on their 
antibody titres in the 96 deep well plate scale during production. 
   
Samples of cell lines which had above 1000mgmL
-1
 antibody titres were classed as high 
producers (Hs). This was the threshold set by Lonza Biologics with respect to cell line 
productivity. Samples which had specific productivity (qP) titres less than 1000mgmL
-1
 
were classed as low producers (Ls). Samples collected were retained for MALDI 
analysis. Viable cell concentration and percentage viable cells were measured using a 
Cedex automated cell counter (Innovatis, Bielefeld, Germany). 
  
7.4.3. MALDI-ToF MS Analysis and Data Preprocessing 
CHO cell line sample preparation for MALDI analysis was carried out as described in 
section 3.3.6.2. All mass spectra were acquired with an Ultra Flex MALDI-ToF mass 
spectrometer (Bruker Daltonics, GmbH, Germany), located in the School of 
Biosciences, University of Kent, Canterbury, Kent, UK. The instrument parameters 
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used as well as the analysis procedure has been described in section 3.3.6.2. Data 
preprocessing was carried out using in-house scripts developed from MATLAB
®
 
v.7.6.0.324 (R2008a the MathWorks, Inc.) and functions from the Bioinformatics 
Toolbox of MATLAB
®
 (v 3.1, R2008a, Eigenvector Research, Inc.). Preprocessing 
studies was carried out as described in section 3.6, to find the appropriate combination 
of preprocessing techniques. 
 
7.4.4. Multivariate Data Analysis 
The application of multivariate data analysis (PCA and PLS-DA) to the spectral data 
was carried out using the MATLAB® software v. 7.12.0.635 (R2011a The MathWorks, 
Inc.) and the PLS Toolbox v. 6.5.1 (Eigenvector Research, Inc.). The PLS-DA 
algorithm used in modeling the CHO cell line spectra data set has been described in 
detail in section 5.6.1. PCA was first applied to get an overview of the preprocessed 
mass spectral data sets to identify groupings in the data sets.  Random sampling was 
used to separate the training set from the test set samples. In this study, 1/5 of the 
spectra data sets were used as the test set and 4/5 as training set.  After random 
sampling, 44 spectra data sets (18 Hs and 26 Ls) were used as the training set whilst 16 
samples (8 Hs and 8 Ls) comprised the test set. 
 
7.4.5. Protein Database Search 
Protein database searches were carried out to assign protein identities to mass spectra 
ion signals obtained from information in the PLS-DA loadings plots. The searches were 
conducted using the MALDI mass spectra protein experimental molecular weights 
(MWs) (m/z ratio peaks or signal ions) and the organism’s theoretical MWs found in the 
UniProtKB/Swiss-Prot database. With the query specified as Chinese Hamster Ovary 
(CHO), the experimental MWs were matched to biomarker peaks contained in the 
Protein Knowledgebase (UniProt) and TrEMBL query form found in the database for 
the identification of the mammalian cell line’s main protein biomarkers. 
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7.5. Results and Discussions  
7.5.1. Principal Component Analysis Modeling of the Spectra Data Sets from 
CHO cell lines 
Principal component analysis (PCA) was applied to get an overview of the 64 
preprocessed CHO cell mass spectral data sets to help identify trends in the data and to 
sample the data into training and test sets. The first four principal components account 
for 46.60% of the original variation (Table 7.1). A plot of PC2 vs PC3 is shown in Fig. 
7.2(a). The four-component model shows evidence of separation between the two 
classes along PC2, with most of the low producer cell line samples lying in the upper 
left quadrant and the high producer cell lines being found in the lower left quadrant. 
Four samples, 2 low producers (Ls) and 2 high producer cell lines (Hs) were outliers as 
they were located outside the 95% confidence region. After removal of the outliers and 
subsequent splitting of the data into training and test set samples, a 2-component PCA 
model was built with the 44 training data sets (Table 7.2). The two component model 
accounted for 93.73% of the variability in the original data set. A plot of PC1 vs PC2 of 
the 2-component model showed a strong evidence of separation between the two classes 
along PC2 (Fig. 7.2(b)). Overall, these suggest that the PCA representation has some 
practical value and that a major part of the spectral variation is related to class 
differences between the high and low producer CHO cell lines. 
 
 
Principal 
component 
(PC)  number 
Eigenvalue of 
covariance (X) 
% Variance 
captured for this 
PC 
Total % 
variance 
captured 
1 5.86 × 10
3
 32.41 32.41 
2 1.24 × 10
3
 6.87 39.28 
3 7.00 × 10
2
 3.87 43.15 
4 6.23 × 10
2
 3.45 46.60 
5 4.85 × 10
2
 2.68 49.28 
6 4.25 × 10
2
 2.35 51.63 
7 3.64 × 10
2
 2.01 53.64 
8 3.46 × 10
2
 1.91 55.55 
Table 7.1: Results of PCA model for all 64 CHO mass spectra data sets 
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Principal 
component 
(PC)  number 
Eigenvalue of 
covariance (X) 
% Variance 
captured for this 
PC 
Total % 
variance 
captured 
1 3.28 × 10
5
 90.13 90.13 
2 1.36 × 10
4
 3.73 93.86 
3 4.91 × 10
3
 1.35 95.21 
4 3.89 × 10
3
 1.07 96.28 
5 2.43 × 10
3
 0.57 96.94 
6 1.53 × 10
3
 0.42 97.36 
7 9.49 × 10
2
 0.26 97.62 
8 8.79 × 10
2
 0.24 97.89 
 
 
 
 
 
 
 
Table 7.2: Results of PCA model for the 44 calibration CHO mass spectra 
data sets after outlier removal 
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Figure 7.2: PCA scores plot for the Chinese hamster ovary mass spectra 
data before and after sampling 
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7.5.2. Partial Least Squares – Discriminant Analysis (PLS-DA) Modeling of the 
Spectra Data Sets from CHO cell lines 
7.5.2.1. Latent Variable (LV) Selection 
The 44 training mass spectra profiles from the CHO cell lines were then modeled by PLS-
DA. The PLS-DA model use the whole m/z ratio region to differentiate between classes 
thus it is possible to investigate which regions were highly weighted in the model when 
classifying a given sample as a low or high producer cell line. Fig. 7.3 shows a plot of 
RMSECV as a function of the number of LVs after cross-validation. It captures the effect 
of increasing the number of LVs in the PLS-DA model. The optimum number of LVs was 
selected to simultaneously maximise the percentage of explained systematic variation 
while achieving correlation with Y. Fig. 7.3 indicates that four LVs should be retained. 
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Figure 7.3: RMSECV as a function of the number of LVs added to the 
PLS-DA model for the CHO cell line data set 
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7.5.2.2. Model Quality 
Results of the PLS-DA analysis are summarised in Table 7.3, 7.4 and Fig. 7.4. The 4-
LV model captured 95.50% of the Y-block of the training data set  (Table 7.3), and the 
100% specificity and sensitivity suggest that the model was excellent (Table 7.4).  This 
was supported by the calculated Y versus measured Y in fitting and prediction for the 
PLS-DA model after cross-validation (Fig. 7.4). There was no deviation identified along 
the y-axis in both the high and the low producer classes, (Fig. 7.4(a)) and (Fig. 7.4(b)) 
respectively, suggesting that that all the useful information is taken into account by the 
model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Modeled class 
Class 1 
(High producers) 
Class 2 
(Low producers) 
Sensitivity (Cal) 1.000 1.000 
Specificity (Cal) 1.000 1.000 
Sensitivity (CV) 1.000 1.000 
Specificity (CV) 1.000 1.000 
Classification error (Cal) 0 0 
 Classification error (CV) 0 0 
RMSEC 0.104 0.104 
RMSECV 0.158 0.158 
R
2 
Cal 0.955 0.955 
R
2
 CV 0.897 0.897 
Latent 
variable 
(LV) 
number 
X-Block Y-Block 
% Variance 
captured for 
this LV 
Total % 
variance 
captured 
% Variance 
captured for 
this LV 
Total % 
variance 
captured 
1 7.78 7.78 78.39 78.39 
2 86.06 93.84 3.68 82.07 
3 0.87 94.71 9.05 91.12 
4 0.58 95.28 4.38 95.50 
5 0.36 95.64 2.51 98.01 
6 1.11 96.75 0.56 98.57 
7 0.39 97.14 0.78 99.35 
8 0.49 97.64 0.28 99.63 
Table 7.3: PLS-DA results showing the quality of the model after calibration 
(Cal) and cross-validation 
Table 7.4: Results of PLS-DA model for the 44 calibration CHO mass spectra 
data sets 
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7.5.2.3. External Validation and Model Performance 
The model was successfully validated with 16 (8 Hs and 8 Ls) test data sets (Table 7.5; 
Fig. 7.5); indicating that the PLS-DA model is informative in terms of class separation. 
Table 7.5 shows that the model had a good performance (75-100% sensitivity and 
specificity). Furthermore, the model had a low classification error of 3.3% for both 
classes. As indicated in Fig. 7.5(a) two high producer samples (class 1) were 
misclassified (coloured in pink) falling below the decision threshold. This resulted into 
a good prediction sensitivity and specificity of 75% and 100% for class 1 respectively. 
No class 2 samples were misclassified giving 100% prediction sensitivity (Fig. 7.5(b)). 
The successfully validation of the model means that the model parameters such as 
scores and loadings are valid. The model performance also validates the choices of the 
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Figure 7.4: PLS-DA calculated Y versus measured Y in fitting and prediction after 
cross-validation for the 44 CHO cell line calibration spectra; (a) High producer 
class, and (b) Low producer class 
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preprocessing methods/parameters used for the spectra data described in section 3.6 
(chapter 3). 
 
Modeled class 
Class 1 
(High producers; Hs) 
Class 2 
(Low producers; Ls) 
Sensitivity (prediction) 0.750 1.000 
Specificity (prediction) 1.000 0.750 
Classification error 
(prediction) 
0.125 0.125 
RMSEP 0.328 0.328 
Prediction Bias -0.067 0.067 
R
2 
prediction 0.596 0.596 
Table 7.5: PLS-DA results showing the performance of the model after external 
validation with 16 test set samples 
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Figure 7.5: PLS-DA calculated Y versus measured Y in fitting and prediction after 
external validation with 16 CHO cell line mass spectra test set samples; (a) High 
producer class, and (b) Low producer class 
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7.5.2.4. Scores Plot 
The model demonstrates the ability to separate the two classes (Fig. 7.6). As can be seen 
in Fig. 7.6, a plot of LV1 vs LV2 (a), and LVs 3 (b) indicates that the model 
concentrates most of the discriminatory information in the first LV. The two classes are 
approximately separated along LV1, with the high producer class having negative 
whilst the low producer class has positive scores.  
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Figure 7.6: PLS-DA scores plot for the 44 CHO cell line calibration mass 
spectra data sets;(a) Scores on LV2, and (b) Scores on LV3 
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7.5.2.5. Loadings Plot 
There is a relationship between the scores and the loadings plot for PLS-DA. The 
loadings plot for LV1 (Fig. 7.7) indicates which m/z ratio ion signals in the MALDI data 
set contain information that is driving the separation of the samples in the scores plot. 
More specifically, it describes the weighting coefficients for each m/z ratio ion signal 
(experimental MWs of proteins) which are associated to variables in the loadings plot. 
  
In Fig. 7.7, it can be seen that variables at approximately 1217, 3056, 3708, 4781, and 
4874 have high loadings with negative contribution. Since high producer CHO cell line 
samples have negative scores in LV1 in the scores plot, it implies that these samples can 
be distinguished from the low producer samples by the presence of m/z ratio signal ions 
associated with variables with negative loadings in the LV1 loadings plot. These signal 
m/z ratio signal ions potentially identify proteins which are differentially expressed in 
high producer cell lines.   
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7.5.3. Protein Database Search for CHO Cell Line Samples 
The PLS-DA loadings plot on LV1 was considered for further analysis.  The variables 
from the loadings plot are associated to m/z ratio signal ions (Table C.1 and C.2, 
Appendix C). Since the m/z ratio signal ions are singly charged protonated protein 
(MH
+
) molecules, the MH
+
 represents the MALDI experimental molecular weights 
(MWs) of the ionised proteins expressed by the cell lines. Thus the m/z ratio ion signals 
(experimental MW of protein ions) were submitted to a protein database search to 
assign protein identities to them. The experimental MWs of protein ions were used as 
search parameters and were matched with sequence derived theoretical MW values in 
the SwissPROT/TrEMBL database (http://expasy.org/proteomics). Tables 7.6 and 7.7 
summarise the results of the database searches. A number of matches resulted in protein 
biomarkers which have been predicted in the CHO genome (Cricetulus griseus). 
Experimental evidence using 2D-PAGE and tandem-mass spectrometry, that some of 
the matched proteins are expressed in CHO cell line culture have been well described in 
the literature (Kaufmann et al., 1999; Lee et al., 2003; Van Dyk et al., 2003; Krawitz et 
al., 2006; Pascoe et al., 2007; Meleady, 2007; Kim et al., 2009; Carlage et al., 2009). 
 
When no protein was found to match an experimental MW, a further search was carried 
out for proteins of related mammalian species such as humans (Homo sapiens) or 
rodents (Mus musculus, mouse; Rattus norvegicus, Rat). For matched CHO proteins 
whose functions are not yet available in the database, the function was inferred from 
related proteins of the above close species and this was mentioned in the ‘remarks’ 
column of Table 7.6 and 7.7. Matches were not found for most experimental MWs 
below 4 kDa. These MWs may be a number of abundant matrix-related ions since most 
of the currently used matrices have MWs less than 4 kDa. They may also act as their 
own matrices, producing a variety of matrix-related ions during laser ionisation (Guo et 
al., 2002).  
 
In Table 7.6 and 7.7, the column ‘protein existence’ includes the value E = ‘ Evidence at 
transcript level level’,  indicating the existence of a protein that has not been proven but 
whose expression data (such as existence of cDNA(s), RT-PCR or Northern blots) 
indicates the existence of a transcript; I = ‘Inferred by homology’, indicates the 
existence of a protein is probable since clear orthologs exist in closely related species; P 
= ‘Predicted’, is used for entries without evidence at protein, transcript, or homology 
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levels; and U = ‘Uncertain’, indicates the existence of the protein is unsure.  Most of the 
proteins that were identified had a value of ‘P’, implying that they are only predicted 
and no MALDI experimental evidence exist that indicates that such proteins are 
expressed in vivo in CHO cells. 
 
7.5.4. Swiss-Prot/TrEMBL Protein Molecular Weight Distribution for CHO cells, 
MALDI Mass Accuracy and Biomarker Identification 
Biomarker assignment and identification for CHO cells was based on several factors. 
Similar to the E. coli K-12 cells (section 6.6.4), biomarker identification was based on 
m/z ratio values or experimental MW ranges can correspond to variable count ranges in 
the PLS-DA loadings plot. An average experimental MW is assigned to a protein 
biomarker if it falls within this range and matches the theoretical MW of the protein 
biomarker based on the mass accuracy of linear mode MALDI-ToF MS instrument as 
described in section 6.6.4. Tables C.3 to C.4 shows variable count ranges and their 
experimental MW ranges as well as the average experimental MWs matching 
theoretical MWs for the all the protein biomarkers shown in Tables 7.6 and 7.7. 
 
In addition to the mass accuracy, assignments took into consideration the molecular 
mass distribution of 24049 protein sequences (providing theoretical MWs) of CHO cell 
proteins derived from genomic open reading frame as well as nongenomic entries found 
in the SwissPROT/TrEMBL database. The molecular mass distribution of known CHO 
cell proteins (Fig. 7.8) shows a positive skewness i.e.  most proteins tend to cluster 
toward the lower end of the MW scale with increasingly fewer proteins at the upper end 
of the MW scale. Fig. 7.8 shows the molecular mass distribution (in bins of 1 kDa) of 
CHO cell proteins deposited in the SwissPROT/TrEMBL sequence database. The 
positive skewness in in Fig. 7.8 suggests that most of the CHO proteins found in the 
SwissPROT/TrEMBL database are lower MW proteins in the range 2 to 24kDa. 
Therefore, it may be expected that unique combinations of lower MW CHO protein in 
the range 2 to 24 kDa can serve as protein biomarkers. Since basic proteins are more 
amenable to protonation during MALDI analysis assignments also considered the 
basicity of the proteins. 
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Figure 7.8: Molecular weight (MW) distribution (in bins of 1 kDa) of 24049 
CHO cell proteins deposited in the SwissPROT/TrEMBL sequence database 
 
The full explanation of superscript letters assigned to column titles in Table 6.5 are as 
follows:    Tables 7.6 and 7.7:    
 
a
Variable counts were derived from PLS-DA loadings plot on LV1 (along which the 
two classes of cell lines were separated in the cores plot).  
b
The intensity of the variables ( m/z ion signals) 
 
is the magnitude of their loadings in 
the loadings plot. High: intensity ≥ ±0.04 units; medium: intensity ≥ ±0.02 and ≤ ±0.04 
units; low: intensity between 0 and ±0.02 units.  
c
Experimetal MWs were the m/z ratio ion (MH
+
) signals associated to the variable 
counts of the from the PLS-DA loadings plot.  
d
Theoretical or sequence MWs were calculated using the Compute pI/MW tool 
(http://web.expasy.org/compute_pi/) of the SwissProt/TrEMBL Protein database.  
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e
Protein names, existence, PI, accession numbers and remarks were from ExPASy 
Proteomics Server (http://www.uniprot.org/uniprot/) of the SwissProt/TrEMBL Protein 
database. Protein existence with value E = Evidence at transcript level; I = Inferred by 
homology; P = Predicted; and U = Uncertain. Remarks indicate protein functions from 
related mammalian species humans (Homo sapiens) or rodents (Mus musculus, mouse; 
Rattus norvegicus, Rat) for matched CHO proteins whose functions are not yet available 
in the database. 
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Table 7.6: SwissProt/TrEMBL Database Proteins Matching Experimental Biomarker Masses 
in MALDI-ToF MS for the High Producer Chinese Hamster Ovaries Cell Line Samples 
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Table 7.7: SwissProt/TrEMBL Database Proteins Matching Experimental Biomarker 
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7.5.5. Differential Protein Expression on High and Low Producer CHO Cell 
Lines  
Differentially expressed proteins were identified and were characterised with respect to 
upregulation as high, medium or low, based on the magnitude of the PLS-DA loadings 
which are related to experimental MWs (m/z ratio ion signals; MH
+
). A total of 123 
differentially expressed proteins were matched for high producer cell lines while 62 
proteins were matched for low producer cell lines as indicated in Tables 7.6 and 7.7. 
The major functionalities of these proteins include protein folding, protein biosynthesis, 
cytoskeletal structure, DNA and RNA metabolism, glycolysis, and cell growth as 
discussed in the following sections. 
 
7.5.6. Protein Folding/Processing Proteins 
Ten proteins which function in protein folding or processing were identified in the high 
producer cell lines whilst just one was identified in the low producers. As can be seen 
from Table 7.6, half of the protein-processing proteins in high producers are peptidyl-
prolyl cis-trans isomerases (PPIases). PPIases accelerate the folding of proteins.  These 
proteins have been shown to catalyse the cis-trans isomerisation of proline imidic 
peptide bonds in oligopeptides. They are thought to be implicated in the folding, 
transport, and assembly of proteins during cellular protein synthesis (Göthel and 
Marahiel, 1999). Other proteins of interest include the humanised IgG recombinant 
antibody light chain, protein processing related proteins such as 60 kDa heat shock 
protein (HSP60), DnaK-type molecular chaperone (DnaK), FK506-binding protein 2 
(FKBP2), Heat shock cognate protein HSP 90-β (HSCP90), and Heat shock protein β-1 
(HSPB1). These protein processing related proteins were identified only in the high 
producer cell lines. The presence of these proteins only in high producers may suggest 
that they are upregulated in high producers. 
 
HSP60 is part of a class of proteins known as molecular chaperones that are required to 
promote folding and assembly of both misfolded and newly synthesised proteins 
preventing their aggregation during translation, and under conditions of cellular stress 
(Itoh et al., 2002). DnaK belongs to the chaperones of the Hsp70 family. The latter 
proteins have also been shown to be involved in a variety of cellular activities such as 
protein transport across membranes and anti-apoptosis (Mosser et al., 2000; Garrido et 
al., 2006). HSPB1 belongs to another class of molecular chaperones known as Small 
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Heat Shock Proteins (sHSP). Apart from their chaperonin function, they also have a 
protective effect on cell viability at elevated temperatures (Jakob et al., 1993). For high 
producer cell lines (Table 7.6) m/z ratio signal ions representing these chaperon proteins 
all had medium intensity based on the magnitude of the loadings (except for FKBP2 
which had a low intensity) indicating perhaps an upregulation for the high producer cell 
lines. An upregulation of chaperons in high producers suggests that the cells are 
overburdened due to high levels of translation thus more foldases are needed to clear up 
the accumulating proteins by accelerating their folding. 
 
IgG recombinant antibody light chain (LC) showed differential expression with a 
medium intensity in high producers (Table 7.6) based on magnitude of the loadings 
whilst the low producers (Table 7.7) showed a low intensity. Moreover, a higher 
number of human IgG heavy and light chain domain proteins were matched in high 
producers than  low producers (19 as opposed to 5) suggesting more production and 
secretion of IgG in high producers than in low producers . This is an important finding, 
as it corroborates proposed theories from previous SDS-PAGE studies which indicated 
a direct link between the amount of secreted antibody on cell surface and cellular 
productivity (Alete et al., 2003; van Dyk et al., 2003; Pascoe et al., 2007). It may be 
that the high producers may be involved in higher antibody production, transport and 
secretion than their low producer counterparts, hence have high intracellular 
concentration, with eventually high amounts being secreted, of the recombinant protein. 
It can thus be concluded that this observation supports the high productivity trends 
associated with high producing cell lines during cell culture. 
  
7.5.7. Protein Biosynthesis Proteins 
Proteins involved with translation or protein biosynthesis were amongst the most 
abundant class of proteins matched. Several proteins, mainly 40S and 60S ribosomal 
subunits, and translation initiation/elongation factors, were identified both in high 
producers (25 proteins) (Table 7.6) and low producers (13 proteins) (Table 7.7). The 
abundance of protein biosynthetic proteins in high producers, notably with proteins such 
as 40S ribosomal protein S15, 40S ribosomal protein S2, 60S acidic ribosomal protein 
P1, 60S ribosomal protein S7, and Protein S100-A9 showing medium intensity in the 
loadings plot implies they were upregulated in high producers. This suggests that high 
producers perhaps have higher rate of protein synthesis than low producers during 
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culture. As expected, the important roles played by these proteins during protein 
synthesis supports the high productivity trend observed in high producers. 
  
7.5.8. Cytoskeleton Proteins 
A number of structural and growth-associated proteins were among the proteins 
matched in the database. Five proteins each were identified in both the high (Table 7.6) 
and low producer (Table 7.7) cell lines. All the cytoskeleton proteins included Annexin 
A7,  β-actin, Calmodulin, Calponin-1, Catenin α-2, Coactosin-like protein, 
Tropomyosin α-1 chain (for high producers only), and Catenin α-3, Calmodulin, Protein 
S100-A11, Protein S100-A6, Protein S100-Z, Tubulin α-chain (for low producers only). 
These proteins function in stabilising the cell cytoskeletal. For example β-Actin is an 
actin filament component at the golgi complex in mammalian cells. It is part of the actin 
cytoskeleton plays an essential role both in endocytic and secretory pathways. 
Tropomyosin is an actin-binding protein that associates with actin filament to regulate 
its stability (Egea et al., 2006).  
 
Proteomic studies with mouse myeloma (NS0) cell lines showed a direct link between 
increased productivity a general increase in cellular cytoskeletal framework (Smales et 
al., 2004; Dinnis et al., 2006). Experimental evidence has suggested a functional 
interaction between cellular cytoskeletal apparatus, where a disruption of actin filaments 
led to a profound negative effect in translation (Stapulionis et al., 1997). The 
identification of cytoskeleton proteins in both high and low producers may suggest a 
normal cellular physiological phenomenon where the global protein synthesis network 
is supported and stabilised by the actin cytoskeletal framework. Hence it is possible that 
the upregulation of cytoskeleton proteins in high producers may be advantageous in 
providing these cell lines with a more stable and efficient protein synthesis framework, 
hence a guarantee of high product yield. 
  
7.5.9. Metabolism Proteins  
A large number of metabolism proteins were also matched, amongst which are a 
number involved in glycolysis while others are associated with nucleic acid metabolism. 
The high producer cell lines matched 20 glycolysis proteins (Table 7.6) whilst the low 
producer cell lines matched just 9 (Table 7.7). Glycolysis proteins were mainly enzymes 
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with the matched ones including aldose reductase, α-enolase, adenosine triphosphate 
(ATP) synthase, glyceraldehyde-3-phospate dehydrogenase (GAPDH), carbonyl 
reductase, NADH dehydrogenase, phosphoglycerate kinase (PK), succinate 
dehydrogenase (SDH), and superoxide dismutase (SOD). The α-enolase protein, 
matched in both high and low producers, is a key enzyme in the glycolytic pathway and 
hence it is ubiquitously present in abundance in the biological world. It is 
multifunctional, serving as a cell surface plasminogen receptor for a variety of 
hematopoetic, epithelial and endothelial cells; heat-shock protein property; cytoskeletal 
and chromatin structure binding properties suggests that α-enolase may play a crucial 
role in transcription and a variety of physiological processes in the cell (Pancholi 2001). 
With its multifunctional role in cellular physiological processes, the presence of α-
enolase in both high and low producers was expected. 
  
Another important metabolic protein matched in high and low producer cell lines is the 
enzyme SOD. In aerobic respiration, many oxidative metabolic processes (e.g cellular 
respiration, xanthine oxidase, NADPH oxidase, lipoxygenase) produce reactive oxygen 
species (ROS) (superoxide radicals, hydrogen peroxide, and singlet oxygen) as by 
products which are deleterious to the cell. The phenomenon of oxidative stress arises as 
a result of hydroxyl radicals (produced from ROS in the presence of metal ions) 
interacting with cellular macromolecules to cause lipid peroxidation, protein 
denaturation, DNA mutation, and eventual cell death. SOD plays a crucial role in the 
defence mechanism against oxidative stress in the cell by reacting with superoxide 
radicals to produce harmless hydrogen peroxide (Bowler et al., 1992). The presence of 
α-enolase in both high and low producers was expected as the cell lines are all involved 
in aerobic respiration. 
 
Important metabolic proteins matched only in high producers include  ATP synthase 
(synthesizes ATP from adenosine diphosphate (ADP) and inorganic phosphate) 
(Nakamoto et al., 2008); carbonyl reductase (cellular protective role by reduction of 
xenobiotic carbonyls and quinones) (Oppermann, 2007); GAPDH (breakdown of 
glucose into energy during glycolysis) (Sirover, 1997); NADH dehydrogenase 
(catalyses electron transfer from NADH to coenzyme Q in the electron transport chain) 
(Weiss et al., 1991); PK (catalyses the high-energy phosphoryl transfer of the acyl 
phosphate of 1,3-bisphosphoglycerate to ADP to produce ATP) (Blake and Rice, 1981); 
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thioredoxin (antioxidant enzyme - major cellular protein disulfide reductases - with 
growth factor properties responsible for maintaining intracellular proteins in their 
reduced state); glutaredoxin (catalyse glutathione-disulfide oxidoreductions overlapping 
the functions of thioredoxins and using electrons from NADPH via glutathione 
reductase) (Arnér and Holmgren, 2000); SDH (couples the Krebs cycle to the electron 
transport chain by the oxidation of succinate and the reduction of ubiquinone 
respectively) (Oyedotun and Lemire, 2004). This trend of differential expression may be 
related to metabolic differences in the cell lines which may in turn influence cellular 
productivity. The exclusive identification of these proteins for high producer cell lines 
suggests that these cell lines were metabolically more active than low producers. 
 
7.5.10.   Nucleic Acid Metabolism Proteins 
Several proteins involved in DNA and RNA metabolism were also matched. 
Approximately half the number of proteins matched for high producers (18 proteins) 
was matched for the low producers (8 proteins). Proteins matched only in high 
producers included transcription elongation factor 1-like, ATP-dependent RNA helicase 
DHX8, DNA polymerase subunit gamma-2, DNA repair protein complementing XP-A, 
DNA repair protein complementing XP-A cells homolog, guanine nucleotide-binding 
protein subunit gamma, non-histone chromosomal protein HMG-14, and splicing factor 
3B subunit 5. In addition, high producers matched more histone proteins than low 
producers. 
  
The matching of more histones in high producers may represent upregulation of these 
proteins. This result differs from previous studies that found a downregulation of 
histones in high-producing CHO cultures (Nissom et al., 2006; Carlage et al., 2009). 
Histones condense DNA into chromatin structures reducing the accessibility of DNA 
for transcription, hence downregulation of histones makes biological sense as 
transcription is enhanced from chromatin templates of high producers. However, though 
results here unexpectedly suggest an upregulation of histones in high producers,  the 
matching of transcription, splicing factors and enzymes (DNA polymerase subunit 
gamma-2, splicing factor 3B subunit 5, and transcription elongation factor 1-like) 
exclusively in high producers was comforting and makes biological sense as this 
suggests more active transcription and more efficient mRNA processing in high 
producers. 
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7.5.11. Cell Cycle Proteins 
Several proteins that are involved in cell cycle regulation were differentially expressed 
in this study. Fourteen cell cycle proteins were matched for high producers (Table 7.6) 
whilst just 9 were matched for low producers (Table 7.7). Important cell cycle proteins 
that were matched only in high producers include Galectin-1, Protein S100-A11 
(Calgizzarin), Stathmin, Bcl-2-like protein 10, E3 ubiquitin-protein ligase RNF144B, 
and Nucleosome assembly protein 1-like 1.  
 
Calgizzarin is a member of a family of calcium-modulated proteins that is involved in a 
variety of cellular processes such as proliferation and differentiation. Studies have 
implicated this protein as a cellular growth inhibitor on the basis of its down-regulation 
in immortalized compared to fibroblast cells (Donato, 2001). Another protein of interest 
is Galectin-1. Galectins are a group of sugar-binding proteins specific for their 
carbohydrate moieties. They modulate a wide range of cellular activities such as tumor 
progression, cell differentiation, cell growth, and apoptosis (Yang and Liu, 2003). 
Galectin-1 has specifically been shown to have growth modulation properties - having 
both negative and positive effects on cell proliferation. 
  
The identification of Galectin-1 and Calgizzarin only in high producers may suggest an 
upregulation of these proteins in high producers, hence a negative growth modulation. 
These results agree well with previous shortgun proteomic and quantitative proteomic 
profiling of high-producing CHO cell lines (Nissom et al., 2006; Carlage et al., 2009). 
This is not surprising with respect to the growth kinetics of the high producers 
compared to the low producers as low producers will tend to grow faster using up much 
needed energy needed for translation. From a productivity perspective, it is 
hypothesised that the presence of growth inhibitory proteins such as Calgizzarin and 
Galectin-1 in high producer cell lines will enhance product yield as the high producers 
will grow slower and commit all their energy into protein production. 
 
7.6. Summary 
In conclusion, MALDI-ToF MS was used for intact cell profiling of IgG-producing 
CHO cell lines during biopharmaceutical bioprocessing. The spectral data generated 
were preprocessed to reduce experimental variabilities that might otherwise have 
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masked biological trends in the data. PLS-DA was used to model the spectra data and 
distinguish between cell lines with respect to productivity (high/low producers; Hs/Ls). 
  
The theory was that variability exists within cell lines, based on their productivity (titre 
of IgG produced) and that PLS-DA can be used to help understand this behaviour. 
Specific m/z ratio regions were identified (with large absolute loadings) and their ability 
to act as discriminatory molecules between Hs and Ls were investigated, with the aim of 
identifying differentially expressed protein biomarkers associated with cell line 
productivity after a protein database searches.  
 
A total of 185 (123 Hs and 62 Ls) differentially expressed proteins were matched and 
identified after SwissProt/TrEMBL protein database search. The identified proteins 
revealed that more proteins involved in biological processes such as protein 
biosynthesis, protein folding, glycolysis and cytoskeleton architecture were upregulated 
in Hs. These findings are consistent with finding in the literature. A subset of these 
protein biomarkers such as molecular chaperons (heat shock protein families), α-
enolase, and superoxide dismutase, and translation initiation/elongation factors have 
already been identified from mammalian cell lines in a series of publications; and found 
to be correlated with specific antibody productivity. These results provide important 
insights into the overall cellular protein biology, and the gene of these protein 
biomarkers may represent valuable genetic engineering targets aimed at improving cell 
line productivity. It is clear that there is a relationship between the upregulation of some 
proteins in high producers and increases in protein productivity. The genes of such 
proteins can be targeted and genetically engineered to produce enhanced cell lines.  
  
This study demonstrates that PLS-DA if combined with linear mode MALDI-ToF MS 
can be a valuable tool for biomarker discovery in the biopharmaceutical bioprocessing 
industry. More specifically to CHO cell lines in culture, this study provides a foundation 
for rapid biomarker profiling of CHO cell lines with the completion of the sequencing 
of the CHO genome. Although the aforementioned points clearly demonstrate that this 
approach has a good potential in the area of mammalian cell culture during 
bioprocessing, further confirmatory studies are needed before the full potential of this 
approach can be realised. This is discussed in the future work section (section 8.2). 
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8. Conclusions and Future Work 
The findings of this thesis are summarised in this chapter. A summary of the chapters is 
presented and additional approaches beyond the scope of this work, that could provide 
avenues of investigation for future work, are suggested. The key contributions of this 
thesis are as follows: 
 
 This thesis has investigated the potential to utilise the approach of ‘intact-cell’ 
MALDI-ToF MS (ICM-MS) combined with PLS-DA to distinguish between 
IgG monoclonal antibody-producing CHO mammalian cell lines based on their 
productivities and identify protein biomarkers through protein database searches 
that are differentially expressed in these cell lines. Although a number of studies 
have been carried out recently to demonstrate how biomarker profiling by ICM-
MS combined with PLS and PLS-DA could be exploited to screen cultured 
mammalian cell lines in bioprocessing, no attempt was made to assign the mass 
spectra ion signals to potential protein biomarkers (Feng et al., 2010; Feng et al., 
2011). Together with the appropriate use of internet accessible protein data base 
searches, ICM-MS combined with PLS-DA has been shown to be effective for 
classifying CHO cell lines based on their productivities and identify protein 
biomarkers associated with the cell line productivities.  
 
 A proof-of-concept study applied to E. coli K-12 cells at different growth phases 
utilising the same methodology identified potential protein biomarkers 
associated with to the different growth phases of the cells.   
 
 Preprocessing is data dependent so preprocessing studies have been carried out 
for each data set used in this work. A number of combinations of data 
preprocessing techniques/parameters have been considered and empirically 
investigated to enable the most appropriate selection of the combination of 
methods/parameters. The parameters of the preprocessing methods were 
modified systematically and applied to the spectra data which was subsequently 
used to calibrate PLS-DA models. The combination of preprocessing 
techniques/parameters that gave an improved and optimum model performance 
was selected as the appropriate preprocessing method. The successful 
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identification of protein biomarkers from the spectra data suggested that the 
preprocessing methods used were valid, as it eliminated differences between 
spectra profiles as a consequence of experimental and instrumental procedures, 
whilst preserving the inherent biological information within the spectra profiles. 
 
8.1. Thesis Summary 
In chapter 1 an overview of the project was presented, including a summary of the main 
aims and objectives of the thesis. Chapter 2 proceeded to provide an overview of 
biopharmaceutical therapeutic proteins, the science and technology of in vitro 
mammalian cell culture which are used in their production as well as a short review on 
the methods that are currently being used for improving large-scale production of 
heterologous proteins from mammalian cell lines. 
 
MALDI-ToF MS was presented in chapter 3 along with a description of how the 
instrument was used to generate data from E. coli cells at different growth phases as 
well as from IgG monoclonal antibody producing CHO cell lines during culturing. 
Aspects relating to mass spectrometry data preprocessing was also discussed and the 
techniques were applied to the two mass spectra data sets. Finally, applications of mass 
spectra data preprocessing reported in the literature were discussed. 
 
In chapter 4, an introduction to proteomics and biomarker discovery relevant to this 
thesis was given. A summary of the approaches used in biomarker discovery 
highlighting the top-down proteomics based approach of ICM-MS, and its applications 
to microorganisms and mammalian cell line analysis for biomarker discovery in the 
biopharmaceutical bioprocessing industry was presented. The chapter also explored the 
importance of bioinformatics and internet accessible protein databases for biomarker 
identification in top-down proteomics. A literature review on applications of proteomic 
biomarker discovery was also presented. 
 
Chapter 5 focused on the multivariate data analysis techniques of principal component 
analysis (PCA), partial least squares (PLS) and PLS – discriminant analysis (PLS-DA). 
It explored the PLS-DA algorithm involved in modeling MALDI-ToF mass spectra data 
collected from E. coli cells at different growth phases as well as IgG monoclonal 
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antibody producing CHO cell lines with the aim of identifying protein biomarkers. The 
chapter also presented results of an example where PCA and PLS-DA were used to 
analyse the mass spectra data generated from cell lysate samples of E. coli K-12 cells at 
different growth phases. 
 
After discussing the advantages of utilising ICM-MS, PLS-DA, and protein databases in 
various areas of proteomics in chapters 4 and 5, chapter 6 served to provide a proof-of-
principle study of ICM-MS, PLS-DA and a database search to identify protein 
biomarkers associated with the growth phases of the E. coli. Firstly, PLS-DA was 
applied to the MALDI-ToF MS data to determine if such an approach could be used to 
distinguish between the cells at different growth phases. The application of PLS-DA 
resulted in the successful classification of the samples according to the growth phase of 
the cells. A further outcome of the analysis was that it was possible to identify the mass-
to-charge (m/z) ratio ion signals that contributed to the classification of the samples. The 
Swiss-Prot/TrEMBL database and primary literature was then used to assign a number 
of these m/z ion signals to proteins and these assignments revealed that the major 
contributors from the exponential phase were ribosomal proteins. Additional 
assignments were possible for the stationary phase and the decline phase cells where the 
proteins identified were consistent with observed biological interpretation. In summary, 
the results suggested that MALDI-ToF and PLS-DA can be used in combination to 
discriminate between E. coli cells in different growth phases and thus could potentially 
be used as a tool in process development in the bioprocessing industry to enhance cell 
growth and cell engineering strategies.  
 
After the proof-of-concept study successfully demonstrated in chapter 6, in chapter 7 
the approach was applied to the mass spectra data of IgG monoclonal antibody-
producing CHO cell lines. The cell lines were classified according to their productivities 
into high and low producer cell lines. The m/z ratio ion signals that contributed to the 
classification of the cell lines were subjected to Swiss-Prot/TrEMBL database search 
and primary literature. These searches revealed a number of m/z ratio ion signals that 
could be assigned to proteins. The identified proteins classified revealed that more 
proteins were in the high than in the low producer cell lines. These proteins are involved 
in biological processes such as protein biosynthesis, protein folding, glycolysis and 
cytoskeleton architecture. The upregulation of these proteins in high producer cell lines 
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were findings that are consistent with those reported in the literature. The ability to 
identify proteins that correlate to cell line productivity may be important in predicting 
the likelihood of a cell line being a high or low producer, provide insight into the 
biology of mammalian cell lines during biopharmaceutical bioprocessing, and may give 
indications of potential genetic engineering targets that may be exploited to engineer 
better cell lines. Chapter 7 provided the main contribution since no previous studies 
have adapted this approach to the best of the author’s knowledge.  
 
Appendix A and B presents additional information relating to the generation and 
analysis of the E. coli K-12  ‘intact’ cell and cell lysate mass spectra data sets 
respectively. Appendix A provides a summary of the chemicals, reagents and laboratory 
instruments used; the modeled population growth curve of E. coli K-12, ATCC 15223 
to show important growth parameters; the results of average wet and dry cell weight 
measurements for the E. coli cells as well as the calibration curves to determine these 
parameters; the results of standard plate count E. coli cells; approximate amount of 
bacterial cell pellets analysed using MALDI MS; the design of experiment results of 
preprocessing techniques applied to all E. coli MALDI mass spectra data sets; the 
preprocessing algorithms; the variables from the loadings plot that are associated with 
m/z ratio ion signals; and the MALDI-ToF instrumental parameters used in this work. 
Appendix B presents additional information relating to the multivariate data analysis of 
the E. coli K-12 cell lysate spectra data sets. Appendix C provides a summary of the 
PLS algorithm used in this thesis as well as information of the variables from the 
loadings plot that are associated with m/z ratio ion signals for the high and low producer 
CHO cell lines. 
  
8.2. Recommendations for Future Work 
The approach using ICM-MS, PLS-DA, and protein database searches has been shown 
to offer much promise as an effective tool in protein biomarker profiling and potentially 
useful as a tool in process development in the bioprocessing industry to enhance cell 
growth and cell engineering strategies. There are however issues that require further 
investigation before the approach can be considered ready to be used in real world 
situations.  
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The sequencing of the CHO genome and compilation of sequence-derived theoretical 
MWs of CHO proteins in internet accessible protein databases has created the 
possibility of identifying potential protein biomarkers of CHO cells by matching the 
sequence-derived theoretical MWs of the database proteins with experimental MWs 
derived from MALDI-TOF mass spectrometry. Assigning m/z ratio peaks or ion signals 
to protein biomarkers in internet accessible databases is facilitated by the fact that most 
of the m/z ratio peaks from MALDI generated mass spectra data represent singly 
charged protein ions, whose molecular weight can be directly inferred as that of the 
protein molecule. 
 
8.2.1. Further Studies for Protein Identification 
Nevertheless, the provision of molecular weight of the proteins by MALDI-MS is not 
enough information to identify a protein. Therefore all protein assignments in this 
project were tentative for a number of reasons including the fact that there may be more 
than one potential match in the protein database corresponding to a molecular weight. 
For example in the E. coli spectra data sets,  the m/z ratio peak of 7332 could be 
assigned to the ribosomal protein RL29 and the cold shock protein-E (CPSE) as both 
have MWs of 7273 Da. Therefore, it is not possible to provide a definitive conclusion 
about the assignment of the peaks. Moreover, adduct ions, mass errors and post-
translational modifications involved with some proteins may impede the assignment 
process. Matrix effects during the MALDI experiment may lead to ion suppression 
where protein ions are masked by matrix ones leading to improper assignments. 
For a proper assignment and thus a positive identification of an individual protein more 
studies would be required. These usually involve tryptic digestion of the samples which 
are then subjected to tandem mass spectrometry analysis (such as two-dimensional 
polyacrylamide gel electrophoresis with matrix assisted laser desorption ionisation time 
of flight MS; 2D-PAGE/MALDI-TOF-MS or liquid chromatography with electrospray 
ionisation MS (nano-LC-ESI-MS/MS)), providing sequence-specific fragments of the 
individual proteins. 
 
8.2.2. Integration of ‘Omics’ Data for Biomarker Discovery 
This research involves a proteomics technology (MALDI-ToF) that has the potential of 
identifying or discovering biomarkers. However, to enhance the contextualisation of the 
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proteomics results, it can be integrated with of data from other platforms such as 
metabolomics or transcriptomics. Thus having the possibility of working with 
transcriptomics data from the same system (E. coli or CHO cell lines) would be more 
interesting as there would be the linkage of known proteins with their identified genes 
or metabolites to relevant biochemical pathways. Correlating the changes in protein 
abundance from proteomics and gene expression from transcriptomics with changes in 
the cell function will permit the exploration of a broad range of biological processes. 
This will help provide insight into the biology of mammalian cell lines during 
biopharmaceutical bioprocessing. 
 
8.2.3. Future Studies using an alternative PLS-DA Algorithm 
Whilst the PLS-DA algorithm improves the arbitrary selection of classification which 
now depends on the distribution of sample predictions than other methods which sets 
threshold at an arbitrary value, that is, 0.5, the algorithm assumes that each sample will 
have a predicted y-value greater/less than the threshold making it to fall to one of the 
class or the other. However this may not be the case as we may have a y-value equal to 
the threshold hence no class and misclassification will be inevitable where sample will 
be included in one of the classes. Consequently, the algorithm needs a ‘Rejection Rule’ 
where such a sample is rejected altogether (Such an algorithm has been proposed by 
Botella et al. (2009). It is recommended that future study should involve using an 
algorithm which provides ‘Rejection Rule’ option in order to avoid the risk of 
misclassification and improve the quality of the models.  
 
8.2.4. Predictive Modelling for Process Development 
There is another dimension to this approach not considered in this project that could 
have a direct contribution to process development in the bioprocessing industry. The 
MALDI-ToF mass spectra data generated from IgG monoclonal antibody-producing 
CHO cell lines can be used to train predictive models of PLS-DA. These models can 
then be used to predict the likelihood of other CHO cell lines being high or low 
producers. Predicting productivity earlier on during biotechnological process 
development may lead to early screening of high producing cell lines which will have 
the desired high productivity during manufacturing (bioreactor stage). 
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Appendix A      Additional information for the ‘intact’ cell E. coli K-12 
project 
Appendix A provides a summary of the chemicals, reagents and laboratory instruments 
used; the modeled population growth curve of E. coli K-12, ATCC 15223 to show 
important growth parameters; the results of average wet and dry cell weight 
measurements for the E. coli cells as well as the calibration curves to determine these 
parameters; the results of standard plate count E. coli cells; approximate amount of 
bacterial cell pellets analysed using MALDI MS; the design of experiment results of 
preprocessing techniques applied to all E. coli MALDI mass spectra data sets; the 
preprocessing algorithms; the variables from the loadings plot that are associated with m/z 
ratio ion signals; and the MALDI-ToF instrumental parameters used in this work. 
Figures 
A.1     Preprocessing algorithm used for the E. coli mass spectra profiles 
 
For the optimal combination of preprocessing techniques and associated parameters, the 
baseline correction quantile value was at 0.1, baseline correction window size was set to 
200, normalisation quantile value, 0.1 or 0.2,  and smoothing span value was at 25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
files=dir('*dat'); 
for i = 1:366; 
files(i).data = load(files(i).name); 
MZ = files(i).data(:,1); 
Y(:,i)=[files(i).data(:,2)]; 
Ynew=Y(4300:end,:); 
MZnew=MZ(4300:end,:); 
[MZR, YR(:,i)]= msresample(MZnew,Ynew(:,i),7000,'range',[2350 
max(MZnew)]); 
YB(:,i)=msbackadj(MZR,YR(:,i),'WINDOWSIZE',200,'QUANTILE',0.1,'PRESER
VEHEIGHTS',true); 
P=[6411 6855 7273 7333 7869 9061 9218 9532 9736]; 
YA(:,i)=msalign(MZR,YB(:,i),P); 
YN(:,i) = msnorm(MZR,YA(:,i),'Quantile',0.1,'MAX',100); 
YS(:,i) = mssgolay(MZR,YN(:,i),'SPAN',25); 
YStcal=[YS']; End 
P=mspeaks(MZR,YS,'Denoising',false,'HeightFilter',10,'SHOWPLOT',false); 
 Figure A.1: Preprocessing algorithm used for the E. coli mass spectra 
 Appendices                                                                                                                
  
 
260 
 
A.2      Preprocessing algorithm used for the CHO cell line mass spectra profiles 
For the optimal combination of preprocessing techniques and associated parameters, the 
baseline correction quantile value was at 0.2, baseline correction window size was set to 
100, normalisation quantile value, 0.1, and smoothing span value was at 25 
 
 
 
 
 
 
 
 
 
 
 
A.3      Cross-validation vector used for the intact cell E. coli data sets 
The cross-validation vector was used for cross-validation of 300 ‘intact’ cells E. coli 
MALDI mass spectra calibration data sets. Leave-class-out-cross-validation was 
performed. The vector was coded as ‘1’ to indicate that the sample involved belonged to 
class 1; ‘2’ for class 2; and ‘3’ for class 3. All samples coded with ‘1’, belonging to the 
same class 1 were removed from the calibration data set and a sub-model based on the 
remaining samples was used to build the PLS-DA model and predict the left out samples. 
The process was repeated with all the 300 calibration data set of classes 2 and 3 had been 
left out once. 
[1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 1 
1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 1 1 1 
1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 1 1 1 1 
1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 31 1 1 1 1 1 1 
1 1 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 1 1 1 1 1 1 1 1 
1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3]  
 
 
files=dir('*txt'); 
for i = 1:80; 
files(i).data = load(files(i).name); 
MZ = files(i).data(:,1); 
Y(:,i)=[files(i).data(:,2)]; 
Ynew=Y(6200:end,:); 
MZnew=MZ(6200:end,:); 
[MZR, YR(:,i)]= msresample(MZnew,Ynew(:,i),7000,'range',[6200 
max(MZnew)]); 
YB(:,i)=msbackadj(MZR,YR(:,i),'WINDOWSIZE',200,'QUANTILE',0.2,'PRESE
RVEHEIGHTS',true); 
P=[6411 6855 7273 7333 7869 9061 9218 9532 9736]; 
YA(:,i)=msalign(MZR,YB(:,i),P); 
YN(:,i) = msnorm(MZR,YA(:,i),'Quantile',0.1,'MAX',100); 
YS(:,i) = mssgolay(MZR,YN(:,i),'SPAN',25); 
YStcal=[YS']; End 
P=mspeaks(MZR,YS,'Denoising',false,'HeightFilter',10,'SHOWPLOT',false); 
Figure A.2: Preprocessing algorithm used for the CHO cell line mass spectra profiles 
Figure A.3: Cross-validation vector used for the intact cell E. coli data sets 
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Tables  
A.1      Results of MALDI-ToF instrument parameter optimisation  
Table A.1 summarises the results of MALDI-ToF instrument parameter optimisation 
when the parameters were altered based on the design matrix.  As can be seen from the 
table, the parameters that were changed were ion source voltage 1 (accelerating voltage), 
ion source voltage 2 (grid voltage), pulse ion extraction (PIE), and the laser beam focus. 
All other parameters were maintained at a fixed value. For good signals, the grid voltage 
was always set at approximately 88% of the accelerating voltage. The two values for the 
accelerating and grid voltage used were 24 and 21, and 24.24 and 21.23 respectively. The 
PIE was altered at intervals of about 50 units ranging from 150-500ns. Only two values 
(35 or 39%) of the laser beam were used. Results were based on the signal-to-noise (s/n) 
ratio of the peaks observed. This was rated from bad to excellent as follows. As can be 
seen from the table, results suggest that higher PIE values in the range 350-500ns gave 
very good signals observed only in taller spectra peaks. PIE value of 300ns gave very 
good signals observed only in smaller peaks while PIE values of 300 and 350ns gave 
excellent signals across all spectra peaks. Consequently, trial 10 was adopted as condition 
for MALDI analysis. 
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Table A.1: Results of MALDI-ToF instrument parameter optimisation 
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A.2     MALDI ground steel target plate layout showing the E. coli cell pellet sample 
arrangement 
Table A.2 shows the MALDI ground steel target plate layout of the E. coli cell pellet 
sample arrangement for analysis. STD (standard) represented the calibrant.  About 1µl of 
calibrant was spotted onto of the MALDI target plate onto six specific sample spots 
surrounded by 20 spots containing samples to be analysed. Each calibrant within each 
group of sample was used to calibrate the instrument before analysing all samples in the 
group.  The samples were named as di (intact cell pellets for cultures at decline phase), mi 
(intact cell pellets for cultures at mid-log or exponential phase), si (intact cell pellets for 
cultures at stationary phase), dl (cell lysate for cultures at decline phase), ml (cell lysate 
for cultures at exponential phase), and sl (cell lysate for cultures at stationary phase). To 
explain the labeling, for example the 20 different MALDI spots of intact cells at the 
decline growth phase were labeled di01, di02, di03,...., di018, di19, di20;  intact cells at 
the exponential growth phase  mi01, mi02, mi03,...., mi018, mi19, mi20. All the other 
sample spots were labeled following this format. 
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Table A.2: MALDI ground steel target plate layout showing the E. coli cell 
pellet sample arrangement 
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A.3     Data used for graph of Figure 3.19 showing the effect of cropping and 
resampling on quality of PLS-DA models across LV2 
Table A.3 presents the data used in plotting graph in Figure 3.19 which shows the effect 
of cropping and resampling on quality of PLS-DA models across latent variables 2 to 11. 
Signal resampling was carried out after cropping the data.  The data sets were resampled 
by down sampling to 7000 data points from 2350 to 20400 m/z ratio values. 
 
Table A.3: Data used for graph of Figure 3.19 
Number 
of latent 
variables 
Average R
2
 (%) Average RMSECV (%) 
Raw 
data 
Data 
after  
cropping 
Data after 
cropping 
and 
resampling 
Raw 
data 
Data 
after  
croppin
g 
Data after 
cropping 
and 
resampling 
2 2.9 32.5 32.6 39.3 39.4 39.3 
3 34.8 48.2 48.2 34.8 34.7 34.7 
4 55 64.3 64.6 29.2 28.7 28.8 
5 62.3 66.9 67.1 28.5 28.4 27.9 
6 60.3 68.5 68.6 27.7 27.6 27.5 
7 64 70 70 27.2 27.4 27.4 
8 65.7 70 70.1 27.2 27.2 27.2 
9 67.4 69.9 69.9 26.9 27.7 27.7 
10 68.8 70.6 70.5 26.9 27.6 27.7 
11 70.5 70.1 70.2 27.6 27.9 27.9 
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A.4     Data used for graph of Figure 3.21 showing the effect of alignment across a 
number of latent variables  
Table A.4 shows the effect of alignment across a number of latent variables. Alignment of 
the spectra data was carried out along five m/z ratio peaks 6411, 6855, 7273, 7333, 7869, 
9061, 9218, 9532, 9736 which were found to be common among most of the spectra 
profiles. The results suggest that applying alignment on the data slightly improved the 
qualities of the PLS-DA models built using the mass spectra data, on average. 
 
 
A.5     Design of experiment (DOE) results of preprocessing techniques applied to 
all E. coli spectra data  
Table A.5 summarises the results for the main effects and interaction plots for the 
preprocessing techniques with output being the RMSEP. RMEP was used because 
prediction error is an absolute measure.  
 
A 2
4
 full factorial design matrix (with 2 center points per block) set up with four factors, 
i.e. baseline correction quantile value, baseline correction window size, normalisation 
quantile value and smoothing span value. All these factors were held at 2 levels (upper 
and lower levels). Eighteen runs were performed with baseline correction quantile value 
at 0.1-0.2, baseline correction window size at 300-500, normalisation quantile value at 
0.1-1 and smoothing span value at 20-25. These intervals were those that gave optimal 
results (high R
2
 and low RMSECV) when the corresponding preprocessing techniques 
Number 
of latent 
variables 
Average R
2
 (%) Average RMSECV (%) 
Raw data 
Data after  
alignment 
Raw 
data 
Data after  
alignment 
2 2.9 35.7 39.3 38.2 
3 34.8 54.2 34.8 32.6 
4 55.0 65.6 29.2 28.5 
5 62.3 67.5 28.5 28.0 
6 60.3 69.3 27.7 27.4 
7 64.0 71.3 27.2 26.2 
8 65.7 73.0 27.2 25.9 
9 67.4 72.7 26.9 26.3 
10 68.8 72.8 26.9 26.2 
11 70.5 73.2 27.6 26.2 
Table A.4: Data used for graph of Figure 3.21 
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were used in isolation. A random design was subsequently set up with baseline correction 
quantile value at 0.1-0.2, baseline correction window size at 100-200, and normalisation 
quantile value at 0.1-0.2, evaluated against a fixed smoothing span value of 25. The 
qualities of the models were evaluated through the R
2
 and the RMSECV whilst the 
performance was evaluated against the root mean square error of prediction (RMSEP) and 
the R
2 
of prediction.  
 
A seen in Fig. 3.22 (chapter 3), the main effects plot suggests that all the preprocessing 
techniques are significant, with baseline correction quantile value and smoothing span 
value being the most significant preprocessing techniques affecting the model 
performance. This goes to support the earlier view that all these techniques were essential 
for preprocessing the spectra data. The main effects for average RMEP are maximised 
when baseline correction quantile value was set at 0.2 and smoothing span value to 20.  
 
From the interaction plots, the following interactions could be observed;  
 baseline correction window size and normalisation quantile value;  
 smoothing span value and normalisation quantile value;  
 baseline correction window size and smoothing span value; and  
 baseline correction window size and quantile value.   
 
Estimated Effects and Coefficients for Average RMSEP (coded units) 
 
Term                                                  Effect     Coef       SE Coef        T            P 
Constant                                                         17.8744     0.1111      160.87     0.000 
Baseline correction window size   0.0800      0.0400      0.1179      0.34          0.767 
Baseline correction quantile va      1.8200     0.9100       0.1179     7.72          0.016 
Normalisation quantile value        -0.1650    -0.0825       0.1179     -0.70         0.556 
Smoothing span value                   -1.4750    -0.7375       0.1179    -6.26         0.025 
Baseline correction window size*  0.0100     0.0050       0.1179     0.04          0.970 
  Baseline correction quantile va 
Baseline correction window size* -0.1650    -0.0825      0.1179    -0.70         0.556 
  Normalisation quantile value 
Baseline correction window size*  -0.0950   -0.0475     0.1179    -0.40         0.726 
  Smoothing span value 
Baseline correction quantile va*    -0.1650    -0.0825     0.1179    -0.70        0.556 
  Normalisation quantile value 
Baseline correction quantile va*     0.0450      0.0225    0.1179      0.19         0.866 
  Smoothing span value 
Normalisation quantile value*        0.1650      0.0825     0.1179     0.70         0.556 
  Smoothing span value 
Baseline correction window size*  -0.1650    -0.0825     0.1179    -0.70        0.556 
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  Baseline correction quantile va* 
  Normalisation quantile value 
Baseline correction window size*   -0.2250    -0.1125    0.1179    -0.95      0.441 
  Baseline correction quantile va* 
  Smoothing span value 
Baseline correction window size*    0.1650     0.0825    0.1179      0.70        0.556 
  Normalisation quantile value* 
  Smoothing span value 
Baseline correction quantile va*      0.1650     0.0825     0.1179     0.70       0.556 
  Normalisation quantile value* 
  Smoothing span value 
Baseline correction window size*    0.1650     0.0825     0.1179     0.70       0.556 
  Baseline correction quantile va* 
  Normalisation quantile value* 
  Smoothing span value 
 
 
S = 0.471405    PRESS = 1024.44 
R-Sq = 98.11%   R-Sq(pred) = 0.00%   R-Sq(adj) = 83.95% 
 
 
 
Analysis of Variance for Average RMSEP (coded units) 
 
Source                      DF   Seq SS   Adj SS   Adj MS      F      P 
Main Effects               4  22.0866  22.0866  5.52165  24.85  0.039 
2-Way Interactions     6   0.3713   0.3713  0.06188   0.28  0.906 
3-Way Interactions     4   0.5292   0.5292  0.13230   0.60  0.705 
4-Way Interactions     1   0.1089   0.1089  0.10890   0.49  0.556 
Residual Error             2   0.4444   0.4444  0.22222 
  Lack of Fit                 1   0.4444   0.4444  0.44444 
  Pure Error                  1   0.0000   0.0000  0.00000 
Total                           17  23.5404 
 
 
Unusual Observations for Average RMSEP 
 
               Average 
Obs  StdOrder    RMSEP       Fit         SE Fit     Residual    St Resid 
  1         1           16.1600     16.1044    0.4698     0.0556      1.41 X 
  2         2           20.4200     20.3644    0.4698     0.0556      1.41 X 
  3         3           16.1600     16.1044    0.4698     0.0556      1.41 X 
  5         5           19.3500     19.2944    0.4698     0.0556      1.41 X 
  6         6           17.7500     17.6944    0.4698     0.0556      1.41 X 
  7         7           18.0100     17.9544    0.4698     0.0556      1.41 X 
  8         8           18.2400     18.1844    0.4698     0.0556      1.41 X 
  9         9           17.7500      17.6944   0.4698     0.0556      1.41 X 
 10        10         17.8100      17.7544   0.4698     0.0556      1.41 X 
 11        11         16.3600      16.3044   0.4698     0.0556      1.41 X 
 12        12         16.3600      16.3044   0.4698     0.0556      1.41 X 
 13        13         18.0100      17.9544   0.4698     0.0556      1.41 X 
 14        14         19.3500      19.2944   0.4698     0.0556      1.41 X 
 15        15         17.8100      17.7544   0.4698     0.0556      1.41 X 
 16        16         18.2400      18.1844   0.4698     0.0556      1.41 X 
 18        18         19.1000      19.0444   0.4698     0.0556      1.41 X 
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X denotes an observation whose X value gives it large leverage. 
 
 
Estimated Coefficients for Average RMSEP using data in uncoded units 
 
Term                                                   Coef 
Constant                                             38.7794 
Baseline correction window size      -0.0460167 
Baseline correction quantile va        -127.750 
Normalisation quantile value           -11.0000 
Smoothing span value                       -1.02800 
Baseline correction window size*      0.405167 
  Baseline correction quantile va 
Baseline correction window size*      0.0366667 
  Normalisation quantile value 
Baseline correction window size*      0.00196667 
  Smoothing span value 
Baseline correction quantile va*        110.000 
  Normalisation quantile value 
Baseline correction quantile va*         6.20000 
  Smoothing span value 
Normalisation quantile value*            0.44000 
  Smoothing span value 
Baseline correction window size*      -0.366667 
  Baseline correction quantile va* 
  Normalisation quantile value 
Baseline correction window size*      -0.0170667 
  Baseline correction quantile va* 
  Smoothing span value 
Baseline correction window size*      -0.00146667 
  Normalisation quantile value* 
  Smoothing span value 
Baseline correction quantile va*         -4.40000 
  Normalisation quantile value* 
  Smoothing span value 
Baseline correction window size*        0.0146667 
  Baseline correction quantile va* 
  Normalisation quantile value* 
  Smoothing span value  
 
 
Table A.5: Design of experiment (DOE) results of preprocessing 
techniques applied to all E. coli spectra data 
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A.6     Variables from the loadings with their corresponding m/z ratio signal ions 
for exponential phase samples  
Table A.6 shows the variables from the loadings plots which are associated to m/z ratio 
signal ions for exponential phase samples. Since most of the m/z ratio ion signals are 
singly charged protonated protein (MH
+
) molecules, they represent the approximate 
MALDI experimental MWs of the ionised proteins expressed by the cultures at the 
exponential phase samples.  The magnitude of the loadings may reveal how expression of 
proteins varies with growth phase. Loadings were considered to have high intensity if the 
magnitude was greater than 0.2; medium intensity if the magnitude was greater than 0.05, 
but less than 0.2; and low intensity if the magnitude was between 0 and 0.05. 
Variables 
from 
loadings 
plot 
Intensity of 
variable from 
loadings plot  
Associated m/z 
(MH
+
) or 
experimental 
MW  
Intensity of 
variable from 
loadings plot 
Intensity 
Associated m/z 
(MH
+
) or 
experimental 
MW 
362 Low 2846.1 2911 Low 7700.7 
615 Low 3222.2 2912 Low 7703.1 
903 Low 3678.6 2913 Low 7705.5 
904 Low 3680.2 2914 Low 7707.8 
905 Low 3681.9 2915 Low 7710.2 
906 Low 3683.5 2983 Low 7872.0 
1326 Low 4403.7 2984 Low 7874.4 
1327 Low 4405.5 2985 Low 7876.8 
1335 Low 4419.9 3302 Low 8654.8 
1337 Medium 4423.5 3396 Low 8882.3 
1443 Medium 4615.8 3520 Medium 9211.0 
1533 Low 4782.4 3521 Medium 9213.6 
1701 Medium 5100.7 3522 Medium 9216.2 
1703 Medium 5104.5 3641 Medium 9527.2 
1810 Medium 5313.0 3642 Medium 9529.9 
1878 Medium 5447.7 3643 Medium 9532.5 
1879 Medium 5449.6 3961 Low 10389.2 
1880 Medium 5451.6 4073 Low 10699.8 
1881 Medium 5453.6 4248 Low 11197.0 
2270 Medium 6256.7 4520 Low 11983.9 
2297 Medium 6314.5 4596 Low 12210.4 
2301 Medium 6323.1 4741 Low 12645.8 
2344 High 6415.8 5175 Low 13997.6 
2538 Medium 6842.2 5599 Low 12219.3 
2539 Medium 6844.4 5604 Low 15403.2 
2540 Medium 6846.6 2756 Medium 7337.7 
2541 Medium 6848.9 2818 Low 7482.0 
2728 High 7273.1 2845 Low 7545.5 
Table A.6: Variables from the loadings with their corresponding m/z ratio ion signals 
for exponential phase samples 
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A.7     Variables from the loadings with their corresponding m/z ratio  signal ions 
for stationary phase samples  
Table A.7 shows the variables from the loadings plots which are associated to m/z ratio 
signal ions for stationary phase samples. The magnitude of the loadings may reveal how 
expression of proteins varies with growth phase. Loadings were considered to have high 
intensity if the magnitude was greater than 0.2; medium intensity if the magnitude was 
greater than 0.05, but less than 0.2; and low intensity if the magnitude was between 0 and 
0.05. 
Table A.7: Variables from the loadings with their corresponding m/z ratio ion 
signals for stationary phase samples 
Variables 
from 
loadings plot 
Intensity of 
variable from 
loadings plot  
Associated m/z 
(MH
+
) or 
experimental 
MW  
Intensity of 
variable from 
loadings plot 
Intensity 
Associated m/z 
(MH
+
) or 
experimental 
MW 
411 Low 2917.15 2915 Medium 7710.20 
628 Low 3242.11 2991 Medium 7891.22 
902 Low 3676.94 3005 Low 7925.00 
909 Low 3688.07 3180 High 8351.03 
1014 Low 3862.56 3168 Low 8321.55 
1070 Low 3956.71 3264 Low 8559.58 
1236 Low 4243.58 3267 Low 8567.07 
1305 Medium 4366.20 3381 Low 8854.33 
1308 Medium 4371.55 3387 Low 8869.58 
1407 Low 4549.61 3463 Medium 9063.84 
1422 Low 4576.96 3553 Low 9296.72 
1538 Low 4791.26 3554 Low 9299.32 
1583 Low 4876.15 3555 Low 9301.92 
1591 Medium 4890.81 3654 High 9561.51 
1701 High 5101.12 3719 Medium 9733.70 
1816 Low 5324.82 3730 High 9763.22 
2271 Medium 6259.30 3731 High 9765.89 
2304 Medium 6329.57 3800 Low 9950.62 
2305 Medium 6331.71 3810 Low 9977.82 
2306 Medium 6333.86 3970 Low 10414.02 
2307 Medium 6336.01 4097 Low 10766.89 
2344 Medium 6416.10 4488 Low 11890.24 
2553 Medium 6875.70 4522 Low 11989.77 
2738 Medium 7296.09 5250 Low 14238.17 
2739 Medium 7298.40 5256 Low 14259.00 
2920 High 7721.85 5615 Low 15440.04 
2921 High 7724.23 6393 Low 18157.87 
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A.8     Variables from the loadings with their corresponding m/z ratio signal ions 
for decline phase samples  
Table A.8 shows the variables from the loadings plots which are associated to m/z ratio 
signal ions for decline phase samples. The magnitude of the loadings may reveal how 
expression of proteins varies with growth phase. Loadings were considered to have high 
intensity if the magnitude was greater than 0.2; medium intensity if the magnitude was 
greater than 0.05, but less than 0.2; and low intensity if the magnitude was between 0 and 
0.05. 
 
Variables 
from 
loadings 
plot 
Intensity of 
variable 
from 
loadings plot  
Associated m/z 
(MH
+
) or 
experimental 
MW  
Intensity of 
variable 
from 
loadings plot 
Intensity 
Associated 
m/z (MH
+
) or 
experimental 
MW 
1222 Low 4219.00 4053 Low 10643.97 
1223 Low 4220.76 4054 Low 10646.76 
1224 Low 4222.51 4055 Low 10649.54 
1225 Low 4224.26 4056 Low 10652.33 
1441 Low 4611.73 4259 Low 11225.56 
1517 Low 4752.10 4474 Low 11849.06 
1574 Low 4858.77 4742 Low 12649.85 
2069 Low 5834.88 5598 Low 15383.06 
2335 Low 6396.33 5599 Low 15386.41 
2540 High 6846.62 5600 Low 15389.76 
2541 High 6848.86 5601 Low 15393.11 
2542 High 6851.09 5602 Low 15396.46 
2676 Low 7153.81 6400 Low 18186.28 
2723 Medium 7261.54 3524 High 9221.37 
2906 Low 7688.67 3641 High 9527.22 
2976 Medium 7855.29 3715 High 9723.24 
3165 High 8069.70 3795 Low 9937.40 
3373 Low 8834.02 3954 Low 10369.98 
3457 High 9048.47 3986 Low 10458.15 
3458 High 9051.04 4052 Low 10641.19 
Table A.8: Variables from the loadings with their corresponding m/z ratio 
ion signals for decline phase samples 
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A.9    Ranges of variables from the loadings with their corresponding m/z ratio 
signal ion ranges for exponential phase sample 
 
The full explanation of superscript letters assigned to column titles in Tables A.9 to 
A.11 are as follows:    
a 
Variable count range were the variables (associated to m/z ratio values or ion signals in 
the MALDI data set) from the PLS-DA loadings plot.  The loadings plot help provide 
the m/z ratio values (which are experimental MWs) of potential protein biomarkers. 
  
bExp’tal MW (m/z ratio value) range mapped to variable count range.   Located within a 
range is an average exp’tal MW which can be matched to the theoretical MW of a 
protein in the database. 
 
c
Average variable count was a variable located within a variable count range from the 
PLS-DA loadings plot that was mapped to a m/z ratio value (exp’tal MW). The latter 
can be matched to the theoretical MW of a protein in the database. 
 
dAverage exp’tal MW was the m/z ratio value (within an exp’tal MW range) that was 
matched to the theoretical MW of a protein in the database  taking into account the mass 
accuracy in the linear mode MALDI-ToF which is 100 ppm, i.e., exp’tal MW masses 
should be within 0.01% of their theoretical MWs (+/- 1 mass unit for 10,000 MW 
protein) 
 
e
The intensity of the variables ( m/z ion signals) 
 
is the magnitude of their loadings in the 
loadings plot. High: intensity ≥ ±0.1 units; medium: intensity ≥ ±0.05 and ≤ ±0.1 units; 
low: intensity between 0 and ±0.05 units.  
 
f
Match or theoretical sequence MW was calculated using the Compute pI/MW tool 
(http://web.expasy.org/compute_pi/). 
 
  
g
Error was the difference between the theoretical sequence MW of the protein in the 
database and the  exp’tal MW of the MALDI experiment obtained from the PLS-DA 
loadings plot 
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h
Proteins names were those of proteins whose theoretical sequence MW in database 
tentatively matches  exp’tal MW of the MALDI experiment obtained from the PLS-DA 
loadings plot. 
Table A.9: Variable count ranges from loadings plot and their corresponding 
experimental MW ranges for exponential phase samples 
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A.10    Ranges of variables from the loadings with their corresponding m/z ratio 
signal ion ranges for stationary phase sample 
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Table A.10: Variable count ranges from loadings plot and their corresponding 
experimental MW ranges for exponential phase samples 
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A.11    Ranges of variables from the loadings with their corresponding m/z ratio 
signal ion ranges for decline phase sample 
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Table A.11: Variable count ranges from loadings plot and their corresponding 
experimental MW ranges for exponential phase samples 
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Appendix B      Additional information for the E. coli K-12 cell lysate 
project     
Appendix B presents additional information relating to the multivariate data analysis of 
the E. coli K-12 cell lysate spectra data sets. It provides a summary of the cross-validation 
vector used; figure of calculated Y versus measured Y in fitting and prediction after leave-
class-out cross-validation for PLS-DA model built with the data sets; figure of calculated 
Y versus measured Y in fitting and prediction after external validation for PLS-DA model 
built with the data sets; results of PCA model for the mass spectra data sets; PLS-DA 
results for the data sets showing percentage variance explained by the LVs calculated for 
X and Y variables; PLS-DA results for the data sets showing the quality of the model after 
calibration and cross-validation; and PLS-DA results for the data sets showing the 
performance of the model after external validation. 
Figures  
B.1      Cross-validation vector used for the E. coli cell lysate data sets  
The cross-validation vector was used for cross-validation of 300 E. coli cell lysate 
MALDI mass spectra calibration data sets. Leave-class-out-cross-validation was 
performed. The vector was coded as ‘1’ to indicate that the sample involved belonged to 
class 1; ‘2’ for class 2; and ‘3’ for class 3. All samples coded with ‘1’, belonging to the 
same class 1 were removed from the calibration data set and a sub-model based on the 
remaining samples was used to build the PLS-DA model and predict the left out samples. 
The process was repeated with all the 300 calibration data set of classes 2 and 3 had been 
left out once. 
 
[1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 1 
1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 1 1 1 
1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 1 1 1 1 
1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 31 1 1 1 1 1 1 
1 1 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 1 1 1 1 1 1 1 1 
1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3]  
 
           Figure B.1: Cross-validation vector used for the E. coli cell lysate data sets 
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B.2      Calculated Y versus measured Y in fitting and prediction after leave-class-
out cross-validation 
Figure B.2 shows the PLS-DA calculated Y versus measured Y in fitting and prediction 
after leave-class-out cross-validation 300 preprocessed calibration spectra data sets for 
cell lysate. No significant deviations can be identified along the y-axis in all three classes 
suggesting that that all the useful information is taken into account by the model.  
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Figure B.2: Calculated Y versus measured Y in fitting and prediction after leave-class-
out cross-validation 
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B.3       PLS-DA calculated Y versus measured Y in fitting and prediction after 
external validation 
Figure B.3 shows the PLS-DA calculated Y versus measured Y in fitting and prediction 
after external validation with 55 test set samples of cell lysate. The decision threshold 
shown in each case (middle dashed red line) is calculated using the distribution of 
predicted Y values obtained during model building. As seen from the model, just one 
class 1 (decline phase) sample (1dl18) was misclassified falling below the decision 
threshold. This gave an excellent prediction sensitivity and specificity of 95.7% and 
95.2% respectively. No class 2 (exponential phase) samples were misclassified giving 
100% prediction sensitivity and specificity. Only two class 3 (stationary phase) samples 
(1sl18 and 3sl16) were misclassified giving very good prediction sensitivity and 
specificity of 88.9% and 85.1% respectively. 
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Figure B.3: PLS-DA calculated Y versus measured Y in fitting and prediction after 
external validation 
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Tables  
B.1      PCA model of the cell lysate mass spectra data sets 
Table B.1 summarises the results of PCA model for the 355 preprocessed E. coli cell 
lysate mass spectra data sets. PCA was applied to get an overview of the mass spectra to 
identify any groupings and to determine if differences occur due to the growth phase. The 
first three principal components were retained and these account for 93.36% of the 
variability. 
 
B.2      PLS-DA percentage variance explained by the LVs calculated for X and Y 
variables  
Table B.2 shows PLS-DA percentage variance explained by the LVs calculated for X and 
Y variables for the 300 preprocessed calibration spectra data sets for E. coli cell lysate. 
The 3-LV PLS-DA model captured 90.50% of the X-block variance and explained 
85.25% of the Y-block variance of the training data 
Principal 
component (PC)  
number 
Eigenvalue of 
covariance (X) 
% Variance 
captured for this 
PC 
Total % 
variance 
captured 
1 9.14 × 10
4
 70.48 70.48 
2 2.04 × 10
4
 15.76 86.24 
3 5.35 × 10
3
 4.13 93.36 
Table B.1: PCA model of the cell lysate mass spectra data sets 
Latent 
variable 
(LV) 
number 
X-Block Y-Block 
% Variance 
captured for 
this LV 
Total % 
variance 
captured 
% Variance 
captured for 
this LV 
Total % 
variance 
captured 
1 71.79 71.79 32.06 32.06 
2 16.62 88.41 32.31 64.38 
3 2.09 90.50 20.87 85.25 
Table B.2: PLS-DA percentage variance explained by the LVs calculated for X 
and Y variables 
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B.3      PLS-DA results showing the quality of the model after calibration and cross-
validation 
Table B.3 summarises the PLS-DA results showing the quality of the model after 
calibration (Cal) and cross-validation (CV) for the 300 preprocessed calibration spectra 
data for E. coli cell lysate. The quality of this model is good, according to the values of R
2
 
calculated both fitting (73.1% for class 1, 93% for class 2 and 67.2% for class 3) and in 
CV (86.3% for class 3). The quality of the model was good both in calibration and CV 
with a sensitivity (proportion of samples correctly classified that belong to the class being 
modeled), and specificity (proportion of samples correctly classified that do not belong to 
the class being modeled) of at least 92%. The high values of R
2
 in fitting (and the 
consequent small values of RMSEC, (0.245 for class1, 0.125 for class 2, and 0.267 for 
class 3) shows that the model is characterised by a large fitting ability. 
 
Modeled class 
Class 1 
(Decline phase) 
Class 2 
(Exponential 
phase) 
Class 3 
(Stationary 
phase)  
Sensitivity (Cal) 0.948 1.000 0.944 
Specificity (Cal) 0.941 0.995 0.927 
Sensitivity (CV) 1.000 1.000 1.000 
Specificity (CV) 0.519 0.957 0.000 
Classification 
error (Cal) 
0.05545 0.00269 0.06405 
 Classification 
error (CV) 
0.24064 0.02150 0.50000 
RMSEC 0.24555 0.12586 0.26716 
RMSECV 0.79172 0.61399 0.90605 
Bias -0.00566 -0.01060 -0.01018 
CV Bias -0.20691 -0.31593 0.25343 
R
2 
Cal 0.73125 0.93043 0.67168 
R
2
 CV 0.03328 0.01120 0.86356 
Table B.3: PLS-DA results showing the quality of the model after calibration and 
cross-validation  
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B.4      PLS-DA results showing the performance of the model after external 
validation  
Table B.4 summarises the PLS-DA results showing the performance of the model after 
external validation with 55 test set samples for cell lysate. This model has an excellent 
prediction sensitivity and specificity of 95.7% and 95.2% respectively. These results are 
supported by those in Fig. B.3. 
 
 
Modeled class 
Class 1 
(Death phase) 
Class 2 
(Exponential 
phase) 
Class 3 
(Stationary 
phase)  
Sensitivity (prediction) 0.957 1.000 0.889 
Specificity (prediction) 0.952 1.000 0.851 
Classification error 
(prediction) 
0.04555 0.00000 0.01300 
RMSEP 0.25455 0.12477 0.30432 
Prediction Bias -0.01623 -0.02150 0.01605 
R
2 
prediction 0.71893 0.93518 0.56058 
Table B.4: PLS-DA results showing the performance of the model 
after external validation 
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Appendix C      Additional information for the CHO cell line spectra 
data sets 
Appendix A provides a summary of the PLS algorithm used in this work as well as 
information of the variables from the loadings plot that are associated with m/z ratio ion 
signals for the high and low producer CHO cell lines. 
Figures  
C.1      The non-iterative partial least squares (NIPALS) algorithm for PLS1 
algorithm  
The non-iterative partial least squares (NIPALS) algorithm for PLS1 algorithm was a 
prerequisite for the PLS-DA algorithm used in this work. The PLS-DA algorithm started 
with the calculation of a PLS model of A latent variables (LVs) with spectra data sets (X-
block) for calibration samples and y vector (Fig. 5.4). From step 12 (equation 13), the 
calculated predicted response value,  ̂  from PLS1 is the starting point of the PLS-DA 
algorithm (section 5.6.1).  
 
The non-iterative partial least squares (NIPALS) algorithm for PLS1 is presented as 
follows: 
Step 1: 
Using a temporary y factor as output scores, u (that summarises the remaining variability 
in y), calculate the loading weights, w, by regressing columns of the X block data of 
calibrated samples on u. Give some initial values to u e.g. the column of y with the largest 
sum of squares. 
 
                        
   
    
                                             (1) 
Step 2: 
Normalise w to unit length       
   
 
‖ ‖
                                                  (2) 
Step 3: Estimate the input scores 
   
  
   
                                             (3) 
Step 4: 
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Estimate the output loadings    
    
    
    
                                           (4) 
Step 5: 
Normalise input loadings, q,  to unit length       
   
 
‖ ‖
                                              (5) 
Step 6: 
Estimate new output scores, u,  
   
   
   
                                              (6) 
Step 7: 
Test the occurrence of convergence on u, by checking that the t has no longer changed 
meaningfully since the last iteration, that is:  
 
‖       ‖
‖ ‖
                                         (7) 
 
where ε is “small” e.g. 10-6 or 10-8. If convergence has occurred it means the PLS 
component has been adequately modelled, proceed to step 8. If not, put t as told  and 
calculate a new u vector by repeating step 1. 
Step 8: 
Estimate the input loadings    
    
   
    
                                         (8) 
Step 9: 
Compute the estimated regression coefficient of the relation, b.            
   
    
    
                                             (9) 
 
where W is the input weights matrix and P is input loading matrix 
Step 10: 
Estimate the input and output residual matrices 
                                               (10) 
                                              (11) 
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If additional PLS  components are necessary, replace X and Y by E and F, 
respectively and repeat steps 1-9. 
Step 11: 
Compute the regression coefficient vector used for the linear PLS predictor 
 ̂                                                  (12) 
Step 12: 
Calculate the y predicted values,   ̂, for calibration data by fitting a linear relationship 
between the independent and dependent variable scores. 
  ̂                                                      (13)   
 
 
Figure C.1: The non-iterative partial least squares (NIPALS) algorithm for PLS1 
algorithm 
 
 
 
Tables  
C.1      The variables from the loadings plot and their corresponding to m/z ratio 
signal ions for high producer cell line samples   
Since most of the m/z ratio signals ions are singly charged protonated protein (MH
+
) 
molecules, they represent the approximate MALDI experimental MWs of the ionised 
proteins expressed by the high producer cell lines. The magnitude of the loadings may 
reveal how expression of proteins varies with growth phase. Loadings were considered to 
have high intensity (H) if the magnitude was greater than 0.04; medium intensity (M) if 
the magnitude was greater than 0.02, but less than 0.04; and low intensity (L) if the 
magnitude was between 0 and 0.02. 
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Variables 
from 
loadings 
plot 
Intensity of 
variable 
from 
loadings 
plot  
Associated m/z 
(MH
+
) or 
experimental 
MW  
Variables 
from 
loadings 
plot 
Intensity 
of 
variable 
from 
loadings 
plot  
Associated m/z 
(MH
+
) or 
experimental 
MW  
518 M 5431.57 3165 M 10160.76 
 641 L 5618.72 3817 L 11550.75 
644 L 5623.33 3936 M 11814.05 
818 L 5893.61 3724 M 11347.04 
1121 L 6379.42 6608 L 18507.62 
1217 H 6537.35 6406 L 17949.32 
1489 L 6995.31 6339 L 17766.03 
1650 L 7273.68 2918 L 9657.46 
1866 L 7655.69 6409 L 17957.55 
1983 L 7866.69 4888 M 14027.33 
2106 L 8091.60 5434 L 15382.40 
2365 M 8575.57 660 L 5648.99 
2673 L 9169.39 2782 L 9385.79 
2676 L 9175.27 2775 L 9385.78 
2777 L 9374.39 6329 L 17738.76 
2879 L 9577.65 3205 L 10243.47 
3048 H 9900.38 3113 L 10053.74 
3154 M 10136.51 4638 L 13425.84 
3255 L 10345.75 4779 L 13762.37 
3482 L 10825.94 4781 L 13767.18 
3629 L 11139.15 4873 H 13978.88 
3620 L 11121.38 5048 L 14415.97 
3703 H 11299.61 5159 L 14692.09 
3708 H 11310.49 5165 L 14706.99 
3934 M 11807.87 5172 L 14724.37 
3874 L 11676.50 5417 L 15337.20 
4075 L 12123.61 5502 L 15553.46 
4078 M 12130.37 5720 L 16130.13 
4292 L 12617.67 5652 L 15940.89 
3938 L 11818.50 5731 L 16143.60 
4631 L 13411.12 5971 L 16773.89 
5434 L 15382.40 6329 L 17738.76 
3161 M 10152.51 6583 L 18435.72 
4631 L 13411.12 2907 L 9635.34 
4783 H 13773.90 8257 M 23385.04 
1112 M 11340.44 8327 L 23601.91 
Table C.1: The variables from the loadings plot and their corresponding to m/z ratio 
ion signals for high producer cell line samples 
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C.2      The variables from the loadings plot and their corresponding to m/z ratio 
signal ions for low producer cell line samples   
Since most of the m/z ratio signal ions are singly charged protonated protein (MH
+
) 
molecules, they represent the approximate MALDI experimental MWs of the ionised 
proteins expressed by the high producer cell lines. The magnitude of the loadings may 
reveal how expression of proteins varies with growth phase. Loadings were considered to 
have high intensity (H) if the magnitude was greater than 0.04; medium intensity (M) if 
the magnitude was greater than 0.02, but less than 0.04; and low intensity (L) if the 
magnitude was between 0 and 0.02. 
 
Variables 
from 
loadings 
plot 
Intensity of 
variable from 
loadings plot  
Associated m/z 
(MH
+
) or 
experimental 
MW  
Variables 
from 
loadings 
plot 
Intensity of 
variable from 
loadings plot  
Associated 
m/z (MH
+
) or 
experimental 
MW  
536 L 5458.76 3817 L 11550.75 
768 L 5815.29 3830 L 11579.37 
979 L 6149.35 3835 L 11590.39 
1179 L 6474.60 534 L 5455.73 
1294 L 6665.42 1180 L 6476.25 
1589 L 7167.57 1293 L 6663.75 
2306 L 8464.08 1466 L 6955.98 
2737 L 9295.27 1589 L 7167.57 
2967 L 9754.76 1781 L 7504.19 
3110 L 10046.03 2308 L 8467.85 
3198 L 10227.40 4783 H 13773.90 
3829 L 11575.46 2967 L 9754.76 
3851 L 11623.96 3110 L 10046.03 
3972 L 11892.56 3654 L 11193.23 
4129 M 12245.63 3970 L 11888.09 
5170 L 14717.39 4126 M 12238.84 
5236 L 14881.76 4830 L 13885.12 
6354 L 17804.70 5230 L 14866.78 
6404 L 17941.54 6205 L 17400.02 
9403 L 27107.20 1112 M 11340.44 
47 L 6382.26 9403 L 27107.20 
72 L 6482.42 711 L 9307.20 
115 L 6656.52 902 L 10250.44 
187 L 6953.20 1091 L 11228.61 
275 L 7324.59 1135 L 11462.73 
396 L 7851.03 1275 L 12223.72 
516 L 8391.16 2202 L 17879.63 
2829 L      22306.94    
Table C.2: The variables from the loadings plot and their corresponding to m/z ratio 
ion signals for low producer cell line samples 
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